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i. Summary
This thesis presents data relating to the use of hydromorphone for the treatment of acute and 
clironic pain. The work was done in order to obtain European product licences for both 
immediate-release and a controlled-release oral formulations.
Hydromorphone is a semi-synthetic derivative of morphine which possesses pharmacologic 
properties qualitatively similar to those produced by morphine, although it is a more water- 
soluble molecule and is approximately five-times more potent than morphine. As with all 
strong opioids, hydromorphone has the potential to produce physical or psychological 
dependence. Hydromorphone has been credited with a lack of active metabolites in contrast 
to morphine, which has an active metabolite, morphine-6-glucuronide.
For the immediate-release tablet, hydromorphone is rapidly absorbed after oral 
administration and undergoes extensive first-pass metabolism, resulting in oral 
bioavailability of 18.7%. Elimination is multiphasic; there is a rapid decline in plasma 
concentrations within the first 3 hours after dosing followed by slower elimination phase. 
The earlier distribution/elimination element is thought to determine hydromorphone’s 
duration o f action, whereas the longer elimination half-life of around 15 hours is of less 
relevance in the clinical setting.
Cmax and AUC(0-24h) for hydromorphone immediate-release are proportional to dose 
level and there is a statistically significant effect of food, but the effects observed are not 
clinically relevant. Sex had little effect on the pharmacokinetics o f oral immediate-release 
hydromorphone and age also had little effect. Renal impairment produced changes in the
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pharmacokinetics o f hydromorphone as did moderate hepatic impairment, both producing 
an increase in hydromorphone bioavailability.
The controlled-release formulation achieves a very flat profile o f release compared with the 
immediate-release, with Tmax being observed at times in excess o f 12 hours. Dose- 
proportional pharmacokinetics were confirmed and marginally increased bioavailability 
demonstrated compared with the immediate-release formulation. The effect of food to 
increase bioavailability is not likely to be clinically significant.
Several published controlled studies o f oral hydromorphone in patients with a variety of 
acute or chronic painful conditions have demonstrated the analgesic efficacy of 
hydromorphone. Nevertheless, novel studies demonstrating efficacy and safety were 
requested, therefore, three major studies were conducted to evaluate hydromorphone’s 
efficacy and safety in acute and chronic pain models.
The first of these was a double-blind, single dose, placebo-controlled, multicentre dose-
ranging study o f 205 postoperative knee replacement patients receiving either 2, 4 or 6 mg
single doses of immediate-release hydromorphone. The principal measure of efficacy was
the sum of the pain intensity differences (SPID) for pain at rest, using self-reported pain on
an 11-point numerical scale over a six-hour period. Hydromorphone 4 and 6 mg were
significantly more effective in reducing pain at rest compared with placebo (p=0.03 for both
comparisons). There was no statistically significant difference between hydromorphone
2mg and placebo. The adjusted means for SPID were -2.3, -5.2, -4.4 and 0.6 for
hydromorphone 2, 4 and 6 mg and placebo, respectively. Results were similar for the
analyses o f SPID for pain on movement. Hydromorphone 4 and 6mg were significantly
more effective compared with placebo (p=0.04 for both comparisons). There was no 
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statistically significant difference between hydromorphone 2 mg and placebo (p=0.60). The 
adjusted means for SPID were -1.3, -5.6, -3,9 and -0 .2  for hydromorphone 2, 4 and 6 mg 
and placebo, respectively. Adverse events were reported by 11 (22%) patients, 15 (31%) 
patients, 17 (33%) patients and 15 (28%) patients, respectively; and there was no 
statistically significant difference between the four groups in the proportion of patients who 
reported adverse events. Nausea, vomiting and pyrexia were the most common adverse 
events.
The second study was a double-blind, multiple-dose, active-controlled, multicentre, dose- 
ranging study of 271 postoperative knee replacement patients receiving three-to-six hourly 
doses of either 2, 4 or 6 mg of immediate-release hydromorphone, compared with 20-mg 
doses of immediate-release morphine. The principal measure o f efficacy was the average 
pain score (same 11-point scale), calculated using an area-under-the-curve methodology and 
analysed using equivalence methodology. The adjusted means for the principal measure, 
namely the AUC (0-48 h) of pain at rest/48 were 4.6 (hydromorphone 2 mg), 4.0 
(hydromorphone 4 mg), 3.5 (hydromorphone 6 mg) and 3.9 (morphine sulphate 20 mg). 
Each dose of hydromorphone was considered equivalent to morphine, based on the 95% 
confidence intervals falling within the range ± 1.5. Analysis o f the AUC (0-48h) o f pain on 
movement/48 for the full analysis set provided adjusted means of 6.6 (hydromorphone 2 
mg), 6.1 (hydromorphone 4 mg), 5.7 (hydromorphone 6 mg) and 5.8 (morphine sulphate 
20 mg). Adverse events were reported by 42 (62%) patients, 42 (59%) patients, 45 (67%) 
patients and 38 (58%) patients, respectively; there was no statistically significant difference 
between the four groups in the proportion of patients who reported adverse events. Nausea, 
vomiting, pyrexia and sedation were the most common adverse events.
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The third study was a double-blind, multiple-dose, active-controlled, multicentre, dose- 
ranging study o f 200 cancer pain patients receiving immediate and controlled-release 
hydromorphone compared with moiphine and analysed using an equivalence methodology. 
The primary efficacy variable was the patients’ se lf  reported “worst pain” on an 11-point 
numerical scale. The study showed that there were decreases in worst pain in both treatment 
groups, confirming the basic efficacy o f the two treatments under the study conditions. For 
the immediate-release formulations, equivalence was proved, again, based on the 95% 
confidence intervals falling within the range ±1 .5  (mean difference o f 0.2, 95% Cl -0 .4  to
0.9), whereas for the controlled-release formulations, hydromorphone was superior to 
morphine (mean difference of -0.8, 95% Cl -1 .6  to -0.01, p=0.046). The overall safety 
profiles of the two treatments were similar and there were no statistically significant 
differences between the treatments for the proportion of patients reporting adverse events. 
The nature o f the adverse events reported during hydromorphone and morphine therapy 
were generally typical o f the events associated with these treatments.
This thesis presents three large, multinational positive studies confirming the efficacy and 
safety of hydromorphone in both acute and chronic pain models.
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This thesis is dedicated to my father, John V.G.A Durnin, formerly Professor in the 
Physiology Department at Glasgow University, who has been nagging me for years to write 
an MD thesis!
1. Acknowledgement
This work was undertaken by Knoll Pharmaceuticals with the purpose of obtaining product 
registrations in European states for a range of formulations of hydromorphone. The work 
was carried out by a large, multinational and multidisciplinary team which included many 
clinicians working as investigators and consultants. My thanlcs goes to the many members 
of this team who made this work possible and enjoyable.
2. Statement of extent of personal contribution
The work presented in this thesis was carried out by Knoll Pharmaceuticals with the aim of 
achieving product registrations in European states. As such, the contents of this thesis must 
remain confidential and not be released to third parties without the prior agreement of 
Abbott Laboratories, (which now owns the proprietary information gathered by Knoll 
Pharmaceuticals).
The clinical teams involved in this work spanned 8 countries and numbered upwards of 30 
individuals. My role, as the Project Clinician, was to design, supervise and report the 
studies. This involved my collaborating with colleagues and associates for each of the tasks 
as presented in Table 1.
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The tasks listed in Table 1 were team efforts. Nevertheless, as Project Clinician, I held 
overall responsibility for the project and contributed directly to all o f the tasks listed. I was 
not supported or supervised in these tasks to a substantial degree by any other medical 
doctor in the employment of Knoll Pharmaceuticals. The clinical experts whom I consulted 
were medical doctors working in clinical practice and clinical research for various 
institutions around Europe and North America. This was my major responsibility in the 
company for a period o f approximately four years.
I have included references for all the publications that have been derived from the work 
presented in this thesis.
The work o f preparing this thesis, including review of the literature, has been carried out by 
me alone, in collaboration with my internal and external thesis advisors as agreed with the 
Medical Faculty.
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3. Introduction
The under-treatment of pain is still a major public health issue, despite the problem being 
highlighted in the medical literature. In the postoperative setting. Smith (1998) highlighted a 
particular deficiency in postoperative pain management. This is what Smith describes as the 
“gap” between the period immediately after the operation when the patient may be receiving 
parenteral opioids by a patient-controlled-analgesia (PCA) system and the time when 
patients are receiving regular oral analgesics such as non-steroidals and simple analgesics. 
This period was identified by an audit as one requiring research and therapeutic effort to 
address what was perceived as a time when patients were at an increased risk of poor pain 
control. Smith identifies oral opioids as the most appropriate treatment for this “gap” period. 
He describes a specific regimen used at a particulai' institution comprising twice-daily 
sustained-release morphine with supplementary doses of immediate-release morphine. 
However, Smith identifies factors which discourage the use of opioids in the “gap” period. 
These include the reduction in intensity of the monitoring of patients at this time and the 
perceived risk from a reduction in gastric emptying in the postoperative period. Specifically, 
the risk from reduced gastric emptying is the accumulation of opioid in solution within the 
stomach during the time of stasis and a rapid absorption of the drug load on 
recommencement of gastric emptying. Smith points out, however, that by using appropriate 
delays from the time of operation and by observing for clinical signs of the return of gastric 
emptying, this risk can be greatly reduced.
In the setting of the management of chronic pain caused by cancer, in a study of cancer 
patients attending clinics in the USA, Cleeland (1994a) established that 42% of those with 
pain were not given “adequate” analgesic therapy. In this study, 36% of patients reported 
pain of sufficient severity to interfere with functional ability. Thus, the deficiencies in pain 
management are an issue of both symptom control and also the consequences of these 
symptoms. In both this study and a review of a later study (Cleeland 1998), factors 
predisposing to insufficient pain control were identified. These included older age and 
minority group status.
These findings in both the postoperative setting and the chronic cancer pain population 
emerged despite the attempts of various bodies to improve the treatment of patients 
suffering pain (American Pain Society 1993, Mayor 2000, Phillips 2000, Vastag 2001a,
28/09/01
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WHO 1996a, 1996b). Components of the overall phenomenon of the under-treatment of 
pain are poor recording of pain data in both the postoperative and chronic cancer pain 
setting (Klopfenstein 2000, Rliodes 2001), insufficient use of a holistic approach to pain 
treatment (Oliver 2001), lack of knowledge regarding the use of opioids on the part of the 
medical profession, insufficient variety in types of opioid drugs and formulations in some 
European countries, difficult administrative barriers to opioid prescribing in some European 
countries (Mercadante 1998) and misconceptions about opioids (Valera 2000, Zenz 2000). 
Probably the commonest of the misconceptions on the side of the physician are that opioids 
are only for use at the end of life and that large proportions of patients receiving opioids will 
develop psychological dependence. There are a number of concerns being raised in the 
medical literature at present concerning the risk of the development of psychological 
dependence to opioids (Passik 2001, Vastag 2001b), but publications suggest that these 
concerns are not confirmed by the available data (Joranson 2000). Regarding the inadequate 
recording of pain, the recent Joint Commission on Accreditation of Healthcare 
Organisations promote the view that pain should be regarded as the “fifth vital sign” in 
patient care, thus reducing the chance of it being overlooked in the routine management of 
patients (Phillips 2000).
Many strong opioids are available for the treatment of pain; the “Gold Standard” being 
morphine. Alternatives are still required, however, because some patients who do not 
respond well to morphine may respond to alternative opioids (Galer 1992). The studies of 
what is laiown as “opioid rotation”, or “opioid switching” tend to be retrospective or 
prospective case series rather than prospective, controlled trials. Nevertheless, there is a 
strong conviction in the palliative care community that changing an opioid can improve pain 
control and diminish adverse effects induced by the opioids. Pure opioid agonists such as 
morphine are laiown to have no “ceiling effect”, in other words, the more of the drug that is 
administered, the more analgesia will be induced. This means that in practice, the dose of 
opioid tends to be titrated both against analgesic effect and opioid-induced side effects. In 
contrast to the pure opioid analgesics, partial opioid agonists such as buprenorphine 
demonstrate a plateauing of analgesic effect with increasing dose. In the setting of palliative 
care for cancer pain patients, however, it is predominantly the pure opioid agonists and 
specifically, morphine, that are advocated. In this setting, the clinical issues encountered are 
the balance of beneficial analgesic effects from the opioid and the harmful effects of the 
opioid-induced side effects.
28/09/01
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In a retrospective case series published by de Stoutz (1995), 80 patients were treated with 
opioid rotation for a variety of symptoms experienced on their existing opioid treatment. In 
these 80 patients, in 53 (66%) cases, the first change in opioid therapy was from morphine 
to hydromorphone and in 90% of all the changes, only morphine, hydromorphone and 
methadone were utilised. The dose that the patients were changed to were calculated as 
being equipotent according to standard conversion tables. In this population, 73% of 
patients experienced an improvement in symptoms. This would appear to be a positive 
finding, but it must be remembered that this was conducted with both treating physician and 
patient being fully aware of what treatments were received and not in the setting of a 
clinical trial with no controls over other modifications in the patients’ overall treatment 
regimens. De Stoutz postulates that the mechanism of the benefit derived from changing the 
opioid used is based on the clearance of toxic metabolites from the previous opioid 
treatment. The lack of good data on the respective metabolite profiles, including 
pharmacological activity therefrom, make this largely a speculative statement, however.
Given that the gold standard treatment is morphine, it is worth noting that there are 
conceptual issues based on the very term “morphine” which could have strong connotations 
in a patient’s mind. These beliefs could compromise a patient from receiving ideal treatment 
for pain control (Kurowska 1996). As such, something as simple as an alternative opioid 
with a name not associated with morphine could offer advantages to some patients.
In some European states, only controlled-release forms are available for some strong 
opioids, which necessitates the use of a mixture of opioids in different formulations to 
provide rescue doses for breakthrough and incident pain. This inevitably compromises 
clinical care, since there are no data to support the use of a combination of opioids to treat 
pain (McQuay 1999). This limited availability of strong opioids in a range of formulations, 
therefore, represents one restriction on practitioners’ ability to treat pain optimally. The 
choice of agents and formulations would be significantly improved if hydromorphone were 
made available in the three dosage forms described below in all European states.
The deficiencies in current knowledge concerning the “gap” in postoperative pain 
management and the lack of prospective, blinded comparison of opioids in the treatment of
28/09/01
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clironic cancer pain therefore presented an opportunity for study of a range of formulations 
of an opioid other than morphine in these two indications.
Hydromorphone hydrochloride is a semi-synthetic derivative o f morphine. Parenteral 
formulations and immediate release tablets (Dilaudid IR) have been in clinical use for 
decades in North America and are indicated for moderate to severe pain, such as that due to 
surgery, cancer, soft tissue and bone trauma, myocardial infarction, burns and renal colic 
(Knoll 1997). Immediate-release tablets are usually administered at a starting dose o f 2 mg 
orally every 4 to 6 h as necessary. The dose is currently recommended to be individually 
adjusted according to the severity of pain, patient response, patient age and weight. Dilaudid 
CR tablets are a new oral controlled-release form of hydromorphone intended for once-daily 
administration for the treatment of moderate to severe chronic pain. The Dilaudid CR 
system allows a relatively constant release of drug over a 24-h period, resulting in stable 
plasma levels of hydromorphone. Dilaudid CR has been developed in tablets containing 8, 
16, 32, or 64 mg hydromorphone.
Knoll Pharmaceuticals embarked on a programme of studies with the aim of registering the 
new controlled-release form of hydromorphone with the Food and Drug Administration in 
the USA. At the time that this work was proceeding, a separate programme of studies was 
begun in Europe with the aim of achieving registration of the existing parenteral 
formulation and immediate-release tablets as well as the new controlled-release tablets with 
European regulatory agencies. These agencies requested that these data be collected in an 
appropriate manner for hydromorphone being regarded as a new chemical entity and not an 
established and well-characterised molecule. The exception to this was the pai'enteral 
formulation, which had existing product licences within the European Union and win eh 
could therefore be based on bibliographic data only and not new clinical studies. The 
requirement, then, was to prove efficacy and safety for both the immediate and the 
controlled-release tablets.
In the planning process for achieving this aim, it was recognised that there was opinion 
building within both the medical community treating pain and within the regulatory 
agencies to the effect that different pain types required separate clinical studies to address 
efficacy and safety. There are clearly limitations on how many subdivision of pain 
syndromes could practicably be undertaken in the design of the research programme. The
28/09/01
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International Association for the Study of Pain classification of clnonic pain alone runs to 
some 222 pages (lASP 1994). The decision was therefore made to separate chronic pain 
from acute pain models. This decision was affected, to some degree, by the knowledge of 
the relatively long time-to-pharmacokinetic-steady-state of the controlled-release 
formulation and the relatively low expectancy of its utility in acute pain in comparison with 
the immediate-release formulation.
The acute pain indication appeared to be amenable to a classic approach of a single-dose, 
placebo-controlled study, followed by a multiple-dose trial. The usual models used for 
single-dose analgesia trials are postoperative or trauma pain. Since the need was for the trial 
to explore the use of the immediate-release tablet, the time immediately following that at 
which the patient ceases to use parenteral opioids by PCA (described as the “gap” above) 
represented an ideal environment in which to study immediate-release hydromorphone 
tablets. Knoll Pharmaceuticals had previous experience of studies in postoperative pain 
which had failed to demonstrate statistical significance compared with placebo. The 
judgement was that this failure was a result of a lack of homogeneity and insufficient pain 
stimulus in the pain model used. It was therefore agreed to study only patients recovering 
from primary Icnee replacement surgery, a moderate-to-severe pain model. The details of the 
technical issues around the design of the studies in post-knee replacement are presented in 
the individual study reports in the main body of the thesis. A major hurdle was encountered 
at an early stage, however, when concerns were raised by ethics committees regarding the 
use o f placebo in this setting. These concerns were allayed through detailed explanation of 
the method by which patients received “escape” medication in the placebo-controlled, 
single-dose study. The whole process of ethical review and the presentation of arguments, 
which consumed several months, was a reminder of the conflict between the need to collect 
placebo-controlled data and the need to not compromise patient care (Lyons 1999). The 
primary efficacy measure seemed self-evident, namely the patient’s self-reported pain. 
However, doubt remained concerning whether the pain in the joint at rest, or on movement 
should be selected. It was known that mobilisation after surgery is a major issue for knee- 
replacement patients and it was also self-evident that pain on movement exceeds that at rest. 
Against this, however, was the expectation that opioids would have more of an effect on 
pain at rest than on movement (Rainer 2000). Finally, it was decided to select pain at rest as 
the primary efficacy endpoint and perform the same analysis on pain on movement as a 
secondary measure. An additional question was which particular pain scale to use. Most
28/09/01
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published studies of acute pain over a short period such as six hours used a four-point 
categorical scale, but the decision was made to use an 11 -point numerical scale in order to 
have a standai'd score across all of the main efficacy studies in this programme.
The multiple-dose study used the same pain model, but again, because of concerns over the 
ethics of placebo controls in this setting, an active control (morphine) was selected. The use 
o f morphine as the comparator also met the requirement of the regulatory agencies that the 
test treatment be compared against the current “gold standard”. The knowledge of 
hydromorphone at the time of designing the comparative study meant that there was a low 
expectation of being able to demonstrate superiority over morphine in a clinically relevant 
parameter. The decision was therefore made to design this study on the basis of 
equivalence. This incurred the problems of requiring a larger study population and also the 
difficulties in prospectively selecting a “clinically equivalent zone” within which the 
primary efficacy parameter had to lie. The equivalence zone (or “delta”) that was used for 
the study was + 1.5 on the 11-point pain scale from the Brief Pain Inventory. The selection 
of 1.5 as the value was based on consultation with clinical experts in pain management but 
it was not possible to validate this with any precise data. The same value has been 
presented as a clinically significant change on an 11-point scale in published papers and 
workshops (Rowbotham 1998, Stubhaug 2000). Conversely, various recommendations 
exist for setting delta, such as half of the difference between active and placebo, 10% of the 
rating scale or half the standard deviation of the measure at baseline. It is impossible to 
validate any of these suggestions, however, since they are based on a subjective assessment 
o f what is significant, based on a subjective measure of the pain experienced. One study 
used data pertaining to the use of breaktlirough pain medication, collected in cancer 
patients, to address this question. The methodology was rather complex and difficult to 
understand, but the author’s suggestion for clinical relevance on an 11-point pain scale was 
a change of two points (Farrar 2000).
Ideally, an equivalence study should have a sensitivity analysis within its design. This 
would conventionally be a placebo treatment arm which would allow demonstration of 
efficacy of the control treatment. This is not ethically feasible within the constraints of a 
multiple-dose pain study for registration purposes, however. One control which was 
included in the equivalence methodology is analyses of both a full or “intent to treat” 
analysis set, as well as a “per protocol” set. The similarity in the results from both these
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analyses confirms that the study was conducted with sufficient rigor to prevent an 
equivalence result simply being the product of regression towards the mean. Finally, the use 
of tlii’ee dose levels of the test drug against a single dose level of the comparator in this 
study raised issues in the equivalence analysis. First, it allowed a form of assay sensitivity, 
since proof of dose responsiveness would argue against all the treatments lacking efficacy. 
Second, there was the issue of multiple comparisons within the equivalence methodology. A 
relatively novel stepped-equivalence methodology was used in order to address this concern 
(Chamion 2000).
The study of chronic pain was determined at an early stage to require cancer pain patients. 
This was partly because cancer pain is a well-established model for chronic pain, but also 
because o f continuing argument over the appropriateness of long-term opioid treatment for 
non-malignant chronic pain in Europe (McQuay 2001). As described above, the comparator 
treatment clearly had to be morphine and since no published study had ever described a 
statistically significant advantage of one opioid over another in the treatment of chronic 
pain, and based on our knowledge of hydromorphone, an equivalence methodology was, 
again, selected.
In both equivalence studies, an interim re-estimation of sample size was incorporated into 
the design. This had become established practice in Knoll Pharmaceuticals for trials of this 
kind and had been demonstrated to be acceptable to regulatory authorities, since it did not 
unblind the data. Additionally, the need for a re-estimation was deemed prudent given that 
the published data on which the original estimation of sample size was based was not felt to 
be robust.
The selection of the primary efficacy endpoint for the cancer pain study caused some 
debate. Given, as described above, that opioids are titrated to effect in respect to pain 
control and almost equally to adverse effects, it was mooted that the primary comparison in 
the study should be of adverse effect incidence on the basis o f equal pain control in both 
treatment arms. This was not done, however, since it was deemed counterintuitive to not use 
a measure of pain as the efficacy variable in an analgesic trial. Additionally, it was not 
thought to be acceptable to regulatory authorities.
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All tlii'ee clinical trials used a parallel group design. In the acute pain model where patients 
were recovering from an acute insult, it was not thought appropriate to attempt a crossover 
design where the baseline pain stimulus would be expected to diminish over the duration of 
the study. This was thought to be the case in the single-dose study which was of six hours’ 
duration, and more so in the multiple-dose study which was of 48 hours’ duration. A 
crossover design would have been more feasible in the chronic cancer pain population and it 
would have had the advantage of a reduced patient population for the same power.
However, it was recognised that the kinds of cancer pain patients requiring strong opioids 
are often at the later stage of disease and are therefore less stable. This would have the 
effect of increasing the dropout rate and invalidating the crossover. Additionally, other 
events in the management of these patients, such as chemo- or radiotherapy, could interfere 
with the comparison of one period with another. Also, the need for continuous treatment to 
manage pain would make it impossible to use washout periods and therefore, carryover 
effects between the treatment periods could be an issue. Lastly, since the indication sought 
was the treatment of chronic pain, the treatment durations had to be sufficiently long for the 
controlled-release therapy to make the comparison clinically valid. Adding to this the need 
to have the patients titrated to effect on immediate-release treatment prior to switching to 
controlled-release, the treatment period of weeks would be unwieldy and ethically difficult 
for a crossover design in this patient population.
In both the postoperative and in the cancer pain setting opioids are rarely used in isolation 
(Kehlet 1999, Mercadante 2001). However, the trials presented in this thesis were designed 
as registration studies for European regulatory authorities and as such, they had to focus on 
the effects of hydromorphone alone. Various items were added to the design and conduct of 
the studies to try and accommodate this conflict between clinical practice and the need to 
collect controlled data for registration purposes.
This thesis presents data relating to the use of hydromorphone for the treatment of acute and 
chronic pain. The data was collected as part of a process to obtain product licences for oral 
hydromorphone preparations. All of the clinical studies in this thesis were conducted to 
Good Clinical Practice standards, comprising full Ethics Committee and Regulatory Agency 
(where appropriate) review and informed consent procedures.
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4. Literature data available
4.1 Chemistry
Hydromorphone is a semi-synthetic derivative of morphine; it is commercially available as 
the hydrochloride salt.
Nomenclature:Hydromorphone hydrochloride 4,5-alpha-epoxy-3-hydroxy-l 7-
methylmorphinan-6-one hydrochloride
Figure 1. structural formula of morphine and hydromorphone (bases):
Me Me
Morphine Hydromorphone
Empirical Formula: 
Appearance:
Relative Molecular Mass: 
Melting Point:
Solubility:
Ci7H,9N0 3 HC1
Fine, white or almost white crystalline powder 
321.8
305 - 315 °C
1 g in ~ 3 ml water; slightly soluble in alcohol
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4.2 Pharmacology
4,2.1 Pre-clinical pharmacology
In the scientific literature, nearly all studies carried out with hydromorphone on animals 
have established the fact that, in general, hydromorphone possesses pharmacologic 
properties qualitatively similar to those produced by morphine; however, hydromorphone is 
approximately five times as potent as morphine in various animal models. The fact that 
hydromorphone is a very potent analgesic in vivo is a reflection of its high in vitro binding 
(Chen 1991) since the binding affinity of hydromorphone (Ki = 0.24 nM) to the p-receptor 
is 7 times that of morphine (Ki = 1.8 nM) (Mignat 1995). With regard to the binding affinity 
to other receptor types the selectivity of morphine is 89-fold versus the ô- and 26-fold 
versus the ic-opioid receptor and that of hydromorphone is 60-fold versus the 5- and 52-fold 
versus the ic-opioid receptor (Mignat et al 1995). These data show that hydromorphone is 
directly comparable to the parent compound morphine. Analgesia appeared to correlate with 
p-binding affinity (Hennies et al 1988).
The hydromorphone doses given to animals in pharmacology studies were, as a rule, 
parenterally administered and based on those used in human therapy. However, in many 
studies higher doses were given, especially if  the purpose of the study was to observe non­
analgesic effects with a view to gaining insights into possible clinical side effects. The usual 
test systems were used, i.e. mouse, rat and dog. However, data for other animal species 
(hamsters, guinea pigs, rabbits, cats, monlceys and sheep) are also available. In all these 
species, the pharmacologic effects were almost identical in quality.
Hydromorphone produces pronounced antinociception, however, it is evident that the 
results of the quantitative evaluation of pain tln eshold depend on the different methods 
and/or species used (ICraushaar 1953). For example, in mice hydromorphone produced a 
sufficient degree of antinociception after exposure to radiant heat at a subcutaneous ED50 of 
0.25 mg/kg, whereas in guinea pigs the ED50 was higher by a factor of 12 (Friebel 1956). 
Hennies et al (1988) measured the tail flick antinociception against radiant heat in rats with 
intravenous opioid administration and a cut-off time of 12 s. The antinociceptive efficacy 
was most marked with hydromorphone (ED50 0.28 mg/kg) followed by morphine (ED50 
1.37 mg/kg) and other compounds tested. Moreover, the investigators found a fairly good
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correlation between the p-binding affinity and antinociceptive efficacy (correlation 
coefficient = 0.883; p < 0.05). In rabbits the antinociceptive effect was determined by 
means o f the tooth-pulp test after intravenous and intraventricular hydromorphone 
administration (2.5 and 5 mg/kg). The effect peaked in approx. 10 and 120 min, 
respectively. A comparative study with morphine (5 and 10 mg/kg) revealed a period of 15 
and 105 min, respectively (Cube et al 1970).
With regard to the effects on the gastrointestinal system, hydromorphone is, like morphine 
emetic in the cat (0.1 mg/kg IM) and dog (0.03 mg/kg S.C.) (Eddy 1934). In addition, 
hydromorphone increases the tone of the intestine, seen in rabbits (0.6 mg/kg S.C.) (Eddy 
1934) and dogs (0.01 mg/kg) (Walton 1935). Gruber (1935) categorised hydromorphone as 
about 10 times more effective than morphine, which corresponds approximately to the 
antinociceptive effect ratio.
Respiratory activity dose-dependently decreased after hydromorphone administration in 
dogs, rabbits, guinea pigs and rats. In the rabbit, the respiratory rate was lowered to 16% of 
normal with 2.25 mg/kg IV and the expiratory volume by 50% with 0.2 to 0.3 mg/kg S.C. 
(Ki'ueger 1943). Overall, hydromorphone proved to be 3 to 9 times more potent than 
morphine in depressing rabbit respiration (Bluniberg 1954, King 1935).
The effects on smooth muscles, other than gastrointestinal, are not marked; both tone and 
activity may be somewhat augmented. Contraction of the vesical sphincter is increased and 
catheterisation may be necessary (Gruber 1935). The effects on the uterus in situ are a 
temporary increase in tone and inhibition of the rate and force of contraction in non­
pregnant animals, but in pregnant animals these effects are not so marked and diminish 
greatly as pregnancy advances (Gruber 1935).
With regard to the effects on the central nervous system, excitement or convulsions have 
been reported in dogs, cats, rabbits, guinea pigs and mice, but usually with doses 
considerably larger than those which induce depression (Eddy 1933, Eddy 1934).
With regard to the effects on the eyes, morphine-like drugs induce miosis in rabbits 
(Murray 1982) and dogs (Sharpe 1985) as well as mydriasis in mice (Rabinowitz 1987), rats 
(Kamenetsky 1997), cats (Sharpe 1991) and monkeys (Hahnenberger 1980).
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According to Hurwitz (1981), liydromoiphone, like morphine, had an antidiuretic effect in 
mice\ both opioids reduced urine volume to the same extent.
While it has not yet been shown whether hydromorphone has effects on the immune system, 
a large number of references has dealt with effects of morphine on various immune 
parameters. Accordingly, morphine is assumed to enhance macrophage apoptosis through 
accumulation of Bax protein and activation of interleukin converting enzyme 1 (ICE-1) 
(Singhal 1998) or promote apoptosis via up-regulation of Fas-receptors (Yin 1999).
4.2.2 Clinical pharmacology
4.2.2.1 General
There is extensive available data in the scientific domain with hydromorphone and related 
opioids and their pharmacology (Reisine 1996). Hydromorphone has qualitative effects 
similar to those of morphine. The precise mechanism of action of opioid analgesics is not 
known, but the effects are thought to be mediated through opioid-specific receptors 
located predominantly in the central nervous system (CNS). Interaction with the p-opioid 
receptor subtype is believed to be responsible for most of hydromorphone’s clinical effects. 
Although estimates vary from study to study, hydromorphone is generally considered to be 
five to seven times as potent as morphine on a milligram-for-milligram basis. 
Hydromorphone HCl is also approximately seven times more soluble than morphine in 
aqueous solution and is therefore capable of being more highly concentrated in parenteral 
solutions.
Opioid analgesics, including hydromorphone, exert their primary effects in the CNS and in 
organs containing smooth muscle, such as the bowel, through interaction with p-opioid 
receptors. Neuro-imaging studies have demonstrated the distinction between 
hydromorphone, as a p-opioid agonist, compared with a kappa agonist (Schlaepfer 1998). 
Due to its interaction at the opioid receptors, hydromorphone shares with other opioids the 
actions, toxicity, and potential for the development of tolerance, physical dependence, and, 
in susceptible individuals, psychological dependence. As a class, opioids produce dose- 
related respiratory depression, nausea and vomiting as well as sedation, drowsiness, mental 
clouding, lethargy, impairment of mental and physical performance, euphoria, anxiety, 
dysphoria, and other mood changes. Physical responses to the presence of opioids include 
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miosis, urinary retention, decreased biliary and pancreatic secretions, and increased biliary 
tract pressure. Constipation occurs frequently and with extended use, opioids may decrease 
intestinal motility and gastric secretions.
4.2.2.2 Dose responsiveness
In a placebo-controlled, double blind cross-over study. Coda [1997(a)] investigated the 
analgesic effects of tln-ee intravenous bolus doses of hydromoiphone (10, 20 and 40 qg/kg) in 
ten healthy volunteers subjected to the experimental pain model of electrical stimulation of 
tootli pulp. Significant dose-dependent analgesia was noted (p<0.001) (Figure 2) with a rapid 
onset of action (5 minutes) and maximum analgesic effect between 10 and 20 minutes after 
maximum plasma hydromorphone concentration had been achieved. However, there was a 
poor correlation between plasma concentration and effect.
Figure 2. Analgesic effect in experimentally Induced pain in 10 healthy volunteers over 2 hours following 
intravenous bolus Injection of different doses of hydromorphone (Adapted from Coda 1997)
Strong pain s| Placeboe -
Pain
intensity
Faint
sensation
40 50 60  70
Time from injection (m inutes)
0 10 3020 80 90 100 110 120
p<0.0001
In a report by Hanna et al (1962), 76 post-operative patients were randomised into a double­
blind, crossover study to compare the effects of intra-muscular hydromorphone (1 ,2 , 3 ,4  
mg/70 kg) to other opioids [morphine 7, 10 mg / 70 kg, alphaprodine 40 mg / 70 kg, 
meperidine (pethidine) 75, lOOmg / 70 kg]. Patients were observed for three hours after the 
dose of hydromorphone. In half of the patients, a second drug was used for comparative 
pui'poses.
The results shown in Table 2 demonstrated that analgesic effect of hydromorphone was 
related to the dose received.
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Table 2. Analgesic mean scores of hydromorphone (H), morphine (M) and pethidine (P) in post-operative patients at 
45, 90, 135 and 180 minutes post dose
Drug Dose / 70 kg No of doses Mean pain relief score
45 min 90 min 135 min 180 min Total
H 1.0 10 1.7 2.2 1.8 1.0 6.7
2.0 36 1.8 2.5 2.3 2.2 8.8
3.0 10 1.8 2.7 2.7 2.7 9.9
4.0 2 1.8 3.0 3.0 3.0 10.8
M 7.0 16 0.9 1.3 1.0 0.5 3.7
10.0 8 1.9 2.3 2.0 1.7 7.9
P 75.0 17 1.8 2.0 1.4 1.0 6.2
100.0 9 1.8 1.9 1.8 1.2 6.7
Pain Score: 0=no reiief;1=pain iess than half gone; 2=pain half gone; 3=complete relief
Mahler and Forrest (1975) reported two double-blind studies in patients with post-operative 
pain in which each patient received two doses of hydromorphone and two doses of 
morphine. The doses of hydromorphone used were 0.5 mg, 1 mg and 2 mg, and morphine 
doses were 5mg and lOmg. Although the statistical analyses were limited in this study, the 
results demonstrated that intra-muscular hydromorphone was effective in reducing post­
operative pain in a dose dependent manner (similar to intra-muscular morphine) as 
measured by sum of pain intensity differences (SPID) and total pain relief (TOTPAR) 
(Tables 3 and 4).
Table 3. Weighted mean (SE = pooled standard error) SPID and TOTPAR responses In 52 post-operative patients 
each of whom received 4 d oses of hydromorphone and morphine
Mean (SE) n=52______________ H 0.5 mg___________ H 1.0 mg_________ M 5 mg_________ M 10 mg_____
SPID 2.25 (0.27) 3.50(0.27) 2.39 (0.27) 3.19 (0.27)
TOTPAR 4.27 (0.44)________6.98 (0.44)_______ 5.26 (0.44)_______ 7.00 (0.44)
ANOVAR - for TOTPAR treatment effects (p<0.005)
Table 4. Weighted mean (SE = pooled standard error) SPID and TOTPAR responses in 18 post-operative patients 
each of whom received 4 d oses of hydromorphone and morphine
Mean (SE) n=18 H 1 mg_________ H 2 mg M 5 mg________ M 10 mg
SPID 4.28 (0.57) 5.50 (0.57) 2.57 (0.57) 3.79 (0.57)
TOTPAR 7.33 (0.76)_______ 10.36 (0.76) 4.89 (0.76)_______ 7.74 (0.76)
No statistical analysis
4.2.2 3 Onset of action and duration of effect
4.2.2.3.1 Intramuscular
A plot of the time-effect curves indicated that the average intra-muscular dose of 
hydromorphone (1.4 mg) has a shorter duration of action than the average intra-muscular 
dose of morphine (11.3 mg) with a relatively higher peak effect (Houde 1986). The 
duration o f action following intra-muscular administration of equianalgesic intra-muscular 
doses o f hydromorphone and morphine was 4 to 5 hours (Mahler and Forrest, 1975; Houde 
1986). The duration of analgesic effect was five hours for hydromorphone 1 mg and 
morphine 10 mg, and seven hours for hydromorphone 2 mg (Hanna 1962).
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In a paper by Brown et al (1973), intra-muscular hydromorphone (0.5, 1 mg) and intra­
muscular morphine (5, 10 mg) were compared in a randomised, double blind, crossover 
study in six volunteers. The time-effect respiratory depression curve for hydromorphone 
was maximal at the first observation at 30 minutes. The effect was diminishing at the time 
of the last assessment at 3 hours.
4.2 .23.2  Intravenous
Following intravenous administration, hydromorphone had a peak effect at 20 min (Seevers 
1936). Duration of action following subcutaneous and intravenous administration could not 
be satisfactorily determined from the study.
4.2.2.3.3 Subcutaneous
Following subcutaneous administration, pealc analgesic effect was seen at 90 min with 
hydromorphone 8 mg (Seevers 1936).
4.2.2.3.4 Oral
Data concerning onset of action of oral hydromorphone is not readily available in the 
literature, partly, no doubt, because of the technical difficulties in measuring onset of action 
(Laska 1991). Inferences are often made from pharmacokinetic data, which are presented 
below and general statements are available as shown in Table 5.
Table 5. Onset and duration of action of oral hydromorphone
Onset of action Duration of action Reference Comments
1.5 to 2 hours 3 to 6 hours American Pain Society 
1990
Slightly shorter 
duration than morphine
- 4 to 6 hours Reisine 1996
0.75 hours* 4 to 6 hours Knoll Laboratories 
1997
- 2 to 4 hours Derby 1998
by inference from Tmax in pharmacokinetic data
4.2.2.4 Relative potency
4.2.2.4.1 Parenteral administration
The extensive literature review by Eddy et al (1957) concluded that 2.5 mg to 5 mg of 
hydromorphone can be considered equivalent in analgesic potency to morphine 10 mg (i.e. a 
relative analgesia potency ratio of 1:2-4). Controlled investigations utilising several
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different pain models have indicated that the equianalgesic ratio is somewhat higher- 
approximately 1:8.
Table 6. Summary of the double-blind studies a ssessin g  the relative analgesic potency of hydromorphone and 
morphine administered intra-muscularly
Reference n Model H:M dose ratio
Goldberg 1965 30 Trauma pain 1:5-7
Hanna 1962 39 Post-operative pain 1:7-10
Mahler 1975 112 Post-operative pain 1:8-10
Seevers 1936 a Experimental pain 1:10
Houde 1986 48 Cancer pain 1:8
Brown et al (1973) compared the respiratory depressant effects of hydromorphone (0.5, 1 
mg) and morphine (5,10 mg) given intra-muscularly to volunteers. Over the 3-hour 
observation period, the respiratory depressant relative potency o f  hydromorphone : morphine 
was 7.99 (95% Cl 5.44 - 10.69) indicating that 1.25 mg of hydromorphone was equivalent 
to approximately 10 mg of morphine. At peak respiratory depressant effect, the relative 
potency of H:M was 10.67 (95% Cl 2.75 - 87.33) suggesting that approximately 0.95 mg of 
hydromorphone was equivalent to approximately 10 mg of morphine.
The study of Houde (1986) also investigated the relative analgesic potency of oral to intra­
muscular hydromorphone. It was found that the relative potency of oral hydromorphone 
was 0.2 (or 1/5) of that for the intra-muscular formulation.
4.2.2.4.2 Oral
The values listed in the literature for the equipotency ratio o f hydromorphone compared 
with morphine range from 2 to 10. Table 7 below presents some of the values quoted from 
different literature sources.
Table 7. Equipotency values for hydromorphone versus morphine
Equipotency value Comm ents R eference
6 Pain relief provided comparable Knoll Laboratories 1997
8 Reisine 1996
4 to 8* American Pain Society 1990 
(#15)
2.67 to 4* Derby 1998
* the smaller value is derived from data derived from single-dose studies o f  morphine
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4.2.2.5 Respiratory effects
Respiratory depression was observed in early clinical reports after administration of oral 
hydromorphone 2 to 2.5 mg (as reviewed by Eddy et al 1957).
The relative potencies of intramuscular hydromorphone and morphine as respiratory 
depressants have been assayed in healthy volunteers, using a carbon dioxide response curve 
produced by rebreathing (Brown et al 1973). After randomised, double blind intra-muscular 
administration of hydromorphone 0.5 and 1 mg and morphine 5 and 10 mg, parallel 
displacement o f the carbon dioxide response curve was consistently observed, with 
hydromorphone calculated to be eight times as potent as morphine in terms of its respiratory 
depressant effect. Thus, in this experimental situation, 1.25 mg was equivalent to morphine 
10 mg.
Respiratory depression was observed in early clinical reports after administration of 
subcutaneous hydromorphone 4 to 5 mg (as reviewed by Eddy et al 1957). The respiratory 
rate fell from 14-17 breaths/minute to 8-9 breaths/minute after administration of 
hydromorphone 2 mg.
4.2.2.6 Antitussive effects
As reported by Eddy et al (1957), clinical investigation of the antitussive action of 
hydromorphone was stimulated by work in the rabbit. Most clinical work has been 
conducted in tuberculosis patients, whose symptoms were typically relieved for 3 to 4 hours 
after oral hydromorphone 2.5 mg; the antitussive response occurring at a more uniform 
dosage than the analgesic response. A 2.5-mg dose of hydromorphone was considered to be 
approximately equipotent to morphine 10 mg, and more effective than codeine 30 mg.
4.2.2.7 Dependence liability
As with all strong opioids, hydromorphone has the potential to produce physical or 
psychological dependence (addiction) and has been associated with illicit abuse and 
overdose (Anon, 1988). It should be recognised that physical dependence is not 
synonymous with psychological dependence (Kanner 1981). In cancer patients receiving 
long-term treatment, psychological dependence rarely develops. Other surveys of hospital 
use in medical patients, burns patients and cancer patients also support the view that
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medical use of opioids rarely, if ever, leads to drug abuse or iatrogenic psychological 
dependence (Porter 1980, Perry 1982).
Dependence liability of hydromorphone was discussed by Eddy et al (1957). Euphoria 
following hydromorphone had been reported in 21/27 published studies between 1926 and 
1942. Eddy concluded that hydromorphone had a euphoric action which was “somewhat 
less” than morphine at “equi-effective” therapeutic doses. He also concluded that it 
produced a “true addiction” and could effectively sustain morphine addiction at a dose 
“one-seventh that of morphine”. One of the studies referred to by Eddy reported euphoria 
to be greatest with heroin 2 mg, then morphine 8 mg followed by hydromorphone 1 mg and 
codeine 64 mg (Seevers 1936).
In a study of the effects of physical dependence, hydromorphone (mean dose 90 mg/day) 
was substituted for morphine 340 mg/day in seven patients who were psychologically and 
physically dependent on morphine (Eddy et al 1957). Abrupt drug withdrawal 12 to 17 
days after substitution resulted in an abstinence syndrome which developed more rapidly 
and was more intense but o f shorter duration than is typically observed with morphine.
4.2.2.8 Pharmacoldnetic / Pharmacodynamic comparisons
Inturrissi (1988) indicated that the degree of pain relief and sedation were a function of 
plasma concentration for both hydromorphone (n=13) and methadone (n=15) although 
Reidenberg (1988) found a poor dose-plasma concentration-analgesic effect correlation in a 
group of 43 patients with clironic severe pain with and without a nerve component (Figure 
3). This finding emphasises that inter-patient variability of response to a given dose is not 
unusual.
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Figure 3. Relationship between hydromorphone daiiy dose, hydromorphone piasma level and pain intensity in 32 
patients without nerve pain (Adapted from Reidenberg 1988)
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In summary, hydromorphone, like other p-opioid agonists, has the principal undesirable 
pharmacological effects of nausea, vomiting, sedation, constipation and respiratory 
depression. These effects necessitate the use of opioid antagonists when larger doses are 
studied in healthy volunteers in order to prevent undesirable side effects. They also impair 
the ability to completely blind a placebo-controlled study of hydromorphone. The 
unwanted pharmacological effects occur irrespective of the route o f administration, but can 
be minimised by using careful titration and prophylactic treatment as appropriate (Mather 
1999) .
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4.3 Metabolism
4.3.1 Pharmacokinetics and Product Metabolism in Animals
4.3.1.1 Absorption
Absorption of hydromorphone was rapid after oral administration in New Zealand White 
rabbits (Chang 1988) and after IP administration in rats (Zheng 1997). The plasma 
pharmacokinetics were very similar across species with linear kinetics, biphasic profiles and 
rapid disappearance from plasma (Chang 1988). However plasma pharmacokinetics may 
not reflect pharmacokinetics in the brain (Hartvig 1989). Oral bioavailability in the male 
rabbit is reported to be 20 % with a plasma half-life of 2.9 hours (Chang 1988). Serum 
binding is low (19±9%, or less) (Parab 1988, Reidenberg 1988) and is mediated by albumin, 
with minimal contribution from ai-acid glycoprotein.
4.3.1.2 Distribution
In the rhesus monlcey, opioid receptor binding was greatest in the amygdala (particularly in 
the anterior portion) followed by the thalamus, hypothalamus, caudate nucleus, and 
midbrain. Binding was low in the cortex, dentate nucleus of the cerebellum, lower 
brainstem, and spinal cord (Kuhar 1973). Following intravenous administration of 10-20 pg 
of radiolabelled hydromorphone to rhesus and cynoniolgus monkeys, radioactivity in the 
brain plateaued at 10-15 min post-injection. In extracranial soft tissue, drug appeared more 
slowly reaching an uptake of 0.70 at 30 min (Hartvig 1989). Radioactivity in the brain was 
low in both primate speeies but the uptake into the brains of rhesus monkeys was 1.4 times 
that seen in cynomolgus monkeys. Plasma elimination half-lives for the rhesus and 
cynomolgus monlceys were 50 and 60 min, respectively.
4.3.1.3 Metabolism and excretion
Opioid agonists are metabolised primarily in the liver, with a small amount o f metabolic 
activity also present in the CNS, kidneys, lungs, and placenta (AHFS 1996). In the rabbit, 
hydromorphone is metabolised by conjugation and reduction to form the 6-a- and 6-p-OH 
metabolites, dihydromorphine and dihydroisomorphine (Cone 1977). Hydromorphone is 
eliminated in a biphasic manner - elimination rate constants after IV (5 mg/kg) and oral (20 
mg/kg) administration in the rabbit were -  0.29 and ~ 0.24, respectively (Chang 1988).
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After a single-dose of hydromorphone, the parent compound and both the 6-a- and 6-p-OH 
metabolites were present in the urine of rats, guinea pigs, rabbits, dogs and humans (Cone 
1977). Free or conjugated hydromorphone predominated: levels of free or conjugated 6-p- 
OH metabolites were generally equal to or higher than those o f the 6-a-OH metabolites. 
Levels of these two metabolites were higher in the guinea pig than in the other species 
studied (8 % and 20 % for the a- and p- forms, respectively, in the guinea pig, 1 - 2 % and 2 
- 5 % respectively in other species). Total recovery of drug and metabolite from the urine 
o f the rat, guinea pig, rabbit and dog were 32 %, 73 %, 28.6 % and 65.4 %, respectively.
The time course for excretion of drug was similar between species with a large majority of 
drug being excreted within 24 h.
4.3.2 Metabolism and Pharmacokinetics in man
4.3.2.1 Metabolism
Hydromorphone has been credited with a lack of active metabolites in contrast to morphine, 
which has an active metabolite, morphine-6-glucuronide (Mather 1999). Indeed, this active 
metabolite is being investigated as an analgesia development project by the pharmaceutical 
company, CeNeS (Anon. 2001). The site of production of the glucuronides to morphine and 
hydromorphone is assumed to be the liver, although for morphine, there is evidence that 
considerable glucuronidation takes place in the intestine (Mikus 1999).
In a study of 24 cancer pain patients receiving variable doses o f hydromorphone by the oral 
or subeutaneous route, single blood samples were used to examine metabolite profiles 
(Quigley 1999). The principal metabolite was hydromorphone-3-glucuronide, with a 61:1 
ratio for FI-3-G:HM. Other metabolites identified were dihydromorphine-6-glucuronide 
(ratio 1.7:1) and dihydromorphine (ratio 0.5:1). The authors suggest that the 6-glucuronide 
metabolite may have pharmacological activity. The authors do not comment on different 
ratios when parenteral and oral routes were compared -  with hydromorphone being subject 
to significant first-pass metabolism, this factor would be expected to be important. In a 
further study o f 18 patients with chronic cancer pain, Hagen (1995) reported a 27:1 ratio of 
H-3-G to parent.
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Urinary excretion of hydromorphone is predominantly in the form of the glucuronide 
(37.9% of administered dose), with 5.6% being free hydromorphone. Of the conjugated 
drug, 1.1% of the administered dose was hydroxy metabolites (Cone 1977).
No references relating to hydromorphone interactions were found in the literature, and 
examples for morphine do not give a consistent indication of known interactions.
4.3.2.2 Pharmacokinetics
43.2.2.1 Genera!
Hydromorphone is rapidly absorbed after oral administration and undergoes extensive first- 
pass metabolism, resulting in oral bioavailability of 18.7% (Drover 1999) not disimilar to 
morphine (29.2%, Hasselstrom 1993). The bioavailability for rectal administration is 
reported as 33% (Parab 1988), but this same paper quotes a value of 50.7% for oral 
bioavailability. The inflated value for oral bioavailability may be a reflection of a less 
specific assay (Hind 2000) in this study. This would, therefore, suggest that in reality, 
bioavailability via the rectal route is well below the 33% value quoted. Hydromorphone 
crosses the placenta (Martindale 1993) and is found in low levels in breast milk (Ellenhorn 
1988). Serum protein binding (species not specified) is quoted as 7.1% and the volume of 
distribution is 2.9 L/kg (Parab 1988).
4.3.2.2.2 Intravenous administration
Parab (1988) reports that after administration of a 2-mg intravenous dose of hydromorphone 
to a group of nine healthy male volunteers, three minutes after administration of the dose, 
63% of the administered hydromorphone had left the plasma and distributed to other tissues. 
The authors reported that this was consistent with findings from studies in mice where 
hydromorphone had distributed within 3.5 minutes of rapid intravenous infusion to well 
perfused organs such as the liver, spleen, kidney and skeletal muscle. The plasma 
concentration-time curve showed a distinct distribution phase followed by a terminal 
elimination phase. Parab quotes a distribution half-life of 0.07 hours. A terminal elimination 
half-life of 2.36 hours is quoted, but these data are based on a less specific assay method 
than that used in the current set of studies described below (Hind 2000). Hill (1991) 
confirmed that pharmacokinetics of 45-second intravenous infusions were dose-proportional 
over the dose range 10 to 40 pg/kg.
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4.3.2.2.3 Iminediate-release formulation
4.3.2.2.3.1 PHARMACOKINETICS AND DOSE PROPORTIONALITY
In an open, randomised, three-way crossover study in 27 healthy male Caucasian 
volunteers, aged from 19 to 53 years, the dose proportionality and the pharmacokinetics of 
inimediate-release hydromorphone following single oral doses of 2 mg, 4 mg and 8 mg 
were examined (Durnin 2001a). The statistical testing performed consisted of 90% 
confidence intervals (CIs) based on the differences between doses (pairwise comparisons) 
as a test of dose proportionality where Cmax and AUC were dose adjusted and log- 
transformed prior to analysis. Also, a regression analysis of Cmax and AUC with dose was 
used to examine linearity across all dose levels simultaneously, as a test of dose 
proportionality.
Hydromorphone was rapidly absorbed into the systemic circulation, reaching peak plasma 
concentrations within 1 hour of dosing (Figure 4). Elimination was multiphasic; there was a 
rapid decline in plasma concentrations within the first 3 hours after dosing followed by 
slower elimination. Because of the secondary peaking, kel was poorly defined for many of 
the profiles and hence AUC(O-co) was unavailable for use in the analysis of dose 
proportionality.
Figure 4. Mean plasma concentrations of hydromorphone following single oral d oses of hydromorphone IR to 
healthy volunteers
5-,
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The statistical regression analysis indicated that Cmax and AUC(0-24h) for hydromorphone 
were proportional to dose level (Table 8). With a doubling of dose, increases of 104% and 
88% were estimated for these parameters, respectively.
Table 8. Mean pharmacokinetic parameters of hydromorphone following single oral d o ses  of hydromorphone IR to 
healthy volunteers
Parameter Dose of hydromorphone 90% Cl of
2 mg 4 mg 8 mg regression
(n=2 6) (n=26) (n=25) coefficient
Cmax 1.25 ± 2.50 ± 5.38 ± 0.94, 1.13
(ng/ml) 0.44 0 . 96 ' 2 . 2 6
Tmax (h) 0.73 ± 0.68 ± 0.74 ± -0.09, 0.19
0. 46 0. 42 0.  31
AUC (0- 4.28 ± 7 . 94 ± 15.0 ± 0.88, 0.95
24h) 0 . 90 1. 65 3 . 0 6
(ng.h/ml)
Results given as mean ± sd
Regression coefficient for log
e
(dose)
Pairwise statistical comparison of pharmacokinetic parameters between dose levels 
confirmed dose proportionality of Cmax and AUC(0-24h) for hydromorphone, since 
90% CIs for the differences between doses were within the (-20% , 25%) range (Table 9). 
The specified range for the confidence intervals is derived from European Union regulatory 
guidelines (EEC 1998).
Table 9. 90% Cl from analysis of variance of dose proportionality comparisons
Parameter 90% confidence intervals^
4 mg - 2 mg 8 mg - 2 mg 8 mg - 4 mg
Cmax -10%, 15% -7%, 19% -8%,  17%
(ng/ml)
Tmax (h) ^ -34%,  0% -17%, 17% 0%, 37%
AUC(0-24h) -12%, -2% -16%,  -7% -9%, 0%
(ng.h/ml)
90% Cl presented for mean difference between doses, 
expressed as a percentage of the lowest dose mean. For 
Cmax and AUC(0-24h), CIs are based on the log- 
transformed data; back-transformed CIs are presented 
 ^ Based on median difference
The results indicated that the pharmacokinetics of oral immediate-release hydromorphone 
were linear over the 2-mg to 8-mg dose range studied.
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4.3.2.2.3.2 FOOD EFFECT AND WITHIN-SUBJECT VARIABILITY
111 an open, randomised, two-treatment (fed and fasted), tlmee-way crossover study in 
24 healthy Caucasian volunteers, the effect o f food on the pharmacokinetics of 
hydromorphone after a single oral 8-mg dose of immediate-release hydromorphone (Durnin 
2001b). Additionally, the within-subject variability in pharmacokinetics o f hydromorphone 
after single fasted oral 8-mg doses of IR was assessed. The statistical analysis consisted of 
90% confidence intervals (Cl) for the differences between the fed and fasted regimens for 
bioequivalence assessment. Estimates of within and between subject variability were 
derived.
The plasma profiles of hydromorphone given without food were very similar to those 
previously observed, with rapid absorption into the systemic circulation reaching Cmax 
within 1 hour (Figure 5). For hydromorphone taken after food, absorption was less rapid, 
and Cmax was lower and occurred slightly later, although still within 1.5 hours o f dosing 
(Figure 5, Table 10). Elimination was multiphasic for both regimens, but the initial rapid 
decline in plasma concentrations was less marked after food. A slower terminal elimination 
phase started about 8 hours after dosing. The terminal half-life of hydromorphone was 
similar for both regimens at around 15 hours. Although peak plasma concentrations were 
lower and occuiTed later after food, AUC increased by 30% indicating greater 
bioavailability of hydromorphone when taken with a meal. A similai’ increase in 
bioavailability after a high-fat meal has previously been documented with morphine 
(Gourlay 1989) and have been reported for other agents where mechanisms of the increase 
with food have been conjectured to be related to changes in the ability of the liver to 
metabolise highly-extracted drugs (Olsson 2001).
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Figure 5. Mean plasma concentrations of hydromorphone in healthy male volunteers following single oral 8-mg 
d oses of hydromorphone IR given with and without food
—o— fasted  1 (n=24) 
fasted  2 (n=24) 
fed (n=24)3 -
2 -
*
Time (h)
Table 10. Mean pharmacokinetic parameters of hydromorphone in healthy male volunteers following single oral 8- 
mg d o ses  of hydromorphone IR given with and without food
Parameter Fasted 1 Fasted 2 Fed 90% Cl for
(n=24) (n=24) (n-24) di f ference^
Cmax
(ng/ml)
4 . 69 ± 
1.71
4.78 ± 
1.75
3.54 ± 
1.38 -33%, -16%
Tmax (h)
0.63 ± 
0 . 2 9
0.51 ± 
0 . 21
1.31 ± 
0. 90 56%, 178%^
AUC(0- 
24h)
12.2 ± 
9 9 12.2 ± 2.7
1 6 . 5  ±
3,5 29%, 42%(ng.h/ml)
AUC (O-oo) 
( n g .h/ml)
16. 9 ± 
3 . 5 
(n=13)
16.9 ± 6.6 
(n=15)
21. 5 ± 
5.3 
(n=19)
13%, 37%
90% Cl presented for mean difference, expressed as a percentage o f  the fasted treatment mean. For 
Cmax and AUC, CIs are based on the log-transformed data; back-transformed CIs are presented 
Based on median difference
Statistical analysis of the pharmacokinetic parameters after administration with and without 
food showed that the two regimens were not equivalent for AUC(0-24h) or Tmax 
(differences were 35% and 111%, respectively) and equivalence could not be confirmed for 
Cmax and AUC(O-oo) (differences were -25% and 24%, respectively). Within-subject 
variability (coefficient of variation), estimated from the two study periods with 
administration while fasted, was considerably less for AUC(0-24h) (about 10%) than for 
Cmax (about 30%).
The conclusion from this study is that there is a statistically significant effect of food on the 
pharmacokinetics of hydromoiphone after dosing with immediate-release tablets, but the
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effects observed are not clinically relevant. The mean effect of food on bioavailability, at 
around 30%, is larger than the intra-individual variability. Nevertheless, this degree of 
variability is unlikely to be clinically relevant, given the multitude of other factors affecting 
analgesic effect. These other variables include mobility, wakefulness and dosing interval. In 
terms of possible safety concerns of the increased bioavailability, this is unlikely since the 
increase in plasma levels was not a product of increased Cmax, but rather elevated levels 
towards the end o f a notional 4-hourly dosing interval. The delay in Tmax with food is also 
unlikely to be clinically relevant since one would assume that if a patient required rapid 
onset o f effect of analgesia, they would probably not be eating a high fat meal at the time.
4.3.2.2.3.3 THE EFFECT OF SEX OF HEALTHY VOLUNTEERS ON 
PHARMACOKINETICS
In an open, parallel-group, single-dose study in 36 healthy Caucasian volunteers, 18 male 
and 18 female, aged 18 to 43 years, the pharmacokinetics of hydromorphone in male and 
female volunteers was compared after a single oral 8-mg dose of immediate-release 
hydromorphone (Durnin 2001c). The statistical analysis consisted of AUC and Cmax being 
log-transformed prior to analysis and 95% confidence intervals (CIs) for the differences 
between groups based on the two-sample t-statistic were calculated.
Plasma profiles were similar for males and females (Figure 6); hydromorphone was rapidly 
absorbed into the systemic circulation, reaching Cmax within 1 hour. Elimination was 
multiphasic; there was a rapid decline in plasma concentrations with a half-life of about 
1.9 hours and some evidence of biliary recycling around 12 hours after dosing. This half-life 
value is similar to previously published values quoted as the terminal elimination half-life of 
hydromorphone (Vailner 1981) and most importantly, this half-life value is representative 
of the effective clinical activity of hydromorphone.
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Figure 6. Mean plasma concentrations of hydromorphone in healthy male and female volunteers following a single  
oral 8-mg d ose of hydromorphone IR
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A slow terminal elimination phase started about 8 hours after dosing, but plasma levels of 
hydromorphone had already fallen to around 10% of Cmax by this time. Because of the 
secondary peaking, kel was poorly defined and could not always be calculated. The mean 
value of the terminal half-life for hydromorphone was around 17 hours in the male 
volunteers (13 o f 18) and 13 hours in the female volunteers (9 of 18).
The effect of sex on the pharmacokinetics of hydromorphone was an increase in Cmax 
(30%) but a difference of less than 2% in AUC(0-24h) in the female group compared to the 
male group (Table 11). From an incomplete dataset, terminal rate constant was 39% greater 
for the female group compared to the male group; however the difference in AUC(O-oo) was 
0.5%. No difference was observed between groups for Tmax.
Table 11. Mean pharmacokinetic parameters of hydromorphone in healthy male and female volunteers following a 
single oral 8-mg dose of hydromorphone IR
Parameter Female (n=18) Male (n=18) 95% C I ^
Cmax (ng/ml) 5.12 ± 3.07 4.09 ± 2.12 - 9 % , 8 5 %
Tmax (h) 0.75 ± 0.31 1.01 ± 0.82 - 4 9 % , 2 5 % ^
AUC(0-24h) 13.4 ±4.7 13.0 ±3.5 -17%,25.1%
(ng.h/ml)
Results presented as mean ± sd
 ^ 95% Cl presented for mean difference^ expressed as a
percentage of the male group mean. For Cmax and AUC, 
CIs are based on the log-transformed data; back- 
transformed CIs are presented 
 ^ Based on median difference
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This study demonstrated that sex had little effect on the pharmacokinetics of oral 
immediate-release hydromorphone. There were no significant differences in AUC(0-24h) 
between the two groups. The difference in Cmax between the two groups is similar to the 
effect previously documented with morphine (McQuay 1990) and is not considered to be 
clinically relevant.
4.3.2.2.3.4 AGE EFFECT
In an open, parallel-group, single-dose study in 36 healthy Caucasian volunteers, 18 young 
(age range 18 to 38 years) and 18 elderly (age range 65 to 74 years) were enrolled to study 
the effect o f age on the pharmacokinetics of hydromorphone after a single oral 4-mg dose of 
immediate-release hydromorphone (Durnin 200Id). For the statistical analysis, AUC and 
Cmax were log-transformed prior to analysis and 95% confidence intervals (CIs) for the 
differences between groups based on the two-sample t-statistic were calculated.
Plasma profiles were similar for young and elderly subjects; hydromorphone was rapidly 
absorbed into the systemic circulation, reaching Cmax within 1 hour (Figure 7). Elimination 
was multiphasic; there was a rapid decline in plasma concentrations with a half-life o f about
1.6 hours for the young and 1.9 hours for the elderly with some evidence of biliary 
recycling 8 to 12 hours after dosing.
Figure 7. Mean plasma concentrations of hydromorphone in healthy young and elderly volunteers following a single 
oral 4-mg d ose  of hydromorphone IR
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A slow terminal elimination phase started about 8 hours after dosing, but plasma levels of 
hydromorphone had already fallen to around 9% and 13% of Cmax by this time for the 
young and elderly groups, respectively. Because of the secondary peaking and the 
comparatively low 4-mg dose used in this study, kel was poorly defined and could not 
always be calculated. The mean value of the terminal half-life for hydromorphone was 
around 12 hours in the young volunteers (8 of 18) and 15 hours in the elderly volunteers (8 
of 18).
The effect of age on the pharmacokinetics of hydromorphone was a modest increase in 
AUC(0-24h) (11%) but a reduction in Cmax (14%) in the elderly compared to the young 
(Table 12). No difference in Tmax was observed. From an incomplete dataset, terminal rate 
constant was reduced by 8% and AUC(O-D) was increased by 10% for the elderly group 
compared to the young group.
Table 12. Mean pharmacokinetic parameters of hydromorphone in healthy young and elderly volunteers following a 
single oral 4-mg dose of hydromorphone IR
Parameter Young
(n=18)
Elderly 
(n=18)
% mean 
diff.
95% CI^
Cmax (ng/ml) 2.49 ± 0.88 2.21 ± 1.06 -14% - 36%,r 16%
Tmax (h) 0.74 ± 0.48 0.75 ± 0.34 0% 0%, 34%^
AUC (0-24h) 6.1 ± 1.3 7.0 ± 2.4 11% -9%, 34%
(ng.h/ml)
Results presented as mean ± sd
 ^ 95% Cl presented for mean difference, expressed as a
percentage of the young group mean. For Cmax and 
AUC(0-24h), CIs are based on the log-transformed data; 
back-transformed CIs are presented 
 ^ Based on median difference
Overall, age had little effect on the pharmacokinetics of hydromorphone. The reduction of 
14% in Cmax and increase of 11% in AUC(0-24h) in the elderly are not considered to be 
clinically relevant. Data from this study therefore indicate that there is no need to adjust the 
starting dose of oral immediate-release hydromorphone in the elderly.
4.3.2.2.3.5 RENAL IMPAIRMENT
An open, parallel-group, single-dose study of 23 volunteers examined the effect of renal 
impairment on the pharmacokinetics of hydromorphone (Durnin 200 le). Volunteers were 
divided into tlii'ee categories of renal impairment according to serum creatinine values 
which were used to derive a creatinine clearance value using the Cockcroft Gault equation
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(Cockcroft 1976). Seven volunteers were recruited with normal renal function (creatinine 
clearance (Cl ):>80 ml/min), eight with moderate renal impairment (Cl : 40-60 ml/min)
Cr Gl­
and eight with severe renal impairment (Cl ; <30 ml/min, including those receiving
Cr
dialysis). The statistical analysis of the data involved analysis of covariance with factors for 
renal group and sex and a covariate for age on log-transformed Cmax and AUC with 
corresponding 95% confidence intervals (CIs).
In the volunteers with normal renal function, hydromorphone was rapidly absorbed reaching 
Cmax within 1 hour (Figure 8). Concentrations of hydromorphone in subjects with 
moderate renal impairment were higher than in subjects with normal renal function. In the 
severe renal impairment group, Cmax was similar to normal volunteers but occurred later 
and was followed by more sustained plasma levels of hydromorphone. Elimination was 
multiphasic in all groups; there was a rapid decline in plasma concentrations for the groups 
with normal and moderately-impaired renal function, a slower decline in the severely- 
impaired group, followed by a slow terminal elimination phase for all groups (Table 13).
Figure 8. Mean plasma concentrations of hydromorphone in volunteers with normal renal function and moderate 
and severe renal Impairment following a single oral 4-mg dose of hydromorphone IR
--0 — severe renal impairment (n=8) 
moderate renal impairment (n=8) 
— normal renal function (n=7)2  1.5_
£2 0.5 J
0 2 4 6 8
Time (h)
28/09/01
MD Thesis for Dr Colin JA Durnin 2001 Page 35
Table 13. Mean pharmacokinetic parameters of hydromorphone in volunteers with normal renal function and 
moderate and severe renal impairment following a single oral 4-mg dose of hydromorphone IR
Parameter
Normal
(n=7)
Renal function 
Moderate 
impairment 
(n=8 )
Severe 
impairment 
(n=8 )
Cmax 1.8 ± 0.6 2.6 ± 1.0 1.4 ± 0.4
(ng/ml)
Tmax (h) 0 . 68 ± 0.19 0.84 ± 0.50 1.96 ± 0.98
AUC (0-t) 8.5 ± 3.1 16.9 ± 6.3 26.8 ± 7.5
(ng.h/ml)
AUC (0-w) 11.3 ± 2.7 20.8 ± 5.7 5 0 . 2  + 2 6 . 7
(ng.h/ml)
kel (/h) 0.077 ± 0.057 0.050 ± 0.012 0.021 ± 0.012
(h) 14.8 ± 11.3 14.4 ± 3.5 39.4 ± 16.0
Results given as mean ± sd
Hence, renal impairment produced changes in the pharmacokinetics of hydromorphone. The 
increased plasma levels of hydromorphone in the group with moderate renal impairment 
resulted in 2-fold increases in mean Cmax and AUC (95% Cl: 43%, 196%). For the group 
with severe renal impairment, hydromorphone appeared to be both more slowly absorbed 
and metabolised, with more sustained levels of hydromorphone, resulting in a 4-fold 
increase in AUC (95% Cl: 168%,502%).
Two subjects with severe renal impairment were given a 4-hour haemodialysis about 
48 hours after dosing; post-dialysis plasma levels of hydromorphone were approximately 
40% of pre-dialysis levels.
The study concluded that the effects of renal impairment on the pharmacokinetics of 
hydromorphone were increases in AUC with decreasing renal function. This is similar to the 
findings of studies of the effects of renal impairment on the pharmacokinetics of morphine 
(Osborne 1994) and the effects may be attributable to the effects of renal dysfunction on 
hepatic clearance of drug (Terao 1985). The ratio of hydromorphone AUCs for normal 
volunteers and subjects with moderate or severe renal impairment was approximately 1:2:4, 
respectively. Haemodialysis was effective at reducing plasma levels of hydromorphone.
Therefore, patients with moderate renal insufficiency should be started on a reduced dose 
and closely monitored during dose titration. In patients with severe renal insufficiency an 
increased dosing interval should also be considered and these patients should in addition be
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monitored during maintenance therapy. Published reports suggest that hydromorphone is 
reasonably well tolerated in patients with impaired renal function (Lee 2001).
4.3.2.2.3.6 HEPATIC IMPAIRMENT
An open, parallel-group, single-dose study in 24 volunteers, 12 with normal hepatic 
function and 12 with moderate hepatic impairment was performed to compare the 
pharmacokinetics of hydromorphone in the two groups (Durnin 20011). Moderate hepatic 
impairment was defined as a Child-Pugh score of 7 to 9 (Child-Pugh score is derived by 
scoring ascites, encephalopathy, bilirubin, albumin and prothrombin time: 5 points = normal 
hepatic function to 10 points = severe hepatic impairment [Pugh 1973]). The cause of 
hepatic impairment was alcoholic cirrhosis in all cases. For the statistical analysis of the 
data, AUC and Cmax were log-transformed prior to analysis and 95% confidence intervals 
(CIs) for the differences between groups were based on the two-sample t-statistic.
Hydromorphone was rapidly absorbed in both groups, reaching Cmax within 1 hour 
(Figure 9). Plasma concentrations of hydromorphone were higher in the subjects with 
moderate hepatic impairment than in subjects with normal hepatic function. This was 
probably a consequence of reduced first-pass metabolism.
Figure 9. Mean plasma concentrations of hydromorphone in volunteers with normal or moderately-impaired hepatic 
function following a single oral 4-mg dose of hydromorphone IR
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Elimination was multiphasic in both groups with an initial rapid decline in plasma 
concentrations followed by a slower elimination phase. Furthermore the terminal
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elimination characteristics of hydromorphone were similar, i.e. reduced hepatic function did 
not have any major effect on elimination of hydromorphone.
The effect of hepatic impairment on the pharmacokinetics of hydromorphone was shown to 
be a marked 4-fold increase in both Cmax and AUC (Table 14). No difference in Tmax was 
observed. No major changes in elimination were observed; the apparent differences may be 
a consequence o f the higher plasma concentrations in hepatic impairment allowing the 
elimination phase to be better defined.
Table 14. Mean pharmacokinetic parameters of hydromorphone in volunteers with normal or moderately-impaired 
hepatic function following a single oral 4-mg d ose of hydromorphone IR
Parameter Hepatic function 
group 
Normal Moderate 
(n=I2) impairment 
(n=12)
% mean 
difference
95% C l ^
Cmax 2 . 0  ± 8.3 ± 4.2 303% 150%, 551%
(ng/ml) 1.3
Tmax ( h ) 0.77 ± 1.09 ± 1.14 0% -65%, 65%^
0.49
AUC ( 0 - 4 8 ) 10 . 4 ± 41.8 ± 14.7 285% 192%, 409%
( n g . h / m l ) 2.3
AUC (O-oo) 11. 6 ± 43.2 +14.8 254% 173%, 359%
( n g . h / m l ) 2 . 0
kel (/h) 0.064 ± 0.090 ± 40% 13%, 66%
0.018 0 . 0 2 2
(h) 11.5 ± 8.3 ± 2.5 *“
3.0
R e s u l t s  p r e s e n t e d  a s  m e a n  + s d
 ^ 95% Cl presented for mean difference, expressed as a
percentage of the normal group mean. For Cmax and AUC,
CIs are based on the log-transformed data; back- 
transformed CIs are presented 
 ^ Based on median difference
The study showed that the effect of moderate hepatic impairment on the pharmacokinetics 
of hydromorphone is an increase in hydromorphone bioavailability, as demonstrated by the 
higher plasma concentrations of hydromorphone and the 4-fold increases in Cmax and 
AUC, compared to the group with normal hepatic function. Therefore, patients with 
moderate hepatic insufficiency should be started on a reduced dose and closely monitored 
during dose titration.
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4.3.2.2.4 Controlled-release formulation
4.3.2.2.4.1 DOSE PROPORTIONALITY
111 a study of 12 healthy young volunteers, the single-dose pharmacokinetics of the 
controlled-release formulation were compared with the immediate release tablets (Angst 
2001). The findings are presented in Table 15.
Table 15. Pharmacokinetic indices after administration of immediate- and controlled-release hydromorphone
Dose Peak plasma 
concentration 
(ng/ml)
Time to peak Cp 
(h)
First-time Cp > 
50% Peak (h)"
Last-time Cp > 
50% peak (h)"
Duration Cp > 
50% peak Cp 
(h)'
8 mg IR 4.74 ± 1.76 0.8 (0 .8 - 1.0) 0,4 ± 0.2 1.6 ±0.8 1.1 ± 0.7
8 mg CR 0.77 ± 0.33 12.0 (9 .0 -13 .5 ) 5.4 ± 1.7 30.9 ± 10.6 24.2 ± 10.3
16 mg CR 1.45 ± 0.43 15.0 (12 .0 - 
18.0)
6.1 ±2.3 31.5 ±9.4 21.6 ± 8.1
32 mg CR 2.41 ±0.85 16 .5 (12 .0 -
21.0)
5.5 ±1.8 35.8 ±6 .9 26.5 ± 7.5
Data are mean ± SD or median and interquartile range.
a This value represents the time after dosing when the piasma concentration first rises to 50% of the Cmax 
b This value represents the time after dosing when the plasma concentration first fails to 50% of the Cmax 
c This value represents the amount of time that the plasma concentration remains at levels greater than 50% of Cmax.
The controlled-release formulation clearly achieves a very flat profile of release compared 
with the immediate-release form and appears to be of practical use for once-daily dosing.
In a study of 31 young healthy volunteers (Velagapudi 2001a), dose-proportional 
pharmacokinetics were confirmed over the tablet strengths of 8, 16, 32 and 64 mg. 
Additionally, other pharmacokinetic data were consistent with those reported from the 
Angst study (see Table 16). Naltrexone doses were co-administered with hydromorphone to 
protect the subjects from severe adverse pharmacological effects of administration of 
hydromorphone.
Table 16. Pharmacokinetic data from study of 31 young healthy volunteers. 
Mean {± SD)
Pharmacokinetic
Parameters
8 mg 16 mg 32 mg 64 mg
Tmax (h) 16.0 (7.2) 16.8(5 .4) 15.7(5.4) 17.4 (5.7)
T,/2 (h) 10.6 (4.3) 10.3 (2.4) 11.0 (3.2) 10.9 (3.8)
Cmax (ng/mL) 0 .929 (1 .01 ) 1.69 (0.78) 3.25 (1.37) 6.61 (1.75)
AUC 0-48 
(ng.h/mL)
18.1 (5.8) 36.5 (11.3) 72.2 (24.3) 156 (30.6)
AUC 0-INF  
(ng.h/mL)
19.5(5 .9) 40 .8 (13 .7 ) 80.3 (29.6) 178.7 (35.2)
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4.3.2.2.4.2 BIOAVAILABILITY
The Angst study was reported in a separate abstract where the absolute bioavailability data 
were presented (Drover 1999). These data were derived from the pharmacokinetics of an 8- 
mg dose of intravenous hydromorphone which was administered during a preceding 
treatment phase of this study. The absolute bioavailability o f the controlled-release 
formulation ranged from 22.0% to 25.9% for the three doses o f controlled-release tablets 
that were tested. These figures compare with 18.7% for the immediate-release tablet. These 
differences are not statistically significant, however. A further study comparing the AUC of 
the controlled-release formulation versus the immediate-release form after dosing to steady 
state confirmed greater bioavailability with the CR form (Shah 1997). The respective values 
for AUC (not specified, but presumably 0 - 2 4  hours) were 45.6 and 41.7 ng.h/ml. This 
study also measured hydromorphone-3-glucuronide and reported similar levels of the 
metabolite with both formulations, but greater parent drug:metabolite ratios with the CR 
formulation which is further evidence for greater bioavailability. Steady state was achieved 
by day two of the four-day study.
The trend towards increased bioavailability with controlled-release formulation dosing may 
be a result of relatively greater absorption of the dose from the lower GI tract. This assumes 
that at the time of peak plasma coneentration, the OROS tablet has progressed significantly 
further down the GI tract than the area of absorption of a dissolved immediate-release tablet 
(which is presumably the duodenum and proximal jejunum). Another factor that could 
account for a greater bioavailability after single doses of the controlled-release formulation 
is the effect of food on bioavailability (see above). The time of fasting in healthy volunteer 
studies tends to range from two to four hours after dosing. During this time period, the vast 
majority o f absorption following administration of an immediate-release tablet would have 
taken place. In contrast, the absorption of hydromorphone in solution, released from the 
controlled release formulation, would still be taking place around the time of meals being 
administered to the volunteers (conventionally, around four to eight hours after dosing). 
Therefore, the increased bioavailability observed with the controlled-release formulation 
could be an artefact of the timing of meals in single dose pharmacokinetic studies.
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4.3.2.2A.3 FOOD EFFECT
In a study of 27 healthy volunteers (Velagapudi 2001b), 16-mg single doses o f the 
controlled-release formulation o f hydromorphone were given in both the fed and fasted state 
to assess the effect o f food on the pharmacokinetics of the controlled-release formulation. 
While the Tmax was significantly earlier (p<0.01) for (fed) treatment B (12.0 h) compared 
with (fasting) treatment A (16.0 h), Cmax values for treatment B (1.352 ng/ml) were within 
20% of those for treatment A (1.107 ng/ml). The AUCs were within 10% for treatment B vs 
treatment A (AUC 0-48: 30.20 vs 31.12 ng.li/ml, and AUCO-INF: 36.09 vs 38.84 ng.M nl, 
respectively). The 90% confidence interval for In AUC 0-INF (fed vs fasted) was 81.9% to 
99.4%. Thus, the results suggested that the effect of food is not likely to be clinically 
significant.
4.4 Acute pain models
4.4.1 Placebo-controlled studies with oral hydromorphone in acute pain
Tliree placebo-controlled studies involving oral hydromorphone in patients with a variety of 
acute or chronic painful conditions have demonstrated the analgesic superiority of 
hydromorphone over placebo. Two studies compared two dosage levels of oral 
hydromorphone (Table 17).
One of these studies (Goldberg 1965) was a multiple-dose study over a period of between 2 
days and 4 weeks. In this trial, in which 2 mg or 4 mg oral hydromorphone was given 4 to 
6 hourly both doses of hydromorphone were shown to be analgesically superior to placebo 
as measured by categorical scales of pain relief. The higher dose (4 mg) was more effective 
than the lower dose (2 mg).
One trial (Jain 1989) compared the efficacy of a single dose of 5 mg with 10 mg 
hydromorphone given as an oral solution in patients with moderate or severe post-operative 
pain. In all measures of analgesia, hydromorphone was superior to placebo and 10 mg was 
superior to 5 mg. In the active groups, onset of analgesia was prompt and peaked around 3 
hours post-dose.
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In both o f these studies, oral hydromorphone was well tolerated at all doses, although the 
occurrence of unwanted effects tended to be less frequent with the lower dose than with the 
higher dose. Somnolence and drowsiness were the most frequently reported adverse events. 
There were no reports of serious adverse events. These studies serve to support the 
analgesic potency and tolerability of oral hydromorphone on a dose-related basis.
A further placebo-controlled study assessed the value of oral hydromorphone (2 mg) plus oral 
lorazepam (2 mg) in reducing pain and anxiety in patients undergoing outpatient bone marrow 
biopsy and aspiration (Wolanskji 1998). There was no difference between placebo and 
hydromorphone plus lorazepam for these parameters.
Table 17. Placebo-controlled studies with oral hydromorphone in acute pain
Author; year; country indication; dose of 
hydromorphone 
(H) { mg)
Design; number of 
patients; 
Duration
Comparator; 
dose ( mg)
Global clinical outcome 
Efficacy Tolerability
Goldberg 1965; USA Acute trauma; 
2 mg or 4 mg 
qds
db;
30;
2 days to 
4 weeks
Placebo (P) H4 mg 
>H2 mg 
>P
P
=H2 mg 
?>H4 mg
Jain 1989; USA Post-operative
pain;
5 mg or 10 mg oral 
solution as single 
dose
db;
61;
6 hours
Placebo (P) H10 mg 
>H5 mg 
>P
P
>H5 mg 
>H10 mg
Wolanskyi 1998; USA Bone marrow 
biopsy and 
aspiration;
2 mg single dose 
(H) plus 2 mg oral 
lorazepam (L)
db;
25;
24 hours
Placebo (P) P=
H+L
Not stated
qds = four times daily; db = double blind; > = descriptively or statistically better than;^’ = trend in favour of; = = 
equivalent
4.4.2 Comparative clinical studies between oral hydromorphone and other 
analgesics in acute pain
Two clinical studies have compared the effect of oral hydromorphone with the comparator 
being morphine in one case and meperidine (pethidine) in the other (Table 18). These 
studies have indicated a morphine:hydromorphone dose equivalence ratio of 6-7.5:1 in 
patients with post-operative pain and that both exhibited unwanted effects typical of opioid 
drugs. Further, hydromorphone was analgesically superior to meperidine (pethidine) in oral 
surgical pain.
Turek (1987) compared the effect of a 5 mg or 10 mg oral solution of hydromorphone given 
as a single dose, with that of 30 mg or 60 mg of morphine using the same formulation and
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route, in 21 patients with moderate to severe post-operative pain. The results indicate that 
in terms o f analgesic potency, measured by categorical scales, hydromorphone 5 mg was 
therapeutically equivalent to 30 mg morphine and 10 mg to 60 mg respectively. This 
suggests a potency ratio of 6:1 for morphine: hydromorphone given by the oral route.
Nasits (1969) compared the efficacy of two different dosages of oral hydromorphone with 
meperidine (pethidine) in 39 patients with pain following oral surgery. Dosages of 
hydromorphone were 1.5 or 2.0 mg and that for meperidine (pethidine) was 100 mg, all 
given 3 hourly for a maximum of 4 doses. Using measures of pain relief as being 
“complete”, “partial” or “none”, a greater proportion of patients receiving 1.5 mg/dose of 
hydromorphone reported complete pain relief than those receiving 2 mg/dose of 
hydromorphone or 100 mg/dose of meperidine (pethidine). Side effects comprising nausea, 
vomiting, headache, dizziness and sedation were greater with the higher dose of 
hydromorphone than the lower dose. Overall there were slightly fewer side effects with 
meperidine (pethidine).
Table 18. Comparative clinical studies between oral hydromorphone and other analgesics in acute pain
Author; year; country Indication; dose of 
hydromorphone 
(H) ( mg)
Design; number 
of patients; 
duration
Comparator; 
dose ( mg)
Global clinical outcome
Efficacy Toier- 
ability
Turek 1987; USA Post-operative db; Morphine H5 mg = M30 mg "Usual
pain; 21; M30 mg or M60 H10 mg = M60 type"
H5 mg or H10 mg <1 day mg mg
single dose single dose (oral
{oral solution) solution)
Nasits 1969; Oral surgical pain; db; Meperidine H I,5 mg Mp
?USA HI .5 mg or H2.0 39; (pethidine) (Mp); >H2.0 mg >M1.5
mg <1 day 100 mg 3 hourly >Mp mg
3 hourly for max 4 for max 4 doses >M2.0
doses mg
db = double blind; xo = cross-over; CRH = controlled-release hydromorphone; > = descriptively or statistically better 
than; > = trend in favour of; = = equivalent to
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4.5 Chronic pain models
4.5.1 Placebo-controlled study with oral hydromorphone in chronic pain
A single placebo-controlled study involving oral hydromorphone in patients with chronic 
painful conditions have demonstrated the analgesic superiority of hydromorphone over 
placebo. The study compared two dosage levels of oral hydromorphone (Table 19). It was a 
multiple-dose study over six days. In this study in which 2-mg or 4 mg oral 
hydromorphone was given 4-hourly both doses of hydromorphone were shown to be 
superior to placebo as measured by categorical scales of pain relief. The higher dose (4 mg) 
was more effective than the lower dose (2 mg) in a dose-related fashion. The study was also 
a crossover design which enabled a rank order of pain relief scores to be made. There was 
clear discrimination of effect consistent with the dose-response findings.
Table 19. Placebo-controlled studies with oral hydromorphone in acute pain
Author; year; country indication; dose of 
hydromorphone 
(H) ( mg)
Design; number 
of patients; 
Duration
Comparator; 
dose ( mg)
Global clinical outcome 
Efficacy Tolerability
Cass 1965; USA Chronic pain db, xo; Placebo (P) H4 mg P
(bone/joint); 29; >H2 mg =H2 mg
2 mg or 4 mg 6 days >P >H4 mg
4 hourly
qds = four times daily; db = double blind; > = descriptively or statistically better than;2  = trend in favour of; = = 
equivalent
In this study, oral hydromorphone was well tolerated at both doses, although the occurrence 
of unwanted effects tended to be less frequent with the lower dose than with the higher 
dose. Drowsiness was the most frequently reported adverse event. There were no reports of 
serious adverse events. This study supports the analgesic potency and tolerability of oral 
hydromorphone on a dose-related basis.
4.5.2 Comparative clinical studies between oral hydromorphone and other 
analgesics in chronic pain
Two clinical studies have compared the effect of oral hydromorphone with the control 
treatment being morphine in one and oxycodone in the other (Table 20).
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Table 20. Comparative clin ical studies between oral hydromorphone and other analgesics in chronic pain
Author; year; 
country
Indication; dose of 
hydromorphone
Design; 
number of 
patients;
Comparator; 
dose ( mg)
Global clinical outcome
Moriarty 1999; UK
(H) ( mg) 
Stable cancer pain; 
CRH 4 mg given 12 
hourly
duration
db
100;
3 days
Controlled-
release
morphine
(CRM)
30 mg given 12 
hourly
Efficacy 
CRH = 
CRM 
1:7.5 
analgesic 
potency
Toler-ability 
CRH = CRM 
(overall)
Hagen 1997; 
Canada
Stable cancer pain; 
CRH 30+ 6 mg/day 
given 12 hourly
db; xo;
44;
7 days
Controlled- 
release 
oxycodone 
(CRO) 124 + 22 
mg/day given 
12 hourly
CRH = 
CRO
CRH > CRO 
(drowsiness)
db = double blind; xo = cross-over; CRH = controlled-release hydromorphone; > = descriptively or statistically 
better than; > = trend in favour of; = = equivalent to
Mori arty (1999) compared the effect of a controlled-release oral formulation of 
hydromorphone 4 mg given 12 hourly for 3 days with 30 mg of controlled-release morphine 
given orally every 12 hours in 100 patients whose cancer pain had been stabilised on 
controlled-release morphine. Both treatments controlled pain satisfactorily. The principal 
measure o f efficacy in this study was the number o f occasions that escape analgesia was 
used. The frequency of use of escape analgesia was low in each group with no differences 
between groups for this measure nor for any pain measure or for patient preference. The 
authors suggest that the morphine:hydromorphone analgesic potency ratio by the oral route 
is 7.5:1. Both medications were well tolerated with no significant differences between them 
for the degree of nausea and sedation.
In a crossover study in 44 patients with stable cancer pain, Hagen (1997) compared the 
effect of oral controlled-release hydromorphone (mean dose 30 mg/day, given 12 hourly) 
with that of oral controlled-release oxycodone (mean dose 124 mg/day, given 12 hourly). 
Using visual analogue scales (VAS) and categorical scales to measure pain and use of 
rescue analgesia over a 7-day study period, both treatments were shown to be effective with 
no differences between them tlu'oughout any 24-hour period. VAS scores for sedation and 
nausea were similarly low for each treatment although drowsiness was reported 
significantly more frequently (p=0.016) with oxycodone.
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5 Clinical studies
The essential features of the clinical studies conducted with hydromorphone are summarised 
in Table 21 below.
Table 21. Study features
Title, country Design Dose regimen, route, 
duration of treatment
Number of patients,
diagnosis,
comparator
Evaluations
Placebo controlled
Single dose in 
postoperative pain 
UK, F, NL
DBPG 2, 4 and 6 mg 
Single oral dose of IR 
tablet
205 post primary 
knee arthroplasty
Placebo
SPiD, adverse 
events
Active controlled
Multiple dose study 
in postoperative pain 
UK, F, NL, Eire
DBPG 3 hourly-as-required oral 
doses of 2, 4 and 6 mg of 
IR tablet 
Up to 48 hours
271 post primary 
knee arthroplasty,
Morphine 20 mg oral
Mean pain score 
(by AUC), 
adverse events
Multiple dose study 
in cancer pain 
UK, Es, Fr, NL, De, 
Sw, Be, Can
DBPG IR phase;
4-houriy oral dosing (12- 
108 mg/day) until dose- 
stabie pain control 
achieved (2- 9 days).
CR phase:
Once daily dosing (16-96 
mg/day) until dose-stabie 
pain control achieved 
(10-15 days).
201 patients with 
cancer pain.
IR phase: 4-hourly 
oral morphine (60- 
540 mg/day).
CR phase: 12-houriy 
oral morphine (60- 
520 mg/day).
“Worst pain”, 
other pain 
scores through 
BPi, adverse 
events
Brief pain Inventory
5.1 Formulations studied
In the two studies of post-operative pain, the hydromorphone immediate-release tablet only 
was used. In the cancer pain study, the immediate-release tablet was used in the initial phase 
of the study. In the second phase of the cancer pain study, the once-daily controlled-release 
hydromorphone tablet was used. Corresponding control treatments were used in all of the 
studies.
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5.2 Placebo-controlled single-dose study in postoperative pain
5.2.1 Study summary
The study was entitled, “A double-blind, single dose, placebo-controlled dose-ranging 
investigation into the efficacy and tolerability of an immediate- release tablet formulation of 
hydromorphone in the treatment of acute post-operative pain”. The co-ordinating 
investigator was Professor D Rowbotham, of Leicester Royal Infirmary, Infirmary Road, 
Leicester, LEI 5WW.
The objectives of the study were i) to compare the efficacy of three single doses (2, 4 and 6 
mg) of hydromorphone with placebo during the post-operative recovery of patients who 
undergo primary knee replacement surgery; each individual patient received only one dose 
administered orally as an immediate-release tablet and ii) to evaluate the tolerability of the 
three single doses (2, 4 and 6 mg) o f hydromorphone and placebo during the post-operative 
period.
The methodology of the study was multicentre, double blind, placebo-controlled, parallel 
group, dose ranging. Assessments were made at baseline (0 hours) and at 0.5, 1, 2, 3, 4, 5 
and 6 hours after dosing with study medication.
The number of patients planned for the study was 200; 50 in each of the four treatment 
groups. Two-hundred-and-five patients entered the study, 51 received hydromorphone 
2 mg, 49 hydromorphone 4 mg, 51 hydromorphone 6 mg and 54 placebo. 204 patients were 
included in the analysis of the principal measure of efficacy. The sample population was 
hospital inpatients who required post-operative analgesic therapy for pain following primary 
knee arthroplasty.
The measures o f efficacy were pain at rest, pain on movement, and time to pain at rest 
returning to the baseline value. The measures of safety were adverse events and sedation.
The principal measure of efficacy was the sum of the pain intensity differences (SPID) for 
pain at rest. Hydromorphone 4 and 6 mg were significantly more effective in reducing pain 
at rest compared with placebo (p=0.03 for both comparisons). There was no statistically 
significant difference between hydromorphone 2mg and placebo. The adjusted means for
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SPID were -2.3, -5.2, -4.4 and 0.6 for hydromorphone 2, 4 and 6 mg and placebo, 
respectively.
Results were similar for the analyses of SPID for pain on movement. Hydromorphone 4 and 
6mg were significantly more effective compared with placebo (p=0.04 for both 
comparisons). There was no statistically significant difference between hydromorphone 2 
mg and placebo (p=0.60). The adjusted means for SPID were -1 .3 , -5.6, -3.9 and -0 .2  for 
hydromorphone 2, 4 and 6 mg and placebo, respectively.
In the analyses at individual time-points for pain at rest, hydromorphone 6 mg was more 
effective in reducing pain than placebo at hour 1 and 2 (p<0.05); both hydromorphone 4 and 
6mg were more effective than placebo at hour 3 (p<0.01). For pain on movement, all 
hydromorphone doses were more effective than placebo at hour 1 (p<0.05 for 2mg and 
p<0.01 for 4 and 6 mg) and hydromorphone 4 mg and 6 mg were more effective than 
placebo at hours 2 and 3 (p<0.05).
For the analysis of the time to pain at rest returning to the baseline value, the overall 
treatment group comparison was not statistically significant (p=0.07), although the pairwise 
comparison between hydromorphone 6mg and placebo was significant (p=0.013). The 
Kaplan-Meier estimates for time for pain at rest returning to baseline value were 165.4,
191.6, 209.5 and 109.7 minutes for the hydromorphone 2, 4 and 6mg groups and the 
placebo groups respectively. The number of patients reporting pain values returning to the 
original baseline was over 60% in all four treatment groups, with highest incidence rate in 
the placebo group (77%) and the lowest in the hydromorphone 6mg group (63%).
Adverse events were reported by 11 (22%) patients, 15 (31%) patients, 17 (33%) patients 
and 15 (28%) patients, respectively; there was no statistically significant difference between 
the four groups in the proportion of patients who reported adverse events. Most adverse 
events were mild and the relationship to therapy was unlikely or none for approximately 
50% of the reported adverse events. Nausea, vomiting and pyrexia were the most common 
adverse events. Generally, the reports of nausea and vomiting were assessed by the 
investigator as being probably or possibly related to treatment, whilst reports of pyrexia 
were assessed as having an unlikely or no relationship to treatment. This is not unexpected 
as nausea and vomiting are commonly reported side effects associated with opioids.
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Including adverse events ongoing at randomisation, similar numbers of patients in the 
hydromorphone 4 mg, 6 mg and placebo groups experienced adverse events commonly 
reported with morphine (13, 11 and 12 patients, respectively); patients in the 
hydromorphone 2 mg group reported fewer of these events (7 patients). Five patients 
withdrew from the study due to adverse events (one in the hydromorphone 2-mg group, 
three in the 4-mg group and one in the placebo group).
Assay sensitivity, the ability to demonstrate the statistieally significant activity of an 
analgesic agent compared to placebo or to another agent, represents a noteworthy 
achievement for any analgesic study (Schachtel, 1991). Hydromorphone 4 mg and 6 mg 
were statistically significantly more efficacious than placebo in the treatment of pain in the 
post-operative recovery of patients who underwent primary Imee replacement surgery. The 
tolerability of the tlrree hydromorphone doses was comparable to placebo. These findings 
confirm impressions gained from more than 50 years o f clinical use in North America. 
Namely, hydromorphone is an effective and safe analgesic in the treatment of acute pain.
5.2.2 Introduction
This was the first o f two studies addressing the time at which patients cease using parenteral 
opioids by PCA for the management of severe postoperative pain, referred to above as the 
“analgesic gap”.
Patients recovering from primary knee artlii'oplasty suffer severe pain. In order to test an 
oral opioid analgesic in this setting, it was necessary to delay the beginning of the study 
period to the time when patients had their pain control stabilised with the use of morphine 
patient controlled analgesia (PCA) and when the patient was able to tolerate oral intake. The 
interval selected was 1 8 - 4 8  hours after the patient left the operating theatre. This was 
judged to include the probable minimal time for a patient to fulfil the criteria and not be of 
such a long duration as to result in recovery from postoperative pain to the degree that oral 
opioid analgesia would no longer be appropriate.
The PCA was controlled in so much as this had to use morphine, and there was an element 
of control in the use of post-operative use of non-steroidal anti-inflammatory drugs 
(NSAID) whereby only a fixed dose and route of diclofenac (100 mg p.r.) could be used.
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However, the use o f NSAIDs was optional. This was to allow for the differences in 
preference between investigators, centres and countries. The type of anaesthetic procedure 
was not controlled, since this was felt to be impracticable in the setting of a multicentre, 
multinational study. The scope of anaesthetic procedure included regional techniques, such 
as spinal anaesthesia and nerve blocks, but these had to complete at the time that the patient 
left the operating theatre. The variability that this was bound to introduce should have been 
lessened in its impact tlnough the minimum 18 hour PCA period bringing patients back to a 
more consistent baseline. Additionally, testing for the motor and sensory effects of regional 
teclmiques was designed to prevent residual effects of these measures affecting measures in 
the period o f the study following randomisation. A minimum degree of pain at baseline 
assessment was not included as a selection criterion.
The study was designed as multicentre and multinational in order to allow for recruitment of 
the 200 patients estimated to be required in a reasonable interval.
The doses used in the study were based on published guidelines (American Pain Society, 
1993). In fact, the study was originally designed to examine 2, 4 and 8-mg doses of 
hydromorphone, but concerns were raised by the UK regulatory agency medical reviewer as 
to the risk of an 8-mg dose in this setting. His concerns were based on an equipotency ratio 
of 7.5, which would make an 8-mg dose of hydromorphone equivalent to 60 mg of 
morphine.
5.2.3 Objectives
Firstly, to compare the efficacy of three single doses (2, 4 and 6 mg) of hydromorphone 
with placebo during the post-operative recovery of patients who undergo primary knee 
replacement surgery, and secondly, to evaluate the tolerability of the three single doses (2, 4 
and 6 mg) of hydromorphone compared with placebo.
5.2.4 Methods
This was a multicentre, phase II, randomised, double-blind, placebo-controlled, 
parallel-group study. The study was conducted at 24 centres in the United Kingdom, 
Netherlands and France; these hospitals had departments/units specialising in the
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management of acute pain. The planned sample size was 200 patients (50 patients in each 
of the four treatment groups).
5.2.4.1 Patient selection
Individuals eligible for entry into this study comprised male or female hospital in-patients, 
aged 18 years or older, who required post-operative analgesic therapy for pain following 
primary loiee artlii’oplasty. These patients were to be willing and able to comply with the 
protocol requirements, and have signed a statement of informed consent before entry.
Individuals not eligible for this study comprised any of the following groups: patients with 
hypersensitivity to morphine sulphate, hydromorphone hydrochloride or any related 
compound; patients with a history of drug/alcohol abuse or addiction within a six month 
period immediately prior to entry; patients who, in the opinion of the investigators, 
exhibited clinically significant complications (e.g. wound haematoma, active infection or 
prolonged nausea/vomiting) during or immediately after the laiee replacement surgery, or 
those who had previously undergone major surgery to the affected knee(s) e.g. high tibial 
osteotomy, open reconstruction of cruciate ligaments, stabilisation of the patella or Imee 
arthroplasty; patients with evidence of clinically significant nemological, haematological, 
endocrine, cardiovascular, hepatic, renal, gastrointestinal (including nausea and vomiting) 
or respiratory dysfunction which, in the opinion of the investigator, would interfere with the 
patients’ participation in the study; patients who had received any investigational drug 
within one month immediately prior to screening for entry into this study; women of child­
bearing potential (all had to be given a pregnancy test) who were diagnosed as being 
pregnant or lactating, and those seeking pregnancy or failing to take adequate contraceptive 
precautions; individuals previously entered into this study; patients who exhibited 
significant opioid respiratory depression and sedation due to the use of morphine sulphate in 
the PCA.
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5.2.4.2 Study procedures
A diagram of the study design is given below;
Figure 10. S ingle-dose acute pain study design
S c re e n in g S u rg e ry P C A  s t a  rt P C A  s t o p p e d
P l a c e b o
H y d r o m  o r p h o n e 2 m g
.2
s H y d r o m  o r p h o n e 4 m g
H y d r o m o r p h o n e 6 m g
s t u d y  p e r i o d
4 8 h o u r s 0 - 6 h o u r s
Candidate patients were informed of the nature of the study, and provided written informed 
consent for participation on admittance to hospital, before the Imee surgery. Before and 
during the surgery, all required medication was to be administered to each participating 
patient in accordance with the usual hospital practice for such cases. However, the use of 
an intravenous or subcutaneous patient-controlled analgesia (PCA) system involving 
morphine sulphate was mandatory for pain control in post-operative recovery. The dose of 
morphine required by each participating patient was to be titrated appropriately using this 
system until the pain was well controlled, as defined by observer ratings of pain in the 
established clinical practice within each individual study centre. In addition to morphine 
PCA, patients could be administered a single 100 mg dose of diclofenac PR immediately 
after surgery. Treatment with paracetamol was allowed for the treatment of pyrexia or 
headache. A minimum 6-hour washout period was required between paracetamol 
administration and baseline assessment and a minimum 18-hour washout period was 
required for diclofenac.
Approximately 18-48 hours into the post-operative recovery period, when the pain had been 
demonstrated to be well controlled for at least two consecutive hours and the resumption of 
oral intake (fluids and medication) for at least four hours resulted in no clinically significant 
nausea or vomiting, the use of PCA was to be stopped. Patients who had received nerve 
blockade were to be assessed to ensure that they had recovered from the effects of the
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blockade to establish that their stabilised pain control was entirely due to the morphine 
PCA.
The 5HT3 antagonist ondansetron was to be used to treat post-operative nausea once the 
patient had taken study medication. Hypnotics, sedatives and tranquillisers were not to be 
administered to recruited patients within a 6-hour period immediately prior to use o f the 
study medication or during the course of the study period.
As soon as the patients requested further analgesia (taken to be the point at which 
significant pain reappeared) each individual patient underwent the first (baseline) study 
assessment of pain intensity (using an 11-point rating scale ranging from 0 = “no pain” to 
10 = “pain as bad as you can imagine” for pain at rest and pain on movement). At this stage 
each patient was to be randomly assigned to one of the four study treatment groups and 
administered with the single dose of study medication. The pain assessments were to be 
repeated after 30 minutes, then at hourly intervals throughout the scheduled six-hour study 
treatment period.
Patients could be withdrawn at any time during the six-hour study treatment period (e.g. 
because o f lack o f efficacy or tolerability problems with the study medication). If a patient 
was withdrawn then the next scheduled pain assessment was to be performed immediately 
before the withdrawal. If the patient did not withdraw consent all remaining assessments 
were to be completed at the scheduled times. At the point of withdrawal the patient was to 
receive the rescue analgesia considered appropriate within the individual hospital (e.g. 
either re-commencement of morphine therapy with the PCA system or initiation of other 
parenteral or oral analgesic therapy). The time of re-medication was to be recorded.
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S.2.4.3 Study assessments
Table 22 below details the timing of the assessments made in the study.
Table 22. Study schedule
Assessment Screening® Study Period
Hours
0 0.5 1 2 3 4 5 6
informed consent X
Eligibility X
Demography X
Medical history, concomitant disease and X
medication
Pain at rest X X X X X X X X
Pain on movement X X X X X X X
Sedation X X X X X X X
Adverse events'’ X X X X X X X X
Prior to surgery.
In addition, a foliow-up review of adverse events was conducted during the 24 hours immediately after 
completion of the study period.
Patients’ self-reported pain was recorded using the numerical pain scale as shown below. It 
was derived from the Brief Pain Inventory (Cleeland 1994b).
0 1 2 3 4 5 6 7 8 9  10
N o Pain as bad
pain as you can
imagine
Numerical pain rating scores are appropriate for assessing pain (McQuay 1998).
The procedure for assessing pain on movement was defined as flexion of the affected knee 
required by a patient (in a supine position) to lower the foot by 15 cm from an elevated, 
fully extended limb position, support for the limb being provided throughout this procedure 
by the investigator. Patients who were unable to have their foot lowered the full 15 cm 
because of severe pain, were to provide a score based upon the movement possible.
Active physiotherapy, other than movement of the knee associated with pain assessment, 
was only performed during the six hour study period provided that 30 minutes had elapsed 
between physiotherapy and the pain assessments. This provided a recovery time from the 
effects of physiotherapy to ensure that pain assessments were not affected by the 
physiotherapy itself. Passive physiotherapy was permitted throughout the study period.
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The tolerability for all recruited patients was to be monitored throughout the study period by 
recording the adverse events experienced. All adverse events were graded for severity 
according to the following definition:
Severity Definition
Mild Does not interfere with routine activities
Moderate Interferes with routine activities
Severe Impossible to perform routine activities
In addition, sedation was to be assessed at hourly intervals throughout the scheduled study 
period. Sedation was to be rated with the following 4-point descriptive scale:
0 = Awake, alert, orientated
1 = Dozing intermittently, drowsy or lethargic but aroused by verbal
stimulus
2 = Mostly sleeping, difficult to arouse but feasible by physical
stimulus
3 = Difficult to waken, little or no response even to physical
stimulus
S.2.4.4 Study medication, blinding and randomisation
Patients received a single dose of either hydromorphone 2 mg, 4 mg or 6 mg or placebo, as 
an instant-release tablet within a capsule (for blinding purposes) orally.
The study medication consisted of brown capsules (size 0) containing 2 mg hydromorphone, 
4 mg hydromorphone, 6 mg hydromorphone or matching placebo. The hydromorphone and 
placebo capsules were identical in appearance, taste and smell. The single dose of 
medication made available for each patient was packed in a sachet (one capsule per sachet). 
The study medication was prepared in identical packaging but allocated individual patient 
numbers. Consequently, both the patient and investigator were unaware of the medication’s 
identity. Sufficient medication supplies were packed and labelled for 400 patients in total 
(100 patients in each of the four treatment groups).
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Allocation of treatment to patients in each of the four study groups was in accordance with a 
computer-generated randomisation list. At the time of randomisation, each patient was to 
be given the next available sequential randomisation number. Each study centre was 
supplied with a sealed envelope for each patient containing details of the administered 
treatment and dose. An envelope was to be opened only in an emergency, when it was 
necessary for a patient’s treatment to be disclosed. This ensured that the investigator was 
able to break the code for an individual without unblinding the rest of the study.
5.2.4.5 Data entry and statistical analysis
All data were entered onto Knoll’s Oracle Clinical® computer database and then verified by 
repeat data entry. A 100% audit was carried out of all records relating to site allocation, 
adverse events, study medication, withdrawal information and the principal measure of 
efficacy entered in the database against that recorded on the case report forms; a random 
sample of 15 patients had all their information checked in the same manner. The error rates 
were 0.35% for adverse events, 0.05% for withdrawal information, 0.55% for site 
allocation, 0.38% for study medication and 0.01% for the principal measure of efficacy.
The error rates were considered to be satisfactory and any discrepancies found were 
amended before analysis. In addition, manual checks and programmed validation checks 
were performed.
The statistical methods described in the protocol were expanded to produce a detailed 
statistical plan. This was discussed and agreed before the blind was broken and data made 
available for analysis.
All calculations were performed using SAS (SAS Institute Inc 1990). Williams’ test (1972) 
was performed using a validated in-house SAS program. All statistical tests performed were 
two-tailed, and the null hypothesis was at all times that the treatment groups (each dose of 
active medication compared to placebo) were equal. Statistical significance was determined 
by reference to the 5% level, unless otherwise stated. Also, 95% confidence intervals are 
presented for the difference between each dose and placebo. These confidence intervals 
were always constructed to correspond with the p-value from Williams’ test (i.e. if  the 
p-value indicated statistical significance at the 5% level then the confidence intervals were 
not to contain zero and vice versa).
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The “full analysis” set (referred to as the intent-to-treat efficacy analysis in the protocol) 
included all patients who took study medication with at least one assessment performed 
within the post-baseline phase. Patients who withdrew from the study and/or were given 
rescue medication had their last observed value for the relevant efficacy variable(s) carried 
forward for all time periods subsequent to withdrawal or re-medication. In all the above 
analyses, any patients with treatment administration errors were analysed according to the 
treatment actually taken.
Due to the expected relatively small number of major protocol violations, no per-protocol 
analysis was performed. All relevant protocol deviations were assessed under blind 
conditions. All patients taking at least one dose of study medication were included in the 
analysis of safety.
The treatment groups were assessed for comparability with respect to baseline information, 
in particular the total dose o f morphine administered as PCA prior to stopping and the time 
from stopping PCA to study medication dispensed. Any clinically significant difference 
was accounted for in the subsequent analysis.
The principal measure o f efficacy was the SPID for the seven post-baseline assessments for 
pain at rest. This together with the following variables was analysed by analysis of 
covariance (Armitage 1987, p282-95) with factors for treatment and country with the 
baseline pain score as a covariate:
• the SPID for the six post-baseline assessments for pain on movement
• the changes from baseline at each of the post-baseline assessments for pain at rest and 
pain on movement
In each case, Williams’ test using estimates from the analysis of covariance (ANCOVA) 
was used to compare each dose of active medication with placebo and hence establish the 
minimum effective dose. For the principal measure of efficacy only, an additional analysis, 
including a factor for the treatment-by-country interaction was performed. If this 
interaction was significant at the 10% level, the source of the interaction and its impact on 
the results were to have been assessed.
As there was an imbalance between the treatment groups for the time from stopping PCA to 
the time study medication was dispensed, it was decided for the principal measure of
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efficacy only, that an additional analysis of covariance would be performed. This included 
an additional factor.having five levels for the elapsed time from stopping PCA to the 
dispensing of study medication, these levels were 0-60, 61-120, 121-180, 181-240, >240 
minutes.
After codebreak it was decided it was appropriate to perform an analysis which gave some 
indication of the duration of action of the respective hydromorphone doses and placebo. 
Therefore, the time to pain at rest returning to the baseline value was analysed using the 
logranlc test with p-values for pairwise comparisons against placebo adjusted by Sidak. To 
allow for the time to drug effect, assessments recorded less than 60 minutes after dosing 
were disregarded from the calculation. Patients who withdrew/re-medicated before pain at 
rest returned to baseline value had their values censored at the time of re­
medication/ withdrawal. Patients who completed the study without returning to their 
baseline value had their values censored at the time of their six-hour assessment.
For all the above analyses, patients who withdrew from the study and/or were given rescue 
medication had their last observed value carried forward for all time periods subsequent to 
withdrawal or re-medication.
The severity of a recurrent adverse event was taken to be the most severe o f the occurrences 
and the relationship to therapy as the most probable. In counting the number o f events 
reported, a continuous event, i.e. reported more than once and which did not cease, was 
counted only once; non-continuous adverse events reported several times by the same 
patient were counted as multiple events. Events present at baseline that did not worsen in 
severity were not included.
The difference between the treatment groups in the proportion of patients with adverse 
events was compared using the chi-square test (Armitage 1987, p205-9). Data on sedation 
were tabulated by treatment group with 95% confidence intervals for the pairwise 
differences with placebo.
Initially the study was analysed in a blind fashion, treatment groups were known only as A, 
B, C and D. Normality assumptions were tested by an examination of the residual plots and 
the Shapiro-Wilk test (1965) of normality; homogeneity of variance was tested using
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Levene’s test (Milliken 1984) about the median. Depending on the degree of departure 
from these assumptions, an alternative nonparametric approach would have been used 
instead. Only when these decisions were made and documented was the full key to the 
randomisation released.
The principal measure of efficacy was the SPID for the seven post-baseline assessments of 
pain at rest. The sample size was estimated to be 50 patients per treatment group. This 
figure allowed a detection of a treatment difference of 7.0 between any dose of 
hydromorphone and placebo -  assuming a variability (sd) of 11.0 (estimated using data 
from a previous study), 90% power, a 5% significance level and a Williams' test. The 
actual variability estimated from the root mean square error (MSE) from the analysis of 
covariance was 12.4.
5.2.5 Results
5.2.5.1 Efficacy
A total of 281 patients were screened for entry into the study between 5 January 1999 and 
31 May 1999, of which 205 actually took study medication. O f the 205 patients 
randomised, 129 completed the study. Table 23 below gives the number of patients entering 
and completing the double-blind phase by centre within each country:
Table 23. Summary of number of patients completing and entering the doubie-biind phase by centre within each  
country
Country/ Treatment group
centre number Hyd, 2 mg Hyd. 4 mg Hyd 6 mg Placebo Overall
France
16/17 (94%) 16/17 (94%) 15/18 (83%) 14/17 (82%) 61/69 (88%)
Netherlands
9/18 (50%) 8/17 (47%) 6/14 (43%) 9/19 (47%) 32/68 (47%)
United Kingdom
8/16 (50%) 8/15 (53%) 11/19 (58%) 9/18 (50%) 36/68 (53%)
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Withdrawals and reason for withdrawal are summarised in Table 24 below.
Table 24 Summary of patient withdrawals during the double-blind phase
Reason for Treatment group
withdrawal Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Placebo
Total number of patients 51 49 51 54
Adverse event
0-3 hours - 2 - 1
> 3-6 hours 1 1 - -
Overall 1 3 - 1
Lack of efficacy
0-3 hours 14 13 14 18
>3-6 hours 1 1 5 3
Overall 15 14 19 21
Protocol violation
0-3 hours 1 - - -
>3-6 hours - - -
Overall 1 - - -
Withdrawal of consent
0-3 hours 1 - - -
>3-6 hours - - - -
Overall 1 - - -
Total withdrawn 18 (35%) 17 (35%) 19 (37%) 22 (41 %)
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A summary of protocol deviations for all patients randomised is provided in Table 25 
below.
Table 25. Protocol deviations
Deviation® Treatment group Overall
Hyd, 2 mg Hyd. 4 mg Hyd. 6 mg Placebo
Major deviations
Took inadmissible analgesics 4 2 4 1 11
Less than 18 hours between rectal 4 1 - 2 7
diclofenac dose and ceasing PCA
Inadmissible duration between - - 1 - 1
surgery and taking study medication
Previous knee replacement surgery - - - 2 2
to affected knee
Previous high tibial osteotomy to 1 - - 1 2
affected knee
Previous open reconstruction of - - - 1 1
cruciate ligaments of affected knee
Number of patients with major 9 3 6 7 24
deviations
M inor deviations
Took anti-emetics less than eight 2 2 - - 4
hours prior to study medication
dosing
Took hypnotics during the study - 1 2 1 4
Took opioids during the study 1 1 1 1 4
Physiotherapy between operation 1 - - - 1
and taking study medication
No written consent at screening - 1 - - 1
Number of patients with minor 4 5 3 2 14
deviations
Number of patients with a deviation 12 7 7 7 33
® Not mutually exclusive
A total of 205 patients entered the double-blind phase of the study, all of whom provided at 
least one post-baseline efficacy assessment. Patient number 738 (placebo group) provided 
no baseline data for pain at rest, therefore 204 patients were included in the analysis of the 
principal measure of efficacy, the SPID of pain at rest. For the analysis o f pain on 
movement, 199 patients were included with six patients providing no baseline data.
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The treatment groups were relatively well balanced with respect to all demographic 
variables tabulated, as summarised in Table 26 below;
Table 26. Summary of entry profile for all patients randomised
Treatment group
Variable Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Placebo Overall
n 51 49 51 54 205
Mean age ± sd (yr)
Female
Caucasian
Mean height ± sd (cm) 
Mean weight ± sd (kg)
68.1 ±9.1 
30 (59%) 
50 (98%)
165.9 ±7.6
78.1 ± 14.8
68.4± 11.1 
34 (69%) 
49 (100%) 
166.7 ±9.2 
82.6 ± 16.4
67.5 ± 10.0 
28 (55%) 
51 (100%) 
167.1 ±8.3 
80.9 ± 12.2
67.1 ±9 .6  
34 (63%) 
52 (96%) 
165.6 ± 8.9 
79.8 ± 16.5
67.8 ±9.9 
126 (61%) 
202 (99%)
166.3 ± 8.5
80.3 ± 15.1
There was a statistically significant imbalance between treatment groups for the time from 
stopping PCA to the time study medication was dispensed. The percentage of patients in 
each group with an elapsed time of <120 minutes was 41%, 47%, 71% and 65% for the 
hydromorphone 2 mg, 4 mg and 6 mg and the placebo groups, respectively. One patient in 
the hydromorphone 6-mg group had 4565 minutes (i.e. just over three days) between 
stopping PCA and the dispensing of study medication. A total of 162 (79%) of patients had 
regional anaesthetic procedures. There were imbalances between countries with respect to 
total duration of PCA use and the corresponding time from the operation to the dispensation 
o f study medication. Patients in the UK, in general, received PCA morphine over a longer 
time period compared to patients in the other two countries. The consumption of morphine 
in mg/hour was broadly similar across the countries, with the lower values in the UK being 
possibly related to diminished morphine use as time from surgery increased. In addition,
41 patients received non-PC A morphine during the post-operative period. Table 27 below 
summarises these imbalances.
Table 27. Summary of selected  PCA variables by country
Country
Variable France Netherlands UK Overall
n 69 68 68 205
Median morphine dose administered as 
PCA (mg)
37.2 39.5 54.5 40.0
Median amount of morphine sulphate 
administered as PCA per hour
1.81 1.80 1.57 1.77
Median total duration of PCA (h) 20.3 21.0 39.0 21.3
Median time from operation to study 
medication dispensed (h)
23.3 23.6 44.4 24.3
Doses in milligrams were treated as equivalent, whether they were administered intravenously or 
subcutaneously, since they are assumed to be equipotent (Twycross 1998).
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Table 28 below presents summary statistics of the total amount of morphine administered 
(including non-PCA) tabulated by whether the single 100-mg dose o f diclofenac was given 
peri-operatively or in early postoperative management. Morphine consumption was higher 
in patients who did not receive the rectal dose.
Table 28. Total morphine administered by diclofenac use
Diclofenac used
Morphine consumption (mg)
n Mean Median sd Range
Yes 32 44,4 38.5 25.7 12,142
No 173 52.0 45.0 32.6 9, 232
Overall 205 50.8 44.0 31.7 9, 232
Predictably, the most commonly reported previous condition was localised osteoarthritis, 
reported by 62 patients (30%). O f the 144 (70%) patients that had concomitant 
musculoskeletal, connective tissue and bone disorders, 72 (50%) had osteoarthritis, 51 
(35%) had localised osteoarthritis and 12 (8%) had rheumatoid arthritis.
A total of 183 (89%) patients reported previous medications in the seven days prior to entry 
including 137 (67%) patients who received anaesthetics, 75 (37%) patients who used 
analgesics, 68 (33%) patients who used psycholeptics (see below) and 57 (28%) patients 
who used anti-inflammatory and anti-rheumatic products. One-hundred-and-ninety-five 
(95%) patients were receiving concomitant medications prior to the operation including 113 
(55%) who were taking antithrombotic agents and 108 (53%) who were taking 
antibacterials for systemic use.
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A total of 158 (77%) patients commenced medications other than morphine sulphate 
between the operation and randomisation. Table 29 below summarises anti-emetics 
commencing between the operation and randomisation:
Table 29 Summary of anti-emetics commencing between the operation and randomisation
Treatment group
Anti-emetic*' Hyd, 2 mg Hyd. 4 mg Hyd. 6 mg Placebo Overall
Total number of patients 51 49 51 54 205
Number of patients 
commencing anti-emetics
21 (41%) 17 (35%) 16 (31%) 17 (31%) 71 (35%)
Cyclizine 3 1 5 - 9
Haloperidol - - - 1 1
Metoclopramide 3 4 1 2 10
Ondansetron hydrochloride 18 13 13 15 59
Not mutually exclusive
Forty-one (20%) patients commenced medications during the double-blind phase including 
20 (10%) patients who took antibacterials for systemic use. A total of ten patients 
commenced using ondansetron hydrochloride during the double-blind phase, one in 
hydromorphone 2 mg group, three in the hydromorphone 4 mg group, two in the 
hydromorphone 6 mg group and four in the placebo group.
For SPID for pain at rest, hydromorphone 4 mg and 6 mg were significantly more effective 
in reducing pain at rest compared with placebo (p=0.03 for both comparisons). There was 
no statistically significant difference between hydromorphone 2mg and placebo (p=0.24). 
The adjusted means for the SPID were -2.3 for hydromorphone 2 mg, -5.2 for 
hydromorphone 4 mg, -4.4 for hydromorphone 6 mg and 0.6 for placebo. Table 30 below 
summarises the data:
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Table 30. Analysis o f covariance fo r SPID fo r pain at rest
SPID for pain at Treatment group
re s f Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Piacebo
n 51 49 51 53
Mean±sd -2.7+14,0 -5.2+13,7 -4.3±13.7 0,8+14,1
Range -35,26 -47,22 -33,33 -33,36
Adjusted mean‘s -2.3 -5.2 -4.4 0.6
Difference in 
adjusted means 
reiative to placebo*’
-2.9 -5.7 -5.0
8 0  (of difference) 2.4 2.4 2.4
Williams’ test (LSD = 
P-value (versus 
placebo)
4.97)
0.24 0.03 0.03
95% Cl for 
difference**
-7.6,1.9 -11.2,-0.o o f -11.2,-O.OOf
® A negative value denotes an improvement from baseline 
Adjusted for baseline and country 
A negative difference favours hydromorphone
Not symmetric around the differences in the adjusted means due to the assumption of a monotonie 
trend
® As Williams’ test was statistically significant, upper bound of confidence interval was made to be 
consistent with the significance of the test i.e. it did not contain zero
In the ANCOVA the terms for country and treatment group-by-country interaction were not 
statistically significant (p=0.054 and p=0.61, respectively), the latter implying that treatment 
differences were comparable across countries. Table 31 below summarises mean SPID pain 
at rest scores by treatment and country:
Table 31. Mean (n) SPID fo r pain at rest by treatm ent group and country
Variable Treatment group
Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Piacebo
Overall -2.7 (51) -5.2 (49) -4.3(51) 0.8 (53)
France -2.7(17) -3.2 (17) 0.3 (18) 1,9(17)
Netherlands -1.6(18) -7.5 (17) -7.5(14) 1.9(18)
United Kingdom -4.1 (16) -4.7 (15) -6.3 (19) -1.4 (18)
As there was an imbalance between treatments in the time from stopping PCA to the time 
study medication was dispensed, an additional analysis was performed with this as a five- 
level factor in the ANCOVA. The results obtained were similar to the main analysis.
For the analyses at individual time-points for pain at rest, the hydromorphone 6 mg versus 
placebo comparison was statistically significant at hour 1 (p=0.02), similarly at hour 2 
(p=0.013). At hour 3, the hydromorphone 4 mg versus placebo and hydromorphone 6 mg 
versus placebo comparisons were statistically significant (p=0.008 in each case). At 4, 5 and
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6 hours, none of the pairWise comparisons were statistically significant. A summary is 
given below in Figure 11 for the mean pain at rest and Table 32 for the adjusted mean 
changes from baseline in pain at rest at each follow-up assessment. The mean decreases in 
pain in the hydromorphone groups were lar gest over the first three hours.
Figure 11. Mean pain at rest (carry forward data)
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Table 32. Adjusted mean changes^ from baseline in pain at rest at each follow-up a ssessm en t (carryforward data)
Hour
Treatment group
Hyd. 2 mg 
(n=51)
Hyd. 4 mg 
(n=49)
Hyd. 6 mg 
(n=51)
Piacebo
(n=53)
0,5 -0.6 -0.6 -0.4 -0.3
1 -1.0 -0.8 -1.1* -0.2
2 -0.5 -0.9 -1.2* -0.1
3 -0.4 -1.0** -0.9** 0.2
4 -0.2 -0.8 -0.5 0.1
5 0.1 -0.7 -0.2 0.3
6 0.4 -0.4 -0.2 0.4
Adjusted for baseline and country 
p<0.05 versus placebo 
p<0.01 versus placebo
For SPID for pain on movement, hydromorphone 4 mg and 6 mg were significantly more 
effective in reducing pain on movement than placebo (p=0.04). There was no statistically
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significant difference between hydromorphone 2 mg and placebo (p=0.60). The adjusted 
means for SPID were -1.3 for hydromorphone 2 mg, -5.6 for hydromorphone 4 mg, -3.9 for 
hydromorphone 6 mg and -0.2 for placebo. Figure 12 and Table 33 below summarises the 
data:
Figure 12. Mean pain on movement (carryforward data)
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Table 33. Analysis o f covariance fo r SPID fo r pain on movement
SPID for pain on Treatment group
movement Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Placebo
n 49 47 51 52
Mean + sd -1.9 + 11.1 -5.7+12.7 -4.2 ± 12.1 0.5+  9.5
Range -26,25 -32,27 -30,34 -18,27
Adjusted mean‘s -1.3 -5.6 -3,9 -0.2
Difference in 
adjusted means 
relative to placebo'"
-1.1 -5.4 -3.7
se (of difference) 2.1 2.1 2.1
Williams' test (LSD = 
P-value (versus 
placebo)
4.31)
0.60 0.04 0.04
95% Cl for 
difference'*
-5.3,3.0 -9.5,-0.001® -9.5,-0.001®
A negative value denotes an improvement from baseline 
Adjusted for baseline and country 
A negative difference favours hydromorphone
Not symmetric around the differences in the adjusted means due to the assumption of a monotonie 
trend
As Williams' test \was statistically significant, upper bound of confidence Interval was made to be 
consistent with the significance of the test i.e. it did not contain zero
For the analyses at individual time-points for pain on movement, the comparisons of all 
hydromorphone doses versus placebo were statistically significant at hour 1 (p=0.012 for 
hydromorphone 2 mg, p=0.006 for hydromorphone 4 mg and p=0.005 for hydromorphone 6 
mg). At hours 2 and 3 the hydromorphone 4 mg and 6 mg comparisons versus placebo 
were statistically significant (p=0.04 at hour 2 and p=0.02 at hour 3 for hydromorphone 4 
mg and 6 mg). At 4, 5 and 6 hours, none of the pairwise comparisons were statistically 
significant. A summary is given in Table 34 below for the adjusted mean changes from 
baseline in pain on movement at each follow-up assessment:
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Table 34. Adjusted mean changes® from baseline in pain on movement at each fo llow -up (carryforward data)
Hour
Treatment group
Hyd. 2 mg 
(n=49)
Hyd. 4 mg 
(n=47)
Hyd. 6 mg 
(n=51)
Placebo
(n=52)
1 -0.7* -0.9** -0.6** 0.2
2 -0.5 -1.2* -1.0* -0.2
3 -0.2 -1.2* -0.9* -0.0
4 -0.2 -1.1 -0.6 -0.0
5 0.1 -0.8 -0.4 -0.2
6 0.2 -0.6 -0.3 0.0
Adjusted for baseline and country
p<0.05 versus placebo 
p<0.01 versus placebo
The proportion of patients reporting the use of rescue analgesia was higher in the placebo 
group (39%) compared to the tliree hydromorphone groups (31% for 2 mg, 33% for 4 mg 
and 33% for 6 mg). The most commonly reported rescue medication was morphine, which 
was taken by 44 patients during the double-blind phase.
For the analysis o f the time to pain at rest returning to the baseline value, the overall 
treatment group comparison was not statistically significant (p=0.07), although the pairwise 
comparison between hydromorphone 6mg and placebo was significant (p=0.013). The 
Kaplan-Meier estimates for time for pain at rest returning to baseline value were 165.4,
191.6, 209.5 and 109.7 minutes for the hydromorphone 2, 4 and 6mg groups and the 
placebo groups respectively. The number of patients reporting pain values returning to the 
original baseline was over 60% in all four treatment groups, with highest incidence rate in 
the placebo group (77%) and the lowest in the hydromorphone 6mg group (63%; Table 35). 
The Kaplan-Meier plot for time to first report of pain at rest returning to the original 
baseline is presented in Figure 13.
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Table 35. Time to first report of pain at rest returning to baseline value
Treatment group
Time to first report of pain at rest 
returning to baseline 
value®
(min)
Hydromorphone
2mg
Hydromorphone
4mg
Hydromorphone
6mg
Placebo
Total number of patients 51 49 51 53
Number of patients reporting 39 (76%) 36 (73%) 32 (63%) 41 (77%)
Comparisons (logrank test) E
Overall 7.15 3 0.07
Hydromorphone 2mg versus placebo 0.76 1 0.38
Hydromorphone 4mg versus placebo 2.18 1 0.14
Hydromorphone 6mg versus placebo 6.23 1 0.013
60 22 18 19 29
61-120 10 7 2 7
121-180 3 2 2 4
181-240 1 2 3 1
>240 3 7 6 -
Mean‘s 165.4 191.6 209.5 109.7
se 19.4 19.9 19.3 9.7
Time calculated from time of dispensing of medication. Assessments recorded less than 60 minutes after dosing 
are disregarded in the calculation as were assessments made after re-medication/withdrawal 
Kaplan-Meier estimate. Patients whose pain did not return to the baseline value who did not re-medicate/withdraw 
within the first six hours had their time censored at the time of their hour 6 assessment
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Hydromorphone 4 mg and 6 mg were therefore clinically and statistically significantly more 
efficacious than placebo in the treatment of pain in the post-operative reeovery of patients 
who underwent primary loiee replacement surgery.
5.2.5,2 Safety
Fifty-one, 49, 51 and 54 patients received single doses of immediate-release 
hydromorphone 2 mg, 4 mg and 6 mg and placebo, respectively.
The number of patients reporting an event during the double-blind phase and the number of 
events in each treatment group are summarised in Table 36 below:
Table 36 Summary of adverse events reported during the double-blind phase
Treatment group
Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Piacebo
Total number of patients 51 49 51 54
Number of patients reporting an adverse event 11 (22%) 15 (31%) 17 (33%) 15 (28%)
Number of events reported 17 20 19 21
The severity and relationship to therapy of adverse events reported during the double-blind 
phase are presented in Table 37 below:
Table 37 Summary of severity and relationship to therapy during the double-blind phase
Severity
Relationship to therapy
No of reports (%)
Treatment group
Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Placebo
Mild 13(76%) 11 (55%) 15 (79%) 15 (71%)
Moderate 4 (24%) 7 (35%) 4(21%) 5 (24%)
Severe - 2 (10%) - 1 (5%)
Probable 3 (18%) 4 (20%) 8 (42%) 7 (33%)
Possible 5 (29%) 6 (30%) 5 (26%) 3 (14%)
Unlikely 4 (24%) 6 (30%) 4 (21%) 5 (24%)
None 5 (29%) 4 (20%) 2 (11%) 6 (29%)
The most commonly reported events (i.e. reported by more than 5% of patients in any 
treatment group) are summarised in Table 38 below:
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Table 38 Summary of adverse events reported by >5% of patients in any treatment group during double-blind 
phase
MedDRA* preferred term Number of patients reporting
Treatment group
Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Placebo
NAUSEA 1 (2%) 3 (6%) 3 (6%) 5 (9%)
VOMITING 1 (2%) 5 (10%) 2 (4%) 2 (4%)
PYREXIA 1 (2%) 3 (6%) 2 (4%) 2 (4%)
HAEMATOMA - - - 3 (6%)
* Medical Dictionary of Regulatory Activities
Generally, the reports of nausea and vomiting were assessed by the investigator as being 
probably or possibly related to treatment, whilst reports of pyrexia were assessed as having 
an unlikely or no relationship to treatment.
Table 39 below lists the number of patients who had the commonly reported side effects 
associated with morphine (Moulin 1996) ongoing during the double-blind phase. This table 
includes patients who had ongoing adverse events at the time of randomisation which were 
not attributable to treatment.
Table 39 Summary of ongoing adverse events commonly reported with morphine during the double-blind phase 
(Mouiin et ai, 1996)
MedDRA preferred term Number of patients reporting
Treatment group
Hyd. 2 mg 
(n=51)
Hyd. 4 mg 
(n=49)
Hyd. 6 mg 
(n=51)
Placebo
(n=54)
ABDOMINAL PAIN 1 (2%) - - 1 (2%)
ABDOMINAL PAIN UPPER 1 (2%) - - -
CONSTIPATION - 1 (2%) - 1 (2%)
DIARRHEA - - - 1 (2%)
DRY MOUTH 1 (2%) - 1 (2%) -
NAUSEA 2 (4%) 4 (8%) 5 (10%) 5 (9%)
VOMITING 1 (2%) 5(10%) 3 (6%) 2 (2%)
DIZZINESS (EXC VERTIGO) - - 2 (4%) -
SEDATION - - - 1 (2%)
SOMNOLENCE - - 1 (2%) -
CONFUSION - 1 (2%) - -
SLEEPING DISORDER 1 (2%) 1 (2%) - 2 (2%)
PRURITUS - 1 (2%) 1 (2%) -
Number of patients reporting any 
of the above
7(14%) 13(27%) 11 (22%) 12 (22%)
Five patients withdrew due to adverse events during the double-blind phase, one in the 
hydromorphone 2-mg group, three in the hydromorphone 4-mg group and one in the 
placebo group. Patient number 667 (hydromorphone 2 mg) withdrew from the study 
because of pain, which was reported as mild and probably related to study medication. He
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was given symptomatic therapy and the outcome was reported as resolved. Patient 519 
(hydromorphone 4 mg) withdrew due to a headache of moderate severity, which was 
reported as being not related to study therapy. She was given symptomatic therapy for the 
headache, which resolved. Patient 529 (hydromorphone 4 mg) withdrew due to moderate 
pyrexia, which was not related to study therapy. He was given symptomatic therapy and the 
event resolved. Patient 837 (hydromorphone 4 mg) withdrew from the study because of 
mild anxiety possibly related to study medication. No action was taken and the event 
resolved. Patient number 581 (placebo) withdrew due to severe nausea probably related to 
study therapy. She was given symptomatic therapy and the nausea resolved.
The difference between treatment groups in the proportion o f patients reporting adverse 
events during the double-blind phase was not statistically significant (p=0.59). There were 
no deaths during the study and no serious adverse events.
The percentage o f patients being awake, alert and orientated was, in general, lower in the 
placebo group at each hourly assessment (Table 40). Scores o f 1 in the sedation scale 
(dozing intermittently, drowsy or lethargic but roused by physical stimulus) were equal at 
baseline, but more prevalent in active treatment groups in the measures made after dosing. 
Generally, the 95% confidence intervals for these measures did not suggest a statistically 
significant finding. Within the treatment groups, there did not appear to be a relationship 
with dose level. The five individual reports of scores of 2 were equally distributed between 
the hydromorphone and placebo groups.
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Table 40. Level of sedation at each assessm en t (observed data)
Time
(hours)
Treatment group n
Level of sedation® 
0 1 2 3 % graded 
as 0
Difference 
relative to 
placebo
95% Cl for 
difference
Baseline Hydromorphone 2mg 51 45 6 88 -3 -14,9
Hydromorphone 4mg 49 41 8 - - 84 -7 -20,6
Hydromorphone 6mg 51 48 3 - - 94 3 -7,13
Placebo 54 49 5 - - 91
1 Hydromorphone 2mg 49 40 9 - 82 10 -6,26
Hydromorphone 4mg 48 35 13 - - 73 1 -16,19
Hydromorphone 6mg 50 38 11 1 - 76 4 -13,21
Placebo 53 38 15 - - 72
2 Hydromorphone 2mg 47 38 9 - - 81 11 -6,29
Hydromorphone 4mg 46 31 15 - - 67 -2 -21,17
Hydromorphone 6mg 49 35 14 - - 71 2 -16,20
Placebo 49 34 15 - - 69
3 Hydromorphone 2mg 44 38 6 - - 86 18 1,36
Hydromorphone 4mg 43 31 12 - - 72 4 -16,23
Hydromorphone 6mg 46 38 8 - - 83 14 -4,32
Placebo 41 28 12 1 - 68
4 Hydromorphone 2mg 42 33 9 - - 79 12 -7,31
Hydromorphone 4mg 40 31 8 1 - 78 11 -9,30
Hydromorphone 6mg 41 35 6 - - 85 19 0,37
Placebo 39 26 12 1 - 67
5 Hydromorphone 2mg 40 30 10 - - 75 8 -12,29
Hydromorphone 4mg 37 30 7 - - 81 14 -5,34
Hydromorphone 6mg 36 31 5 - - 86 19 0,39
Placebo 36 24 11 1 - 67
6 Hydromorphone 2mg 41 36 5 88 4 -11,20
Hydromorphone 4mg 37 32 5 - - 86 3 -13,20
Hydromorphone 6mg 34 28 6 - - 82 -1 -19,17
Placebo 36 30 6 83
3 Measured on a 4-point scale (0 = awake, alert, orientated; 1 = dozing Intermittently, drowsy or lethargic but aroused 
by physical stimulus; 2 = mostly sleeping, difficult to arouse but feasible by physical stimulus; 3 = difficult to waken, 
little or no response even to physical stimulus)
Therefore, it would appear that in this setting, the tolerability of the three hydromorphone 
doses was comparable to placebo.
5.2.6 Discussion
This study collected standardised data in a complex and varied setting. Treatment for 
postoperative pain varies between practitioners in the same hospital, so differences in 
practice are inevitably an issue in a study conducted across multiple centres in three 
countries. The need to control variables in the study conflicts with the ability to recruit 
sufficient numbers of centres and patients in order to be able to conduct the study in a 
practicable manner.
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The controls in this study began once the patient left the operating theatre. Morphine PCA 
(subcutaneous or intravenous) was to be the principal analgesic, with an optional single 
dose of 100 mg of rectal diclofenac. Paracetamol and NSAID treatments have become 
extremely well established in the treatment of post-operative patients (Kehlet 1999), so 
excluding them would have caused severe difficulties in the management of the study. For 
the purpose of managing pyrexia and headache during the PCA period, paracetamol was 
permitted provided that at least 6 hours elapsed between administration and the study 
baseline assessment. This was to ensure that the analgesia assessed at baseline was 
attributable only to morphine PCA, Active physiotherapy was to precede pain assessments 
by at least 30 minutes, thus enabling an assessment of background pain, rather than acute 
pain attributable to the physiotherapy itself.
The elements that were not controlled by the study were the anaesthetic procedure itself and 
the use of a single rectal dose of 100 mg diclofenac peri-operatively for early post-operative 
pain management in some study centres. The variability in anaesthetic technique resulted in 
some patients receiving regional anaesthetic procedures which had long durations of action. 
This resulted in the use of morphine PCA being superimposed on persisting effects from 
regional anaesthesia. However, the effects o f these long-duration treatements should have 
resolved by the time of randomisation (a minimum of 18-hours post surgery).
Hydromorphone 4 mg and 6 mg were significantly more effective than placebo in the relief 
o f post-operative pain. Mean SPID values for pain at rest, the principal efficacy measure, 
were -5 .2  and -4 .4  for hydromorphone 4 and 6 mg, respectively (p-0.03 compared with 
placebo). These results are comparable with other placebo controlled study of opioids in 
postoperative pain, although these studies used a 4-point categorical pain score, rather than 
the 11-point numerical one used here (Baird 1980, Sunshine 1996).
The study precision was adequate to meet the study objectives, the LSD for the principal 
efficacy measure was 4.97 compared to the detectable difference o f 7.0 quoted in the 
protocol, despite the variability (S.D.) being slightly larger at 12.4 than predicted (11.0).
All treatment differences were less than 7.0, however this value was never deemed to be the 
smallest clinically relevant difference.
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Results were similar for the analyses of pain on movement: mean values for SPID were -5.6 
and -3 .9  for hydromorphone 4 mg and 6 mg, respectively (p=0.04 compared with placebo). 
Both doses were also superior to placebo in the analysis of the AUC for pain on movement 
(p=0.03). Again, the decreases in pain on movement were greatest during the first three 
hours post-treatment.
A total of 76 (37%) patients withdrew from the study. Of these patients, the proportion 
using rescue medication was highest in the placebo group (39%). Completion rates in the 
respective countries varied (88% in France, 53% in the UK and 47% in the Netherlands). 
Within countries, there were marked differences between centres in respect to the 
percentage of patients completing the 6-hour study period. Within each centre, however, 
the completion rate did not vary greatly between the study treatments. This suggests that 
the variability was due to investigator differences, rather than treatment-related factors. 
Seventy of the patients who withdrew from the study used rescue medication. Morphine 
was the most commonly used rescue medication, being administered in 44 (63%) patients. 
The proportion of patients receiving morphine as rescue medication was similar across the 
dose groups. The dropout rate meant that values for the efficacy endpoint (pain at rest) had 
to be imputed for the times of measurement after which an individual patient withdrew from 
the study. A last-observation-carried-forward method was used for this, as recommended by 
the Food and Drug Administration of the USA (FDA 1995).
A total of 148 patients (72%) reported pain at rest which returned to the original baseline 
value. The highest proportion occurred in the placebo group (77%), whilst the lowest 
proportion was in the hydromoiphone 6 mg group (63%). The Kaplan-Meier estimates for 
time for pain at rest returning to baseline value were 165.4, 191.6, 209.5 and 109.7 minutes 
for the hydromorphone 2, 4 and 6 mg groups and the placebo group, respectively. The 
comparison between hydromorphone 6 mg and placebo was statistically significant, 
although the comparison between 2 mg and placebo and 4 mg and placebo were not 
statistically significant.
The absolute mean change measured in the 11-point niuuerical rating scale used was 
relatively small, being somewhat less than one point. The study was sufficiently precise to 
be able to attach a statistical significance to this difference, but the clinical significance of 
this degree of change is a separate issue. This amount of change would probably not be
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regarded as significant in a clinical setting, but there are several factors in the study setting 
which constrain the outcome. One of these is the variability of patients’ response to opioid 
analgesia (Ogilvy 1994) and the inability to allow for this variability in the study setting 
where dose level and dosing regimen is fixed. A second factor is the use of hydromorphone 
as a monotherapy in the study setting. In the clinical setting, combinations of opioids and 
non-opioid agents would be used (Ogilvy 1994, Kehlet 1999). Another factor in the study 
setting is the expectation of the patient regarding the degree of analgesia. Although the 
study was double-blind, the process of informed consent ensured that patients were aware 
that they might receive a placebo dose and further, that they had the opportunity to leave the 
study at any time and receive alternative analgesia, hence the large numbers of patients 
withdrawing due to lack of efficacy. These factors combined to create a poor expectation of 
pain relief on the patients’ part and patients’ expectations can affect the degree of analgesia 
that they experience (Polio 2001, Rowbotham 2001).
The study did not include a formal statistical analysis of dose ranging. However, in the 
efficacy parameters studied, it was possible to discern a trend between dose and response. 
The general finding in terms of efficacy was that 2 mg could not be distinguished from 
placebo, while both 4 and 6 mg could be distinguished from placebo to a statistically 
significant degree and to a greater extent than the 2 mg dose, but not from each other. This 
pattern was seen in several of the efficacy analysis performed, including sum of pain 
intensity differences for pain at rest and on movement and differences in pain scores at 
individual time points. The surrogate markers for duration of action and time for pain score 
to return to baseline value did not demonstrate a statistically significant difference, but were 
suggestive of this same trend.
The duration of effect from the different active treatments can be inferred from several of 
the efficacy parameters studied. In terms of the pairwise comparisons with placebo of pain 
scores, the 2 mg dose’s effect was absent from 2 hours post-dose and for 4 and 6 mg, the 
effect was absent from 4 hours. These figures depend upon the power of the study, 
however. From inspecting the plots of the pain scores, the 2 mg dose seems to lose its 
effect from 2 hours post-dose and the 4 and 6 mg doses from 5 hours for pain on movement 
and for pain at rest, the effect seems to persist until the end of the 6 hour period. In terms of 
the time for pain score to return to baseline value, the duration of effect appears to be 
between 2 and 3 hours for the 2-mg dose, and between 3 and 4 hours for the 4 and 6-mg
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doses. This compared with a value of between 1 and 2 hours for the placebo group. The 
duration of action demonstrated from this study therefore appears to confirm the 
recommended dosing interval of 3 to 4 hourly and seems to correspond with the distribution 
/ elimination half-life observed in recent pharmacokinetic studies, rather than the longer 
terminal elimination half-life (U.S. Department of Health and Human Services, 1992).
There was an imbalance between countries in terms of post-operative analgesia. PCA was 
used for longer in the UK than in France or the Netherlands, leading to a much higher total 
morphine consumption. Many variables come into play in determining the duration of PCA 
from standard institutional medical practice to the availability of infusion pumps. However, 
use of morphine in milligrams per hour was comparable.
The safety profile o f hydromorphone was good. There was no statistically significant 
difference between the four treatment groups in the proportion of patients reporting adverse 
events. Most adverse events were mild and the relationship to therapy was unlikely or none 
for approximately 50% of the reported events. Nausea, vomiting and pyrexia were the most 
common adverse events. Generally, the reports of nausea and vomiting were assessed by 
the investigator as being probably or possibly related to treatment, whilst reports of pyrexia 
were assessed as having an unlikely or no relationship to treatment. This is not unexpected 
as nausea and vomiting are commonly reported side effects associated with opioids. Similar 
numbers of patients in the hydromorphone 4-mg, 6 mg and placebo groups experienced 
adverse events commonly reported with morphine; patients in the hydromorphone 2-mg 
group reported fewer o f these events. More specific questioning of patients regarding 
sedation failed to demonstrate a difference between active and placebo doses. Finally, only 
five patients withdrew from the study due to adverse events (one in the 2-mg group, three in 
the 4-mg group, none in the 6-mg group and one in the placebo group).
5.2.7 Conclusions
The relevance of this study to the acute pain setting, in general, is strong, as post-operative 
knee-replacement patients are an accepted model of moderate-to-severe pain. Svensson 
(2000) recently highlighted the important nature of the later post-operative period, which 
follows the immediate recovery from surgery. The population was relatively old (mean age 
67.8 years), which is typical of the more general post-surgical population.
28/09/01
MD Thesis for Dr Colin JA Durnin 2001 Page 79
Assay sensitivity, the ability to demonstrate the statistically significant activity of an 
analgesic agent compared to placebo or to another agent, represents a noteworthy 
achievement for any analgesic study (Schachtel, 1991). Hydromorphone 4 mg and 6 mg 
were statistically significantly more efficacious than placebo in the treatment of pain in the 
post-operative recovery of patients who underwent primary knee replacement surgery. The 
tolerability o f the three hydromorphone doses was comparable to placebo. These findings 
confirm impressions gained from more than 50 year's of clinical use in North America. 
Namely, hydromorphone is an effective and safe analgesic in the treatment of acute pain.
The results o f this study were given as an oral presentation at the European Congress of 
Anaesthesiology in Florence, Italy, June 2001. The presenting author was Dr Slappendel. 
(Slappendel 2001a).
10/01/02
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5.3 Active-controlled multiple-dose study in postoperative pain
5.3.1 Study summary
The title o f the study is “A double-blind, repeat-dose, active-control dose-ranging 
investigation into the efficaey and tolerability of an immediate-release tablet formulation of 
hydromorphone versus morphine in the treatment of acute post-operative pain”. The co­
ordinating investigator was Professor D Rowbotham, of Leicester Royal Infirmary, 
Infirmary Road, Leicester, LEI 5WW.
The objectives o f the study were to demonstrate that multiple dosing of hydromorphone was 
within the range of the efficacy of morphine for the control of pain in post-operative 
patients who had undergone primary Imee replacement surgery and to evaluate the safety of 
multiple doses of hydromorphone compared with morphine during the post-operative study 
period.
The methodology was very similar to the single-dose study, being multicentre and double 
blind, but was repeat-dose and active-controlled and sought equivalence, rather than a 
statistically significant difference. Patients received doses o f hydromorphone 2, 4 or 6 mg 
or morphine 20 mg every 3-6 hours over a 48-hour treatment period. One additional 50% 
“rescue” dose of the respective medication was permitted from one to two hours after the 
first dose of study medication. Assessments of pain, respiratory rate, sedation, nausea and 
vomiting were made at baseline (0 hours) and intervals throughout the treatment period.
The planned number of patients was 240, 60 in each of the four treatment groups. 271 
patients entered the randomised phase, 68 received hydromorphone 2 mg,
71 hydromorphone 4 mg, 67 hydromorphone 6 mg and 65 morphine sulphate 20 mg. A 
total of 268 patients were included in the “full analysis” set for the principal measure of 
efficacy.
The patients were in-patients, aged >18 years of age, who required post-operative analgesic 
therapy for pain following primary Imee arthroplasty. At baseline, patients were to rate 
their pain in their knee as > 4 according to the Brief Pain Inventory (BPI).
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The efficacy parameters selected were pain at rest, pain on movement and average dose of 
study medication used. The safety parameters were adverse events, respiratory rate, 
sedation, nausea and vomiting.
The efficacy results were that the adjusted means for the principal measure, namely the 
AUC (0-48 h) of pain at rest/48 for the “full analysis” set were 4.6 (hydromorphone 2 mg), 
4.0 (hydromorphone 4 mg), 3.5 (hydromorphone 6 mg) and 3.9 (morphine sulphate 20 mg). 
Each dose of hydromorphone was considered equivalent to morphine if the two one-sided 
tests for non-inferiority and non-superiority were not significant at the 2.5% level. This was 
the case and thus it was concluded that the means for all three hydromorphone treatments 
were within +/- 1.5 o f the mean for morphine sulphate 20 mg. The results also implied an 
ordering between the treatments, with hydromorphone 6 mg as the most effective treatment, 
hydromorphone 2 mg as the least effective treatment and hydromorphone 4 mg and 
morphine sulphate 20 mg being very similar.
Analysis of the AUC (0-48 h) of pain at rest/48 for the per-protocol set provided adjusted 
means of 3.9 (hydromorphone 2 mg), 3.8 (hydromorphone 4 mg) 3.4 (hydromorphone 6 
mg) and 3.8 (morphine sulphate 20 mg). The adjusted means were lower than in the “full 
analysis” set, with hydromorphone 6 mg still the most favoured treatment in terms of 
efficacy. The adjusted means were lower because the per-protocol set did not include, 
amongst others, 20 patients who did not provide at least three hours’ data and whose pain 
scores were in general much higher.
For the analysis of the AUC (0-48h) of pain at rest/48 for the “full analysis” set including 
assessments subsequent to withdrawal, the actual adjusted means for the four treatments 
were similar, the largest difference being 0.5 for the difference between hydromorphone 2 
mg and morphine sulphate 20 mg, in favour of the latter. The reason for the lack of 
difference between the treatments was that subsequent to withdrawal, the majority of 
patients were taking other rescue analgesia for their condition.
Analysis o f the AUC (0-48h) of pain on movement/48 for the “full analysis” set provided 
adjusted means of 6.6 (hydromorphone 2 mg), 6.1 (hydromorphone 4 mg), 5.7 
(hydromorphone 6 mg) and 5.8 (morphine sulphate 20 mg). The difference between 
hydromorphone 2 mg and morphine sulphate 20 mg, just failed to reach statistical
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significance at the 1,7% level as indicated by the Sidak adjusted 95% confidence interval 
(-0 .02, 1.6).
The proportion of patients requiring the 50% rescue dose was 49%, 45% and 39% for the 
hydromorphone 2 mg, 4 mg and 6 mg groups respectively. The corresponding figure for 
morphine sulphate 20-mg was 49%. There was no statistically significant difference 
between the treatment groups in the time to use of the 50% rescue dose.
The proportion of patients requiring rescue analgesia (other than the 50% rescue dose) 
during or on withdrawal from the double-blind phase was 34%, 25%, and 25% for the 
hydromorphone 2 mg, 4 mg and 6 mg groups respectively. The corresponding figure for 
morphine sulphate 20-mg was 31%. The most common rescue analgesia used was 
morphine with 48 (18%) patients reporting its use. There was no statistically significant 
difference (p=0.22) between the four treatment groups in the time to first use of rescue 
medication/second dose of study medication/withdrawal (whichever the sooner). None of 
the three pairwise comparisons between the three hydromorphone doses and morphine 
sulphate 20 mg was statistically significant at the 1.7% level (Sidak adjusted 5% level). The 
mean Kaplan-Meier estimates were 186.4, 292.9 and 228.4 minutes for the hydromorphone 
2 mg, 4 mg and 6 mg groups respectively. The corresponding figure for the morphine 
sulphate 20-mg group was 275.1 minutes.
Including only those patients in the “full analysis” set, the mean average dose of 
hydromorphone including the 50% rescue dose was 0.54, 0.85 and 1.20 mg/hour for the 2 
mg, 4 mg and 6 mg groups respectively. For the morphine sulphate 20 mg group, the mean 
average dose including the 50% rescue dose was 4.49 mg/hour. Converting the above data 
into percentages, patients in the hydromorphone 2-mg treatment group received on average 
27% of their randomised dose per hour. The equivalent figures for the other tlu ee treatment 
groups were smaller; 21% (hydromorphone 4 mg), 20% (hydromorphone 6 mg) and 22% 
(morphine sulphate 20 mg).
Adverse events were reported by 42 (62%) patients, 42 (59%) patients, 45 (67%) patients 
and 38 (58%) patients, respectively for the hydromorphone 2 mg, 4 mg, and 6 mg and 
morphine sulphate 20 mg dose groups; there was no statistically significant difference 
between the four groups in the proportion of patients who reported adverse events. Most
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adverse events were mild and the relationship to therapy was unlikely or none for 
approximately 40% of the reported adverse events. Nausea, vomiting, pyrexia and sedation 
were the most common adverse events. Generally, the reports of nausea, vomiting and 
sedation were assessed by the investigator as being probably or possibly related to 
treatment, whilst reports of pyrexia were assessed as having an unlikely or no relationship to 
treatment. This is not unexpected as nausea, vomiting and sedation are commonly reported 
side effects associated with opioids. Some of the event rates are suggestive of trends, but 
statistical testing of these differences failed to demonstrate significance. A total of 14 
patients withdrew from the study due to adverse events (3, 5 and 5 in the hydromorphone 2 
mg, 4 mg and 6 mg treatment groups, respectively and one in the morphine sulphate 20 mg 
treatment group). The serious adverse events reported by patients treated with 
hydromorphone during the double-blind phase of the study were all considered to have an 
unlikely or no relationship to study medication by the investigator. There were no clinically 
significant differences in respiratory rate, level of sedation or nausea and vomiting gradings 
between the four treatment groups.
The study concluded that hydromorphone 2mg, 4mg and 6mg were considered equivalent to 
morphine 20mg in the treatment of pain in the post-operative recovery of patients who 
underwent primary knee replacement surgery. Efficacy increased with increasing doses, the 
6 mg dose being statistically significantly more potent than the 2 mg dose. The 4-mg dose 
was closest in efficacy to the morphine sulphate 20-mg dose, suggesting an equipotency 
ratio of 5 for this setting. The tolerability o f the three hydromorphone doses was 
compai'able to morphine sulphate 20 mg. These findings confirm impressions gained from 
more than 50 years of clinical use in North America. Namely, hydromorphone is an 
effective and safe analgesic in the treatment of acute pain.
5.3.2 Introduction
This study was designed as a direct successor to the single-dose study in postoperative pain. 
Consequently, the same doses of hydromorphone and the same patient population and 
treatment procedures were used. The major distinction between the two studies is that the 
multiple-dose study examined a dosing period of two days, as opposed to the six-hour study 
period in the single-dose study, and the compaiator in the multiple-dose study was 
morphine instead of placebo. The dose of morphine (20 mg) was selected to represent
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clinical practice and to be equipotent to 4 mg of hydromorphone, assuming an equipotency 
ratio of 1:5.
Largely, the same countries participated and in many cases, the same centres participated in 
both studies. The aim was to standardise as much as possible between the two studies and 
the majority of differences were brought about through practical requirements of dosing for 
longer intervals. The major difference in dosing regimen was brought about because it was 
felt that it was inappropriate to impose a fixed dosing regimen of oral opioids in this patient 
population. Therefore, after the initial dose, dosing was on a flexible “three to six hourly as 
required” basis. Additionally, a half-strength “rescue” dose was added between the first 
dose and the next possible dose at tlnee hours after the first dose. This was added because of 
concerns over the possibility of high dropout rates in a two-day study in this setting, 
especially during the first “settling in” part of the study. Additionally, this change was made 
since the statistical analysis of this study was based on equivalence rather than difference, 
and it was considered more important to minimise the dropout rate in order to achieve as 
high as possible completion rate for patients “per protocol” (CPMP 1999, Jones 1996).
One other difference between the two studies was brought about because of a perceived 
wealoiess in the single-dose study -  namely, a lack of a qualifying pain score at the time of 
randomisation. Tlu'ough adding a qualifying pain score, patients are more likely to comply 
with the perceived need for pain to be o f moderate to severe in its severity, and thus be 
appropriate for the administration of an oral opioid. The particular value selected was 
greater than, or equal to four on an 11 -point pain scale. This threshold should have resulted 
in the omission of patients with only mild pain (Serlin 1995). Additionally, having patients 
start the study with a higher pain score makes it easier to detect differences between 
treatments. The imposition of a qualifying pain score had some practical consequences, 
however, since it was important to avoid the scenario of repeat assessments of patients until 
the point at which the pain score was high enough for them to qualify for the study.
As an equivalence study, there was a requirement to pre-specify what would be considered 
to be a clinically significant change in the primary efficacy endpoint (pain score as reported 
by the patient). The pain scale was the 11-point numerical one used in the single-dose study 
and the clinically equivalent range agreed was ±1.5. This value was agreed tlirough 
consultation with opinion leaders during the planning of the study. Other values have been
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proposed for a clinically equivalent range (see section 5.3.6). The problem is that the 
clinically equivalent range on a subjective rating scale is impossible to define. Various 
attempts have been made to do this, especially in the area of quality of life assessments, but 
the arguments are essentially circular, since the question is based on a subjective assessment 
on another subjective assessment.
5.3.3 Objectives
The objectives o f the study were:
• To demonstrate that multiple dosing of hydromorphone was equivalent to morphine for 
the control of pain in postoperative patients who had undergone primary knee 
replacement surgery.
• To evaluate the safety of multiple doses of hydromorphone compared with morphine 
during the post-operative study period.
5.3.4 Methods
This was a multicentre, phase II, randomised, double blind, active-control, parallel-group 
equivalence study. The study was conducted at 27 centres in the United Kingdom, Eire, 
Netherlands and France. Twelve centres were common to the single and multiple-dose 
postoperative pain studies. The planned sample size was 200 patients receiving study 
medication following entry into the study (50 patients in each of the four study treatment 
groups). A planned blinded re-estimation of sample size was performed after 50 patients 
completed treatment in order to re-evaluate the number of patients required to enter the 
study. This resulted in the sample size increasing to 240 patients.
5.3.4.1 Patient selection
The selection criteria for patients were identical to the single-dose study.
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5.3.4.2 Study procedures
A diagram of the study design is given below:
Figure 14. Multiple-dose postoperative pain study design
HYDROIVDRPHONE 2 mgEND
PCA
HYDROMORPHONE 4 mg
18 to 48 hours
HYDROMORPHONE 6 mg
START
PCASCREENING SURGERY
48 hours
The consent, screening and baseline procedures were identical to the single-dose study, with 
the exception of the qualifying pain score required in this study. Each patient underwent the 
baseline study assessment of pain intensity (using an 11-point rating scale ranging from 0 = 
“no pain” to 10 = “pain as bad as you can imagine”). Patients with a score of four or more 
for pain at rest were then entered into the study; patients not meeting this criterion left the 
study and received appropriate medical care. Patients were not informed in advance of what 
score was necessary to enter the study. Each patient had their pain scored at baseline on one 
occasion only. The randomisation process was identical to the single-dose study. 
Assessments of pain, respiratory rate, sedation, nausea and vomiting were repeated at 
intervals throughout the scheduled forty-eight hour study treatment period. Assessment of 
pain at rest preceded assessment of pain on movement at each timepoint in the same way as 
described for the single-dose study. After the first dose, assessments were performed at 30 
minutes and then hourly for the first six hours. After 6 hours the assessments were 
performed every 3 hours, with a maximum of 6 hours between assessments. These were the 
recommended timings, but they did not have to be strictly adhered to. An assessment must 
have preceded any administration of study medication, including the 50% “rescue” dose.
The arrangements for how physiotherapy interfered with pain assessments were the same as 
in the single-dose study. Assessments continued on a 3- hourly basis for the duration of the 
study, irrespective of whether or not the patient continued to receive study medication. If
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patients were sleeping when an evaluation was due, they could be roused in order to 
complete the evaluation.
One minor change from the single-dose study was that in this study, instead of using 
diclofenac for post-operative NSAID treatment, the French centres used 50-mg i.v. doses of 
ketoprofen. An 8-hour washout period was required between the last dose of ketoprofen and 
the baseline pain assessment. Another modification from the single-dose study was that in 
addition to ondansetron, cyclizine could be used in the post-randomisation phase of the 
study to treat nausea if a sufficient response to ondansetron had not been achieved.
If the patient requested further analgesia between the first and second dose of study 
medication, a single 50% “rescue” dose of the study medication could be administrated in 
addition to the planned 3-6 hourly-when-required regimen. The 50% “rescue” dose could 
not be administered within the first hour of receiving the first dose of study medication. The 
choice of the one-hour interval prior to use of the “rescue” dose was based on the known 
pharmacokinetics of the respective immediate-release formulations, the known onset of 
action from the single-dose study and from established clinical practice in the use of oral 
opioids. Assessments then continued with the next dose of medication administered, if 
required, at the scheduled time point. Further requests for “rescue” analgesia resulted in the 
patient being withdrawn from the study.
Patients could be withdrawn at any time during the study treatment period (e.g. because of 
lack of efficacy or tolerability problems with the study medication). If a patient was 
withdrawn, they immediately had their vital signs recorded and underwent a physical 
examination, pain assessment and had their status assessed. If the patient did not withdraw 
consent then the pain assessments were to be continued as per protocol. At the point of 
withdrawal the patient was to receive the rescue analgesia considered appropriate within the 
individual hospital (e.g. either re-commencement of morphine therapy with the PCA system 
or initiation of other parenteral/oral analgesic therapy). The time of re-medication was 
recorded.
The tolerability for all recruited patients was to be monitored throughout the study period by 
recording the adverse events experienced. In addition, respiratory rate, sedation, nausea and 
vomiting were to be assessed at hourly intervals throughout the first 6 hours of the study
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and then every 3 hours. Sedation and nausea were assessed using a 4-point scale. The 
sedation scale was the same as was used in the single-dose study and the nausea scale was 
the same as was used for all adverse events in the single-dose study.
5.3.4 3 Study assessments
Table 41 below details the timing of the assessments made in the study.
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S.3.4.4 Study medication, blinding and randomisation
Patients received either hydromorphone 2 mg, 4 mg or 6 mg or morphine 20 mg, as an 
instant-release tablet within a capsule (for blinding purposes) orally. Patients could also 
receive rescue medication containing 50% of the full dose of hydromorphone/morphine, as 
appropriate. The study medication consisted of brown capsules (size 0) containing 2 mg 
hydromorphone, 4 mg hydromorphone, 6 mg hydromorphone or 20 mg morphine. In 
addition, the following doses of rescue medication were supplied: 1 mg hydromorphone,
2 mg hydromorphone, 3 mg hydromorphone or 10 mg morphine.
Sufficient medication supplies were packed and labelled for 600 patients in total (150 
patients in each of the four treatment groups). The repeat dose o f medication made 
available for each patient was packed in bottles (16 capsules per bottle). In addition, a 
single dose of rescue medication was supplied to each patient in a separate sachet and 
labelled “rescue medication”.
53.4.5 Data entry and statistical analysis
The same procedures for data entry and quality assurance were used as for the single-dose 
study. A random sample of 17 patients had all their information checked. The error rates 
were 0.05% for adverse events, 0.04% for withdrawal information, 0.09% for randomisation 
number records, 0.01% for study medication and <0.01% for the principal measure of 
efficacy. The error rates were considered to be satisfactory and any discrepancies found 
were amended before analysis.
Any one of the three hydromorphone regimens was to be considered equivalent to morphine 
20 mg, if the 95% two-sided confidence interval for the treatment difference, measured 
using the AUC (0-48 h) for pain at rest/48 (principal measure of efficacy) fell wholly within 
the interval ±1.5.
For all efficacy variables 95% two-sided confidence intervals (with Sidak adjustment i.e. 
98.3% intervals (Sidak 1967) for the three comparisons) for the difference between each 
hydromorphone dose and morphine 20 mg were calculated.
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The “full analysis” set (referred to as the intent-to-treat efficacy analysis in the protocol) 
included all patients with data recorded for at least one hour within the post-baseline phase. 
Patients who withdrew from the study had their last observed value for the relevant efficacy 
variable carried forward for all time periods subsequent to withdrawal in all analyses. For 
all analyses, endpoint was defined as the last assessment prior to withdrawal from the study. 
In all the above analyses, any patients with treatment administration errors were to be 
analysed according to the treatment to which they were randomised. All efficacy variables 
were analysed using this set.
Because this was an equivalence study a per-protocol analysis was also performed. The 
per-protocol analysis set was to include all patients in the “full analysis” set excluding 
patients with major protocol violations and deviations. Any difference between this 
analysis and the analysis involving the “full analysis” set was explored and explanations 
identified. All relevant protocol deviations were assessed under blind conditions and 
documented. Only the analyses relating to the principal measure of efficacy were analysed 
using this set. All patients taking at least one dose of study medication were included in the 
analysis of safety. No assessments were excluded from this set.
The treatment groups were assessed for comparability with respect to baseline information, 
in particular the total dose of morphine administered as PCA prior to stopping, the time 
from stopping PCA to taking study medication, use of an NSAID between the operation and 
randomisation, whether the patient received a general or regional anaesthetic and use of 
anti-emetic medication prior to randomisation. Any clinically significant difference was 
accounted for in the subsequent analysis.
The principal measure of efficacy was the AUC (0-48h) for pain at rest/48. The AUC was 
calculated using the trapezoidal rule. Exact timings in relation to the first dose of study 
medication were used for the AUC calculation for all assessments after randomisation. All 
baseline assessments were taken as time 0, irrespective of the exact timing in relation to the 
first dose. If data for less than 48 hours was provided then the last observed value was 
carried forward up to 48-hour time point. Data recorded after 48 hours was ignored in the 
AUC analysis. The reason for dividing the AUC value by 48 was so the value could easily 
be interpreted based on the original BPI scale. If two assessments were recorded at exactly 
the same time then the worst of the recorded pain scores was used in the analysis.
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The actual approach to the testing for equivalence was to follow a two-stage procedure. 
Firstly non-inferiority was investigated. A stepped approach was taken, where the 
morphine 20-mg group was initially compared with the hydromorphone 6-mg group. 
Providing that non-inferiority of hydromorphone 6 mg against morphine 20 mg was proven, 
then hydromorphone 4 mg was to be compared with morphine 20 mg and if non-inferiority 
was again eonfirnied, hydromorphone 2 mg was to be tested against morphine 20 mg. At 
each stage non-inferiority was inferred if the treatment difference (hydromorphone -  
morphine 20 mg) was significantly less than 1,5 (one-sided at the 2.5% level). A negative 
difference favoured hydromorphone. The second part (testing for non-superiority) was to 
be performed if non-inferiority was inferred for one or more hydromorphone dosing 
regimens. Again a stepped approach was to be taken where the morphine 20-mg group was 
compared initially with hydromorphone 2 mg. If non-superiority was proven, 
hydromorphone 4 mg was to be tested against morphine 20 mg, and if this also implied 
non-superiority, hydromorphone 6 mg was to be tested against morphine 20 mg for non­
superiority. At each stage non-superiority was to be inferred if the treatment difference was 
significantly greater than -1.5. Control of the overall type I error for multiplicity was 
achieved by following a closed test procedure for each part. Non-inferiority testing was of 
prime interest and had an overall type I error of 2.5%. If equivalence (i.e. both non­
inferiority and non-superiority) was proven at more than one dose of hydromorphone, an 
informal approach based on examining mean responses and incidenee of adverse events was 
to be used to determine the most efficacious dose of hydromorphone.
The testing procedure as described above was applied to an analysis of covariance 
(Armitage 1987, p.282-95) with factors for treatment and country with the baseline value 
for pain at rest used as a covariate. The 95% two-sided confidence interval (98.3% after 
adjusting for multiple testing) was also calculated for the difference between the adjusted 
means for each hydromorphone dose and morphine 20 mg. An additional analysis, 
including a factor for the treatment-by-country interaction, was performed. If this 
interaction was significant at the 10% level, the source of the interaction and its impact on 
treatment equivalence was assessed.
As it was anticipated that few patients were to be recruited in Eire, these patients were 
pooled with patients recruited from the United Kingdom in the analysis.
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The 95% two-sided confidence intervals (with Sidak adjustment for the three comparisons) 
for the difference between the adjusted means for each hydromorphone dose and morphine 
20 mg were also calculated for the AUC (0-48h) for pain on movement/48. The adjusted 
means were estimated using the same approach as for the principal measure with the score 
at baseline for the variable used as a covariate (no additional analysis, including a factor for 
the treatment-by-centre interaction, was performed) although no actual equivalence region 
was defined.
The average dose (mg/lir) of study medication (including the 50% “rescue” dose if 
appropriate) received for each patient during the study for each treatment regimen was 
tabulated, in order to investigate the impact of the flexible dosing regimen aspect of the 
study.
Mean profiles o f pain at rest and pain on movement by treatment were provided for the “full 
analysis” set. Because many of the later assessments were not recorded at set time points, 
values for each patient were calculated on an hourly basis, based on the exact timing of the 
assessments in relation to the first dose of study medication. In each case the nearest 
assessment to each hourly timepoint was talcen. If two assessments were equally near, the 
earliest recorded assessment was taken.
Adverse event data was handled in the same way as the single-dose study. The difference 
between the treatment groups in the proportion of patients with adverse events was 
compared using the chi-square test (Armitage 1987, p.205-9). If the overall test was 
significant at the 5% level then pairwise comparisons were performed for each 
hydromorphone dose against morphine 20 mg.
Reason for and time of withdrawal were reported. The time to withdrawal was compared 
between treatment groups using the logrank test. Pairwise comparisons were performed for 
each hydromorphone dose against morphine 20 mg with Sidak adjustment. A graph of the 
Kaplan-Meier estimates for each treatment group of time to withdrawal was provided.
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Changes from baseline to endpoint for respiration rate were tabulated by treatment group 
with the 95% confidence intervals with Sidak adjustment for the pairwise differences 
between each hydromorphone dose and morphine 20 mg.
The sedation level and degree of nausea at endpoint were tabulated by treatment group. The 
percentage of patients scoring zero on each of the respective scales were calculated with the 
95% confidence intervals with Sidak adjustment for the pairwise differences for each 
hydromorphone dose against morphine 20 mg.
The number o f occurrences of vomiting during the double-blind phase was tabulated by 
treatment group. The percentage of patients not reporting any occurrences were calculated 
with the 95% confidence intervals with Sidak adjustment for the pairwise differences for 
each hydromorphone dose against morphine 20 mg.
Assumption checking regarding the distribution of data was carried out in the same way as 
for the single-dose study.
Any one of the three hydromorphone regimens was to be considered equivalent to morphine 
sulphate 20 mg, if the 95% two-sided confidence interval for the treatment difference, 
measured using the AUC (0-48h) for pain at rest/48 (principal measure of efficacy) fell 
wholly within the interval ±1.5. The original sample size in the study was 50 patients per 
treatment group. Assuming the variability (S.D.) to be 2.0 (estimated from a previous study 
(Baird 1995)) and 90% power, and a true difference of zero between hydromorphone 4 mg 
and morphine 20 mg and a difference of 0.25 in favour of hydromorphone 6 mg over 
morphine 20 mg then 41 evaluable patients per group were required (if this difference was 
zero, power was 85%, which was the minimum power). Power referred to significant 
non-inferiority of the 4 mg and 6 mg doses and was found by multiplying the power for 
each of these comparisons. A two-sample t-test (Armitage 1987,106-8) (6=1.5) was used 
for the calculation.
After 52 patients had completed the study, the variability for the principal measure was re- 
estimated to be 2.24. This was calculated by taking the root mean square error from the 
analysis of covariance model with factors for treatment group and country with baseline as a 
covariate. This root mean square error was the sole output from a program that accessed the
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treatment code (Peace 1993). An appointed independent person within the Biostatistics and 
Data Management department, who had access to the randomisation code, ran this program. 
A member of the Company’s Quality Assurance department witnessed the running of this 
program. Using the revised variability and 90% power, and assuming a true difference of 
zero between hydromorphone 4 mg and morphine sulphate 20 mg and a difference of 0.25 
in favour o f hydromorphone 6 mg over morphine sulphate 20 mg it was estimated that 60 
evaluable patients per group were required. The methodology used to obtain the new 
sample size estimate was slightly different to that used for the original calculation in the 
protocol. This revised and more precise approach allowed for the correlations between the 
paired comparisons in the test procedure (Channon 2000).
The actual variability estimated from the root mean square error (MSB) from the analysis of 
covai'iance was 2.16 for the “full analysis” set. The corresponding figure for the per- 
protocol set was 1.92.
5.3.5 Results
A total of 377 patients were screened for entry into the study between 5 July 1999 and 27 
March 2000 of whom 271 actually took study medication. O f the 271 patients randomised, 
172 completed the study. Patients were recruited into the study from four countries. Table 
42 below gives the number of patients completing and entering the double-blind phase 
within each country:
Table 42. Summary of number of patients completing and entering the double-blind phase by centre within each  
country
Country Treatment group
Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg Overall
Eire
1/1 (100%) 1/1 (100%) 2/2 (100%)
France
13/18 (72%) 14/18 (78%) 14/17 (82%) 14/17 (82%) 55/70 (79%)
Netherlands
11/25 (44%) 15/25 (60%) 11/23 (48%) 13/24 (54%) 50/97 (52%)
United Kingdom
15/25 (60%) 19/27 (70%) 15/26 (58%) 16/24 (67%) 66/102 (64%)
Withdrawals and reason for withdrawal, as recorded by the investigator, are summarised in 
the Table 43 below. There was no statistically significant difference between treatment 
groups in the time to withdrawal (p=0.43), patients in the hydromorphone 2 mg treatment
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group had the lowest mean time to withdrawal (1227.3 minutes) and patients in the 
hydromorphone 6 mg treatment group had the highest time (1691.2 minutes). The 
proportions withdrawing due to lack of efficacy were 24%, 14% and 12% in the 
hydromorphone 2 mg, 4 mg and 6 mg groups compared to 20% in the morphine 20 mg 
group. Many patients who were classified as having withdrawn due to protocol violation 
were those requiring rescue analgesia. Additionally, withdrawal of consent could have been 
linked with the patient’s perception of insufficient efficacy. Therefore, it is probably more 
appropriate to consider withdrawals as a whole, rather than deal with each sub-category.
Table 43. Summary of patient withdrawals during the double-blind phase
Reason for Treatment group
withdrawal Hydromorphone Hydromorphone Hydromorphone Morphine
2 mg 4 mg 6 mg 20 mg
Total number of patients 68 71 67 65
Adverse event 3 5 5 1
Lack of efficacy 16 10 8 13
Protocol violation 4 5 9 5
Administrative reasons - - - 1
Withdrawal of consent 6 2 4 2
Total withdrawn 29 (43%) 22 (31%) 26 (39%) 22 (34%)
Time to withdrawal (min)
Mean'’ 1227.3 1632.9 1691,2 1460.1
se 78.2 76.0 96.1 83.8
Range 29, 1680 70, 1981 11,2190 60,1862
Comparisons of time to withdrawal (logrank test) df e!
Overall 2.79 3 0.43
Hydromorphone 2 mg versus morphine 20 mg 1.18 1 0.28
Hydromorphone 4 mg versus morphine 20 mg 0.20 1 0.65
Hydromorphone 6 mg versus morphine 20 mg 0.19 1 0.66
Statistically significant if p<0.017 using Sidak adjustment 
Kaplan-Meier estimate
A summary of protocol deviations for all patients randomised is provided in Table 44 
below.
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Table 44. Summary of protocol deviations during the double-blind phase
Deviation'’ Treatment group Overall
Hyd. 2 mg Hyd. 4 mg Hyd, 6 mg Morphine 20mg
Major deviations leading to patients being excluded from PP'' population
Withdrew from the study within three 
hours of the first study medication 
dose'’
7 4 3 6 20
Baseline pain at rest assessments 
more than one hour prior to the first 
dose of study medication
3 2 1 1 7
Took inadmissible analgesics prior 
to first dosing with study medication
1 1 2 1 5
inadmissible analgesics starting 
during the first 60 minutes of the 
doubie-biind phase
1 1 2
Previous major surgery to affected 
knee
- - 1 - 1
Hip {rather than knee) replacement 
performed
- 1 - - 1
Baseline pain at rest less than 4 - - 1 - 1
Number of patients excluded from 10 8 9 9 
PP* population
Major deviations leading to patients being partially excluded from PP* population”
36
inadmissible analgesics starting 
after the first 60 minutes of the 
double-blind phase prior to 
completion/withdrawal
4 3 3 5 15
At least one assessment where 
physiotherapy was performed within 
30 minutes of assessment
4 4 3 5 16
At least one occurrence of study 
medication two hours or less apart
- 1 - 2 3
Number of patients having data 
partially excluded from PP 
population
8 a 6 12 34
Number of patients with at least one 18 
major deviation
Other deviations not leading to exclusion of data
15 15 20 68
Received PCA for <18 hours 3 6 3 4 16
More than 48 hours between surgery 
and first study medication dose
1 1 1 3 6
Baseline pain at rest assessments 
recorded after first dosing of study 
medication"
2 1 1 4
50% rescue dose more than three 
hours after initial dose of study 
medication
1 2 3
Study medication taken after 
withdrawal
- 1 1 - 2
Less than one hour between 50% 
rescue dose and second study 
medication dose
1 1
50% rescue dose less than one hour 
after the first study medication dose
- 1 - - 1
Number of patients with minor 
deviations
7 10 6 9 32
Number of patients with at least one 
deviation
23 21 18 26 88
508) who failed to provide efficacy data for at least one hour, so were not included in the “full 
analysis” set, Assessments subsequent to deviation excluded, The maximum time reported 
after first dose was 10 minutes
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5.3.5.1 Efficacy
A total o f 271 patients entered the double-blind phase of the study. Three patients failed to 
provide data for at least one hour for the principal measiu'e of efficacy, so were not included 
in the “full analysis” set which included 268 patients. One patient in the morphine 20mg 
group (number 410) did not have the splint removed after surgery, as a result this patient did 
not provide any pain-on-movement data.
Regarding demographic information; the treatment groups were relatively well balanced 
with respect to all variables tabulated as summarised in the Table 45 below:
Table 45. Summary of entry profile for all patients randomised
Treatment group
Variable Hyd, 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20mg Overall
n 68 71 67 65 271
Mean age±sd(yr)
Female
Caucasian
Mean height + sd(cm) 
Mean weight ± sd (kg)
67.2 ±8.4 
44 (65%) 
67 (98.5%) 
165.4 ±9.0 
79.6 ± 14.5
68.8 ±8.8 
51 (72%) 
71 (100%) 
163.8 ±11.7 
76.3 ± 13.7
69.1± 9.3 
50 (75%) 
66 (98.5%)
163.3 ± 10,3
77.3 ±14.4
68.3 ± 10.0 
46 (71%) 
63 (96.9%) 
165.2 ± 9.0 
76.0 ± 14.4
68.3 ± 9.1 
191 (70%)
267 (98.5%) 
164.4 ± 10.1
77.3 ± 14.2
Table 46 presents data on the American Society of Anesthesiologists (ASA) classification, 
affected limb, details of post-operative analgesia and time from operation to study 
medication dispensed. The treatment groups were well balanced with respect to these 
variables.
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There were imbalances between countries with respect to total duration of PCA use and the 
corresponding time from the operation to the taking of the first study medication dose, ASA 
classification, type of prosthesis, use of anaesthetics and the use of diclofenac/ketoprofen 
perioperatively and in the early stages of post-operative management. A total of 23% of 
patients (with known gradings) were graded III using ASA in the UK+Eire centres 
compared to 10% in the French centres and 3% in the Dutch centres. The use of general 
anaesthetics was much more common (83%) in the UK+Eire compared to the centres in 
mainland Europe (21% use in France and 9% use in the Netherlands). Etowever, regional 
anaesthetics were only used on 58% of patients recruited in UK+Eire whereas 88% of 
patients in the Netherlands and 81% of patients in France had regional anaesthetics. Six 
patients had no information recorded about anaesthetic use, either regional or general. For 
tabulation purposes these patients were assumed to have taken neither, although this was 
certainly not the case. Only one patient in the non-French centres did not have a total 
prosthesis, whereas in France 53 (76%) reported a total prosthesis, 15 (21%) had a 
unicompartmental prosthesis and 2 (3%) had a patella and femoral head prosthesis. Use of 
diclofenac/ketoprofen perioperatively or in early post-operative management was more 
prevalent in France (53% of patients reporting), compared to the Netherlands (31% of 
patients reporting) and UK+Eire (19% of patients reporting). Patients in the UK+Eire, in 
general, received PCA morphine over a longer time period compared to patients in the other 
two countries. The use of morphine in mg/hour was broadly similar across countries. Table 
47 below summarises these imbalances.
Table 47. Summary of selected  PCA variables by country
Variable France
Country
Netherlands UK+Eire Overall
n 70 97 104 271
% graded as ASA grade III 
(excluding patients with no 
grades recorded)
10% 3% 23% 13%
% using general anaesthetics 21% 9% 83% 41%
% using regional anaesthetics 81% 88% 58% 75%
% with totai prosthesis 76% 100% 99% 93%
% using diclofenac/ketoprofen 
perioperatively or in early 
post-operative management
53% 31% 19% 32%
Median (range) morphine dose 33,5 31.6 47.0 37.0
administered as PCA (mg) (2, 104) (4, 106) (5, 229) (2, 229)
Median (range) amount of 1.40 1.65 1,65 1.60
morphine sulphate administered 
as PCA per hour (mg/h)
(0.1, 2,8) (0.2, 5,8) (0.2, 8.3) (0,1, 8.3)
Median totai duration of PCA (h) 21.1 20.0 35.2 21.3
Median time from operation to 
study medication dispensed (h)
23.7 22.8 41.0 24.4
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Table 48 below summarises the total amount of morphine administered (including non- 
PC A) tabulated by whether the single 100 mg rectal dose of diclofenac or 50 mg i.v dose of 
ketoprofen was given peri-operatively or in early post operative management. Morphine 
consumption was higher in patients who did not receive the diclofenac/ketoprofen dose. 
However, this comparison could have been affected by the national differences in the use of 
NSAIDs and PCA. Since the UK used less NSAIDs and persisted with PCA for longer, this 
would bias this result towards morphine consumption being greater in the non-NSAID 
group.
Table 48. Total morphine administered by diclofenac/ketoprofen use
Received diciofenac/ 
ketoprofen dose
Morphine consumption (mg)
n Mean Median sd Range
Yes 87 36.7 30.0 24.3 4,121
No 184 48.3 42.0 34.3 2,247
Overaii 271 44.6 38.0 31.9 2,247
The most commonly reported ongoing diseases were osteoarthritis reported by 94 (35%) 
patients, localised osteoartlnitis reported by 40 (15%) patients, rheumatoid arthritis reported 
by 25 (9%) patients and artlirosis reported by 22 (8%) patients.
A total of 226 (83%) patients reported previous medications prior to the end of the operation 
including 123 (45%) patients who received psycholeptics, 112 (41%) patients who used 
analgesics, 80 (30%) patients who used anti-inflammatory and anti-rheumatic products and 
44 (16%) patients who used antibacterials for systemic use. A total of 263 (97%) patients 
had ongoing concomitant medications (excluding anaesthetics, extra non-PCA doses of 
morphine and single 100 mg rectal doses of diclofenac or i.v doses of ketoprofen given 
immediately after the operation) at the end of the operation, including 131 (48%) who were 
using antibacterials for systemic use and 124 (46%) who started antithrombotic agents. One 
hundred and sixty nine (62%) patients commenced medications between the end of the 
operation and randomisation, including 89 (33%) who started antithrombotic agents and 60 
(22%) who started antibacterials for systemic use. Sixty-eight (25%) patients commenced 
medications during the double-blind phase including 12 (4%) patients who took analgesics 
for reasons other than rescue purpose, either for a headache or pyrexia. In each case, data 
recorded after the commencement of analgesia were excluded from the per-protocol dataset. 
A total of 102 (38%) patients commenced anti-emetics between the end of the operation and 
randomisation with 89 (33%) using ondansetron. Forty-five (17%) patients commenced 
anti-emetics during the double-blind phase including 42 (16%) patients who used
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ondansetron. The percent reporting in the tliree hydromorphone groups were 16% (2 mg), 
18% (4 mg), 21% (6 mg) compared to 11% for the morphine 20 mg group.
Table 49 below summarises the data concerning the interval between doses of study 
medication. There appears to be a trend towards more frequent dosing with lower doses.
Table 49. Average time between d oses (all patients randomised)
Average time between doses Treatment group
(h) Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg
Total number of patients 68 71 67 65
Number who only had one dose 9 (13%) 6 (8%) 7 (10%) 10 (15%)
Number who had more than one 
dose
59 (87%) 65 (92%) 60 (90%) 55 (85%)
<3 . - 1 1
3 to <4.5 18 9 8 8
4.5 to <6 12 14 18 10
6 to <7.5 13 16 8 12
7.5 to <9 8 6 8 5
9 to <12 6 15 11 14
12 to <15 - 2 3 2
>15 2 3 3 3
Median 5.6 6.6 6.4 7.0
Range 3.0,23.1 3.0,23,4 2.9,20.3 2.5,22.8
5.3.5. LI "Full analysis ” set
For the principal measure of efficacy, namely the AUC (0-48 h) of pain at rest/48 for the 
“full analysis” set, the treatments were considered equivalent if  the two one-sided tests for 
non-inferiority and non-superiority were significant at the 2.5% level. This was the case 
and thus it was concluded that the means for all three hydromorphone treatments were 
within +/- 1.5 of the mean for morphine sulphate 20 mg. The actual adjusted means for the 
four treatments were 4.6 (hydromorphone 2 mg), 4.0 (hydromorphone 4 mg), 3.5 
(hydromorphone 6 mg) and 3.9 (morphine sulphate 20 mg). In the analysis of covariance 
the terms for treatment group (p=0.047) and country (p=0.002) were statistically significant. 
The significance of the treatment group effect was particularly influenced by the difference 
between the hydromorphone 2 mg and 6 mg groups, which was 1.1 in favour of 
hydromorphone 6 mg. Efficacy increased with increasing doses, the 6 mg dose being 
statistically significantly more potent than the 2 mg dose.
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Mean AUC pain scores were in general larger in the Dutch centres. The treatment group- 
by-country interaction was not statistically significant (p=0.93), implying that treatment 
differences were comparable across countries. Table 50 below summarises the data;
Table 50. Analysis of covariance for the AUG (0-48h) of pain at rest/48 (“full analysis” set)
AUC (0-48h) for pain Treatment group
at rest/48^ Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg
(n=67) (n=71) (n=65) (n=65)
Mean ± sd 4.6 ±2.4 3.9 ±2.2 3.4 ±2 .0 4.0 ±2 .6
Range 0.1, 10.0 0.8, 10.0 0.1, 8.9 0.3, 9.9
Adjusted mean" 4.6 4.0 3.5 3.9
Difference in adjusted means 0.7 0.1 -0.4
relative to morphine 20mg”
se (of difference) 0.4 0.4 0.4
98.3% Cl for difference" -0.2, 1.6” -0.8, 0.9 -1.3, 0.5
p (non-inferiority)' 0.014 <0.001 <0.001
p (non-superiority)® <0.001 <0.001 0.002
scale (0 = no pain; 10 = pain as bad as you can imagine)
Adjusted for baseline and country 
A negative difference favours hydromorphone 
Sidak adjusted 95% Cl
Although the upper limit of the Cl is above 1.5, hydromorphone 2mg was considered non-inferior to 
morphine 20mg. Testing of non-inferiority and non-superiority followed a closed test procedure, 
whereas the CIs presented have been adjusted for multiplicity and are at the 98.3% level 
One sided t-test of null hypothesis hydromorphone -  morphine 20mg > 1.5 (non-inferior if p<0.025) 
One sided t-test of null hypothesis hydromorphone -  morphine 20mg < 1.5 (non-superior if p<0.025)
Figure 15 below present the mean profile for pain at rest for the “full analysis” set. It 
clearly shows that in terms of efficacy hydromorphone 2 mg was the least favoured 
treatment and hydromorphone 6mg the most favoured treatment.
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Figure 15. Mean profile for pain at rest (“full analysis” set)
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5.3.5.Î.2 Per-protocol set
The analysis for the AUC (0-48 h) of pain at rest/48 for the per-protocol set, the actual 
adjusted means for the four treatments were 3.9 (hydromorphone 2 mg), 3.8 
(hydromorphone 4 mg) 3.4 (hydromorphone 6 mg) and 3.8 (morphine sulphate 20 mg) (see 
Table 51). The adjusted means in general were lower than in the “full analysis” set, with 
hydromorphone 6 mg still the most favoured treatment in terms of efficacy. The adjusted 
means were lower because the per-protocol set did not include, amongst others, the 20 
patients who did not provide at least three hours data (included in these 20 patients were 
tlii'ee patients also excluded from the “full analysis” set as they provided data for less than 
one hour).
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Table 51, Analysis of covariance for the AUC (0-48h) of pain at rest/48 {per-protocol set)
Treatment group
AUC (0-48h) for pain at rest/48® Hydromorphone 
2 mg
Hydromorphone Hydromorphone 
4 mg 6 mg
Morphine 
20 mg
Total number of patients 58 63 58 56
Mean 4.1 3.8 3.4 3.7
sd 2.1 2.0 1.8 2.5
Range 0.1,9.6 0.8,9.8 0.1,7.1 0.1,9.8
Adjusted mean*’ 3.9 3.8 3.4 3.8
Difference in adjusted means 0.2 0.02 -0.3
reiative to morphine 20 mg'’ 
se (of difference) 0.4 0.4 0.4
98.3% Cl for difference'* -0.7,1.0 -0.8,0.9 -1.2,0.5
p (non-inferiority)® <0.001 <0.001 <0.001
p (non-superiority)' <0.001 <0.001 <0.001
Analysis of covariance F e
Baseiine 33.72 1,228 <0.001
Treatment group 0.72 3.228 0.54
Country 4.15 2,228 0.02
Treatment group-by-country 1.99 6,222 0.07
a The reason for dividing the AUC by 48 was so the value could be easily interpreted with the original scale (0 = no 
pain; 10 = pain as bad as you can imagine) 
b Adjusted for baseline and country
c A negative difference favours hydromorphone
d Sidak adjusted 95% Cl
e One sided t-test of null hypothesis hydromorphone -  morphine 20 mg > 1.5 (non-inferior if p<0.025)
f One sided t-test of null hypothesis hydromorphone -  morphine 20 mg < -1.5 (non-superior if p<0.025)
In the analysis of covariance the term for country (p=0.02) was statistically significant and 
also the term for treatment-by country interaction was significant at the 10% level (p^0.07). 
The adjusted means for each treatment group by country are provided in Table 52 below:
Table 52. Adjusted m eans for the AUC (0-48h) of pain at rest/48 (“per protocol” set)
Country Adjusted means for AUC (0-48h) for pain at rest/48
Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg
France 3.7 (n=16) 3.6 (n=16) 3.5 (n=17) 3.6 (n=15)
Netheriands 5.3 (n=21) 3.8 (n=23) 3.8 (n=18) 3.9 (n=21)
UK4-Eire 2.8 (n=21) 3.9 (n=24) 3.0 (n=23) 3.7 (n=20)
Overall 3.9 (n=58) 3.8 (n=63) 3.4 (N=58) 3.8 (n=56)
The significant interaction term was influenced by the hydromorphone 2-mg means for the 
Netherlands and the UK+Eire. Patients who received hydromorphone 6 mg in the UK+Eire 
centres also seemed to perform better, in terms of efficacy than patients who received the 
same dose in the other two countries.
5.5.5.1.3 “Full analysis ” set including assessments subsequent to wnthdrawal
For the analysis the AUC (0-48h) of pain at rest/48 for the “full analysis” set including 
assessments subsequent to withdrawal, the actual adjusted means for the four treatments 
were similar, the largest difference being 0.5 for the difference between hydromorphone 2
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mg and morphine sulphate 20 mg, in favour of the latter (see Table 53). The reason for the 
lack of difference between the treatments was that subsequent to withdrawal, the majority of 
patients were taking other rescue analgesia for their condition.
Table 53. Analysis of covariance for the AUC (0-48h) of pain at rest/48 (“full analysis” set but also including 
a ssessm en ts subsequent to withdrawal)
AUC (0-48h) for pain at rest/48®
Treatment group
Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Morphine 
20 mg
Totai number of patients 67 71 65 65
Mean 3.5 3.1 3,1 3.0
sd 1.6 1.2 1.4 1.6
Range 0.1,9.6 0.8,6.5 0.2,6.2 0.3,8.6
Adjusted mean** 3.4 3.1 3.2 3.0
Difference in adjusted means 0.5 0.1 0.2
relative to morphine 20 mg®
se (of difference) 0.2 0.2 0.2
98.3% Cl for difference® -0.1,1.0 -0.4,0.7 -0.4,0.8
p (non-inferiority)® <0.001 <0.001 <0.001
p (non-superiority)' <0.001 <0.001 <0.001
Anaiysis of covariance F df E
Baseline 38.52 1,261 <0.001
Treatment group 1.32 3,261 0.27
Country 0.90 2,261 0.41
Treatment group-by-country 0.72 6,255 0.63
a The reason for dividing the AUC by 48 was so the vaiue couid be easily interpreted with the original scale (0 = no 
pain; 10 = pain as bad as you can imagine) 
b Adjusted for baseline and country 
c A negative difference favours hydromorphone 
d Sidak adjusted 95% Cl
e One sided t-test of nuli hypothesis hydromorphone -  morphine 20 mg > 1.5 (non-inferior if p<0.025) 
f  One sided t-test of null hypothesis hydromorphone -  morphine 20 mg < -1.5 (non-superior if p<0.025)
The impact o f using additional rescue analgesia following withdrawal on reducing the pain 
scores can be seen in Table 54 below which compares the pain score recorded immediately
before withdrawal to the score recorded at the end of the study. Combining all the treatment
groups together mean pain scores were reduced by 3.1 from a value of 5.8 immediately 
prior to withdrawal to a value of 2.7 at the end of the study. Note that pain scores on 
withdrawal were much lower in the hydromorphone 6-mg group.
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Table 54. Mean (+ sd) changes in pain at rest scores immediately prior to w ithdrawal to the end of study
Assessment Treatment group
Hyd. 2 mg Hyd, 4 mg Hyd. 6 mg Morphine 20 mg Overall
(n=26) (n=20) (n=25) (n=20) (n=91)
Prior to withdrawal 6.6 ±2.6 6.4 ±2.8 4.2 ±3.3 6.1 ±3 .5 5.8 ±3.1
End of study 2.3 ±1 .9 3.1 ±2.5 3.3 ±2.6 2.3 ±2 .0 2.7 ±2.3
Change -4.3 ± 3.2 -3.3 ±3.2 -0.9 ±2 .9 -3.9 ±2.9 -3.1 ±3.3
5.3.5.1.4 Other analyses
For the AUC (0-48h) of pain on movement/48 for the “full analysis” set, the actual adjusted 
means for the four treatments were 6.6 (hydromorphone 2 mg), 6.1 (hydromorphone 4 mg),
5.7 (hydromorphone 6 mg) and 5.8 (morphine sulphate 20 mg). In the analysis of 
covariance the term for treatment group (p=0.04) and country (p<0.001) were statistically 
significant. The difference between hydromorphone 2 mg and morphine sulphate 20 mg, 
just failed to reach statistical significance at the 1.7% level as indicated by the Sidak 
adjusted 95% confidence interval (-0.02, 1.6). As for the AUC analyses involving pain at 
rest, means were in general larger in the Netherlands. Table 55 below summarises the data:
Table 55. Analysis o f covariance fo r the AUC (0-48h) o f pain on movement/48 (“ fu ll analysis” set)
AUC {0-48h) for pain Treatment group
on movement/48® Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg
(n=67)_________ (n=71)_________ (n=65)_______  (n~64)
Mean± sd 6.6 ±2.2 6.1 ±2.0 5.6 ±2 .0 5.8 ±2.2
Range 1.5, 10.0 2,3, 10.0 1.3, 9.9 1.5, 10.0
Adjusted mean® 6.6 6.1 5.7 5.8
Difference In adjusted means 0.8 0.3 -0.1
relative to morphine 20mg®
se (of difference) 0.3 0.3 0.3
98.3% Cl for difference® -0.02, 1.6 -0.5, 1.1 -0.9, 0.7
The reason for dividing the AUC by 48 was so the value could be easily interpreted with the 
original scale (0 = no pain; 10 = pain as bad as you can imagine)
Adjusted for baseline and country 
A negative difference favours hydromorphone HCI 
Sidak adjusted 95% Cl
Figure 16 below presents the mean profile for pain on movement for the “full analysis” set. 
They clearly show that hydromorphone 2 mg was the least favoured treatment and 
hydromorphone 6 mg the most favoured treatment in terms of efficacy.
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Figure 16. Mean profile for pain on movement (“full analysis” set)
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The proportion of patients requiring the 50% rescue dose was 49%, 45% and 39% for the 
hydromorphone 2 mg, 4 mg and 6 mg groups respectively. The corresponding figure for 
morphine sulphate 20 mg was 49%. There was no statistically significant difference 
between the treatment groups in the time to use of the 50% rescue dose (Table 56).
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Table 56. Time to  use o f 50% rescue dose (alt patients randomised)
Time to use of 50% rescue dose Treatment group
(min)** Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Morphine 
20 mg
Total number of patients 68 71 67 65
Number of patients reporting use of 50% 33 (49%) 32 (45%) 26 (39%) 32 (49%)
rescue dose
<60 1
60-89 20 14 13 12
90-119 6 5 3 6
>120 7 12 10 14
Comparisons (logrank test)
Overall 1.38 3 0.71
Hydromorphone 2 mg versus morphine 20 mg 0.27 1 0.61
Hydromorphone 4 mg versus morphine 20 mg 0.01 1 0.91
Hydromorphone 6 mg versus morphine 20 mg 0.52 1 0.47
Mean'^ 608.8 131.8 126.8 780.3
se 63.4 5.1 4.3 233.5
a Time calculated from time of first dose of study medication
b Statistically significant if p<0.017 by Sidak adjustment
c Kaplan-Meier estimate. Patients who did not use the 50% rescue dose had their time censored at the time of their 
withdrawal or 180 minutes post-dose whichever was the sooner. Excluding the three patients (one in 
hydromorphone 2 mg group and two in the morphine 20 mg group) who used their 50% rescue dose after their 
second dose of study medication the mean (se) Kaplan-Meier estimates were 117.9 (4.7) for hydromorphone 2 mg 
and 133.2 (5.3) for morphine 20 mg
Figure 17 presents the Kaplan-Meier estimates for each treatment. This illustrates that more 
patients required the 50% rescue dose in the hydromorphone 2-mg group from 70 minutes 
post-baseline onwards.
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The proportion of patients requiring rescue analgesia (other than the 50% rescue dose) 
during or on withdrawal from the double-blind phase was 34%, 25%, and 25% for the 
hydromorphone 2 mg, 4 mg and 6 mg groups respectively. The corresponding figure for 
morphine sulphate 20 mg was 31%. The most common rescue analgesia used was 
morphine with 48 (18%) patients reporting its use (Table 57).
Table 57. Details of rescue analgesia used during or on withdrawal from the double-blind phase (all patients 
randomised)
Analgesia” Treatment group
Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Morphine 
20 mg
Total number of patients 68 71 67 65
Number of patients reporting the use 
of rescue analgesia
23 (34%) 18 (25%) 17 (25%) 20 (31%)
Buprenorphine - 1 - -
Codeine - - 2 -
Diclofenac 3 1 3 2
Dihydrocodeine - 1 2 2
Haloperidol 1 - 1 -
Ibu profen - - 1 -
Ketoprofen 1 1 2 2
Meloxicam 2 2 1 2
Morphine 15 11 9 13
Naproxen - - 1 -
Paracetamol 7 4 5 4
Paracetamol+codeine 3 3 - 1
Paracetamoi+dextropropoxyphene 1 1 2 1
Paracetamoi+dihydrocodeine 1 - - -
Piritramide 1 - - -
Propacetamol 2 1 2 1
Tramadol 2 2 1 -
Tylex - - - 1
a Not mutually exclusive
Including only those patients in the “full analysis” set, the mean average dose of 
hydromorphone including the 50% rescue dose was 0.54, 0.85 and 1.20 mg/hour for the 2 
mg, 4 mg and 6 mg groups respectively. For the morphine sulphate 20 mg group, the mean 
average dose including the 50% rescue dose was 4.49 mg/hour. Converting the above data 
into percentages, patients in the hydromorphone 2-mg treatment group received on average 
27% of their randomised dose per hour. The equivalent figures for the other three treatment 
groups were smaller; 21% (hydromorphone 4 mg), 20% (hydromoiphone 6 mg) and 22% 
(morphine sulphate 20 mg).
5.3.5.]. 5 Statistical/analytical issues
Due to the nature o f the analysis, patients who withdrew from the analysis had their last 
recorded pain score prior to withdrawal carried forward to 48 hours for purposes of
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calculating the AUG. As illustrated in Table 58 below the mean AUG for pain at rest for the 
patients who withdrew early from the study was much larger than for the other patients in 
the “full analysis” set:
Table 58 Mean AUG (0-48h) of pain at rest/48 for early withdrawals versus other patients (“full analysis” set)
Patient population Means for AUG (0-48h) for pain at rest/48
Hyd. 2mg Hyd. 4mg Hyd. 6mg Morphine
20mg
Overall
Early withdrawals® 8.1 (n=6) 9.2 (n=4) 6.9 (n=1) 7.5 (n=6) 8.1 (n=17)
Other patients 4.3 (n=61) 3.6 (n=67) 3.4 (n=64) 3.6 (n=59) 3.7(n=251)
® Includes patients who withdrew within three hours of first dosing
As a result o f excluding the very early withdrawals, the variability decreased and therefore 
the Sidak adjusted confidence intervals were much narrower in the per-protocol dataset.
Using the interpolation technique as advocated by Ghannon (2000), it was possible to 
calculate the equipotent dose of hydromorphone against morphine sulphate 20 mg, 
assuming an equivalence zone of +/- 1.5. For the principal measure of efficacy, the 
equipotent doses were 4.2 mg for the “full analysis” set and 4.1 mg for the per-protocol set. 
For AUG (0-48 h) of pain on movement/48 the equipotent doses for the “full analysis” set 
was much higher, namely 5.5 mg.
5.3.5.1.6 Efficacy conclusions
Hydromorphone 2 mg, 4 mg and 6 mg, when dosed on a flexible basis and assuming a 
clinical equivalence zone of ± 1.5, were considered equivalent to morphine 20 mg in the 
treatment of pain in the post-operative recovery of patients who underwent primary knee 
replacement surgery. Efficacy increased with increasing doses, the 6 mg dose being 
statistically significantly more potent than the 2 mg dose.
S.3.5.2 Safety
Table 59 below summarises the total dosage (in mg including the 50% rescue dose) of study 
medication for each of the four treatment groups for the time that each individual patient 
remained in the study. The exposure, proportional to the dose administered on each 
occasion, appears broadly similar across the groups. It should be stressed, however, that the 
time to withdrawal for patients in the hydromorphone 2-mg group was shorter than the other
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three treatment groups. Thus, the time over which dosing took place is not accounted for in 
this presentation o f the data.
Table 59. Total dosage of study medication taken -  all patients randomised
Treatment group
Total dosage (mg) Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg
n 68 71 67 65
Mean 11.0 21.5 31.5 101.2
sd 6.4 12.0 15.9 62.8
Range 2, 28 4, 66 6, 63 20, 330
Total 747 1528 2112 6580
Of the 271 patients randomised to study medication, 68, 71, 67 and 65 patients received 
hydromorphone 2 mg, 4 mg and 6 mg and morphine sulphate 20 mg respectively. A 
summary of exposure, based on the total number of doses taken is provided in Table 60 
below.
Table 60. Extent of exposure (all patients randomised)
Total number of doses taken Treatment group
(excluding 50% rescue dose) Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg
Total number of patients 68 71 67 65
1 9 6 7 10
2 11 10 9 8
3 to 4 10 16 14 14
5 to 6 11 18 14 18
7 to 8 17 12 16 8
9 to 12 9 8 7 6
13 to 16 1 1 - 1
Median (all patients) 5.0 5.0 5.0 5.0
Range 1,14 1,16 1,10 1,16
Sum 357 366 339 313
A total o f 123 (45%) of patients took the 50% rescue dose. This included 33 (49%) patients 
in the hydromorphone 2 mg treatment group, 32 (45%) patients in the hydromorphone 4 mg 
treatment group, 26 (39%) patients in the hydromorphone 6 mg treatment group and 32 
(49%) patients in the morphine sulphate 20 mg treatment group.
Three patients completed the study despite only taking one dose o f study medication. The 
patients involved were numbers 417 (morphine sulphate 20 mg), 575 (hydromorphone 2 
mg) and 590 (hydromorphone 4 mg). Patient number 417 did however receive the 50% 
rescue dose.
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The number o f patients reporting an event during the double-blind phase and the number of 
events in each treatment group are summarised in Table 61 below:
Table 61. Summary of adverse events reported during the double-blind phase
Treatment group
Hyd. 2 mg Hyd. 4 mg Hyd, 6 mg Morphine 20 mg
Total number of patients 68 71 67 65
Number of patients reporting an adverse 
event
42 (62%) 42 (69%) 45 (67%) 38 (58%)
Number of events reported 83 97 102 76
The severity and relationship to therapy of adverse events reported during the double-blind 
phase are summarised in Table 62 below:
Table 62. Summary of severity and relationship to therapy during the double-blind phase
No of reports (%)
Treatment group
Hyd. 2 mg Hyd. 4 mg Hyd. 6 mg Morphine 20 mg
Severity Mild 60 (72%) 68 (70%) 75 (74%) 49 (64%)
Moderate 22 (27%) 23 (24%) 20 (20%) 21 (28%)
Severe 1 (1%) 6 (6%) 7 (7%) 5 (7%)
Unknown - - - 1 (1%)
Relationship Definite - 1 (1%) - -
to therapy Probable 8 (10%) 9 (9%) 11 (11%) 8 (11%)
Possible 40 (48%) 50 (52%) 53 (52%) 31 (41%)
Unlikely 24 (29%) 20 (21%) 27 (26%) 18 (24%)
None 7 (8%) 17 (18%) 11 (11%) 19(25%)
Unknown 4 (5%) -
The most commonly reported events (i.e. reported by more than 5% of patients in any 
treatment group) are summarised in Table 63 below:
Table 63. Summary of adverse events reported by >5% of patients in any treatment group during double-blind 
phase
MedDRA preferred term Number of patients reporting
Treatment group
Hyd. 2 mg 
(n=68)
Hyd. 4 mg 
(n=71)
Hyd. 6 mg 
(n=67)
Morphine 20 mg 
(n=65)
NAUSEA 29 (43%) 30 (42%) 28 (42%) 19 (29%)
VOMITING 3 (4%) 10(14%) 11 (16%) 7 (11%)
PYREXIA 4 (6%) 6 (8%) 9 (13%) 6 (9%)
SEDATION 6 (9%) 3 (4%) 4 (6%) 2 (3%)
HEADACHE 5 (7%) 2 (3%) 3 (4%) 1 (2%)
CONFUSION - 4 (6%) 3 (4%) 1 (2%)
ANAEMIA 1 (1%) - 4 (6%) 1 (2%)
Nausea was more commonly reported on hydromorphone treatment. A total of 87 (42%) 
patients treated with hydromorphone reported nausea compared to 19 (29%) patients in the
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morphine sulphate 20 mg treatment group. Generally, the reports of nausea, vomiting and 
sedation were assessed by the investigator as being probably or possibly related to 
treatment, whilst reports of pyrexia were assessed as having an unlikely or no relationship to 
treatment. The difference between treatment groups in the proportion of patients reporting 
adverse events during the double-blind phase was not statistically significant (p=0.72).
Table 64 below lists the number of patients who had the commonly reported side effects 
associated with morphine (Moulin 1996) ongoing or starting during the double-blind phase. 
Therefore, this table includes patients who had ongoing adverse events at the time of 
randomisation which were not attributable to treatment.
Table 64. Summary of adverse events commonly reported with morphine, ongoing or starting during double-blind 
phase (Moulin 1996)
MedDRA preferred term Number of patients reporting (%)
Treatment group
Hyd. 2 mg 
(n=68)
Hyd. 4 mg 
(n=71)
Hyd. 6 mg 
(n=67)
Morphine 20 mg 
(n=65)
VISION BLURRED - - - 1 (2%)
ABDOMINAL PAIN 1 (1%) - - -
ABDOMINAL PAIN UPPER - 1 (1%) 1 (1%) -
CONSTIPATION 2 (3%) 2 (3%) 5 (7%) 3 (5%)
DRY THROAT - - 1 (2%)
NAUSEA 30 (44%) 35 (49%) 29 (43%) 22 (34%)
VOMITING 3 (4%) 13 (18%) 12 (18%) 7(11%)
MALAISE - - 1 (1%) -
DIZZINESS (EXC VERTIGO) 1 (1%) 1 (1%) - 1 (2%)
SEDATION 6 (9%) 4 (6%) 4 (6%) 3 (5%)
SOMNOLENCE - 1 (1%) 1 (1%) 1 (2%)
CONFUSION - 4 (6%) 3 (4%) 1 (2%)
SLEEPING DISORDER 1 (1%) 1 (1%) - -
PRURITUS 1 (1%) 2 (3%) 1 (1%) -
Number of patients reporting any 
of the above
37 (54%) 43(61%) 40 (60%) 27 (42%)
Five patients reported serious adverse events during the double-blind phase. Three of these 
patients (hydromorphone 4 mg: patient number 461, hydromorphone 6 mg: patient number 
41, morphine sulphate 20 mg: patient number 12) were withdrawn from the study as a 
consequence of their serious adverse events. Another patient (number 449, hydromorphone 
2 mg) subsequently withdrew his consent. In addition, all the events resolved, all were of 
either moderate or severe severity and all those experienced by patients treated with 
hydromorphone were considered to have an unlikely or no relationship to therapy by the 
investigator. There were no deaths during the study.
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Patient number 449 (hydromorphone 2 mg) experienced pain in the abdomen/stomach. 
Subsequently, he withdrew his consent to participate in the study after 24 hours of the 
double-blind phase. Cholecystitis was diagnosed and the patient underwent a 
choleeystectomy operation. Patient number 461 (hydromorphone 4 mg) experienced a 
transient ischaemic attack and was transferred to an intensive care unit. Treatment with 
study medication was permanently stopped because of this adverse event after 1470 minutes 
o f the randomised phase and the patient received symptomatic therapy. Patient number 41 
(hydromorphone 6 mg) complained of chest pain upon deep inspiration. Arterial blood 
gases indicated poor oxygenation. A pulmonary embolism was diagnosed. The patient 
received symptomatic therapy and as a result of the adverse event was permanently 
withdrawn from the study after 1760 minutes of the randomised phase. Patient number 12 
(morphine sulphate 20 mg) experienced dizziness, sweating, blurred vision, tachypnoea and 
had a blood pressure of 100/60 and a 70% decrease in oxygen saturation during 
physiotherapy. Both the sweating and blurred vision were considered to have a possible 
relationship to treatment by the investigator, whilst the dizziness and tachypnoea were 
eonsidered to have an unlikely or no relationship to treatment, respectively. Atrial 
fibrillation was diagnosed and as a result he was permanently withdrawn from the study 
after 60 minutes of the randomised phase. Patient number 561 (morphine sulphate 20 mg) 
experienced increased heart rate, phlebitis and a pulmonary embolism. This adverse event 
was considered to have no relationship to therapy by the investigator. The patient 
underwent symptomatic therapy until the events resolved.
Table 65 presents the results of the analysis of the AUC (0-48 hours) o f respiration rate/48 
for the observed data. For this analysis, the actual adjusted means (breaths/min) were 17.6 
(hydromorphone 2 mg), 17.6 (hydromorphone 4 mg), 17.3 (hydromorphone 6 mg) and 17.4 
(morphine sulphate 20 mg). In the analysis of covariance the term for treatment group was 
not statistically significant (p=0.80).
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Table 65. Analysis of covariance for the AUC (0-48h) of respiration rate/48 {observed data)
AUC (0-48h) for respiration Treatment group
rate/48® Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Morphine 
20 mg
Total number of patients 68 71 67 65
Mean 17.6 17.4 17.5 17.6
sd 2.8 2.9 3.2 2.6
Range 12.2, 25.5 11.2, 26.7 12.3, 25.7 13.0, 25.7
Adjusted mean^ 17.6 17.6 17.3 17.4
Difference in adjusted means 
relative to morphine 20mg®
0.3 0.2 -0.1
se (of difference) 0.4 0.4 0.4
98.3% Cl for difference" -0.7, 1.2 -0.7, 1.2 -1.0, 0.9
Analysis of covariance F g E
Baseline 95.87 1, 264 <0.001
Treatment group 0.33 3, 264 0.80
Country 14.04 2, 264 <0.001
a The reason for dividing the AUC by 48 was so the value could be easily interpreted with the original recorded 
values
b Adjusted for baseline and country
c A negative difference favours hydromorphone
d Sidak adjusted 95% Cl
Table 66 presents the results of the analysis of the AUC (0-48 hours) of level of sedation/48 
for the observed data. For this analysis, the actual adjusted means were 0.19 
(hydromorphone 2 mg), 0.23 (hydromorphone 4 mg), 0.25 (hydromorphone 6 mg) and 0.26 
(morphine sulphate 20 mg). In the analysis of covariance the term for treatment group was 
not statistically significant (p=0.23).
Table 66. Analysis of covariance for the AUC (0-48h) of level of sedation/48 (observed data)
AUC (0-48h) for level of Treatment group
sedation/48® Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Morphine 
20 mg
Total number of patients 68 71 67 65
Mean 0.19 0.23 0.24 0.26
sd 0.20 0.20 0.22 0.25
Range 0.00, 0.93 0.00, 0.84 0.00, 0.96 0.00, 0.95
Adjusted mean" 0.19 0.23 0.25 0.26
Difference in adjusted means 
relative to morphine 20mg"
-0.07 -0.03 -0.01
se (of difference) 0.04 0.04 0.04
98.3% Cl for difference" -0.16, 0.02 -0.12, 0.06 -0.10, 0.08
Analysis of covariance F 2
Baseline 2.96 1, 264 0.09
Treatment group 1.46 3, 264 0.23
Country 0.18 2, 264 0.83
a The reason for dividing the AUC by 48 was so the value could be easily interpreted with the original scale
(0 = awake, alert, orientated; 1 = dozing intermittently, drowsy or lethargic but aroused by physical stimulus;
2 = mostly sleeping, difficult to arouse but feasible by physical stimulus; 3 = difficult to waken, little or no
response even to physical stimulus) 
b Adjusted for baseline and country
c A negative difference favours hydromorphone
d Sidak adjusted 95% Cl
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Table 67 presents the results of the analysis of the AUC (0-48 hours) of degree of nausea/48 
for the observed data. For this analysis, the actual adjusted means were 0.10 
(hydromorphone 2 mg), 0.12 (hydromorphone 4 mg), 0.07 (hydromorphone 6 mg) and 0.05 
(morphine sulphate 20 mg). In the analysis of covariance the term for treatment group was 
not statistically significant (p=0.15). Although there were trends for more nausea in the 
three hydromorphone treatment groups, all tlmee Sidak-adjusted 95% confidence intervals 
contained zero, implying that the pairwise comparison for each o f the three doses against 
morphine sulphate 20 mg were not statistically significant at the 1.7% level.
Table 67. Analysis of covariance for the AUC (0-48h) of degree of nausea/48 (observed data)
AUC (0-48h) for degree of Treatment group
nausea/48® Hydromorphone 
2 mg
Hydromorphone 
4 mg
Hydromorphone 
6 mg
Morphine 
20 mg
Total number of patients 68 71 67 65
Mean 0.11 0.13 0.08 0.05
sd 0.29 0.22 0.18 0.12
Range 0.00, 1.78 0.00, 0.95 0.00, 1.00 0.00, 0.71
Adjusted mean" 0.10 0.12 0.07 0.05
Difference in adjusted means 
relative to morphine 20mg"
0.06 0.08 0.03
se (of difference) 0.04 0.04 0.04
98.3% Cl for difference" -0.03, 0.15 -0.01, 0.16 -0.06, 0.11
Analysis of covariance ' F g Ë
Baseline 7.98 1,264 0.005
Treatment group 1.79 3, 264 0.15
Country 3.14 2, 264 0.045
a The reason for dividing the AUC by 48 was so the vaiue couid be easily interpreted with the original scale
(0 = none; 1 = mild; 2 = moderate; 3 = severe) 
b Adjusted for baseline and country
c A negative difference favours hydromorphone
d Sidak adjusted 95% Cl
As shown in Figure 18, the degree o f  nausea reported was less in the morphine sulphate 20-m g treatment 
group, particularly during the early stages o f the double-blind phase.
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Two (3%), 12 (17%) and 11 (16%) patients in the hydromorphone 2 mg, 4 mg and 6 mg 
treatment groups, respectively, recorded occurrences of vomiting during the double-blind 
phase compared to seven (11%) patients who received morphine sulphate 20 mg (Table 68). 
These data slightly contradict the data presented in Table 63 as this data was recorded in a 
separate section of the CRT to that of adverse events.
Table 68. Number of occurrences of vomiting reported during doubie-biind phase {observed data)
Number of occurrences of vomiting
Treatment group n 0 1 2 3 4 % not Difference relative 98.3% Cl for
reporting any to morphine difference® 
_____________________________________________________________ vomiting 20 mg____________________
Hydromorphone 2 mg 68 66 2 - - - 97% 8% -3%,18%
Hydromorphone 4 mg 71 59 8 3 1 - 83% -6% -20%,8%
Hydromorphone 6 mg 67 56 7 3 1 - 84% -6% -20%,9%
Morphine 20 mg 65 58 4 2_____ -_____ 1________ 89%______________________________________
a Sidak adjusted 95% Ci
The tolerability of the tlnee hydromorphone doses in this study is comparable with that 
from 20 mg of morphine. The pattern of events o f the treatments is typical o f strong 
opioids, with additional events, such as pyrexia, being a feature o f the postoperative setting. 
Some o f the event rates are suggestive of trends, but statistical testing of these differences 
failed to demonstrate significance. This is typical of the need for far larger patient numbers 
to detect differences in adverse event profiles compared with numbers needed for efficacy 
assessment (McQuay 1998, Edwards 1999).
5.3.6 Discussion
One of the elements that was not controlled by the study, as in the case of the single-dose
study also, was the anaesthetic procedure itself. The variability in anaesthetic technique
resulted in some patients receiving regional anaesthetic procedures which could have long
durations of action. General anaesthetics were much more commonly used in study centres
in the UK and Eire compared to the centres in mainland Europe. Conversely, study centres
in France and the Netherlands commonly used regional anaesthetics. These same data were
not collected in the single-dose study, but it is likely that if they had been collected, the
findings would have been the same, since many centres participated in both studies.
However, the minimum of 18 hours from the patient leaving the operating theatre to the
time of randomisation should have allowed for the effects of regional procedures to
diminish to negligible levels. Investigators were instructed to confirm this by testing motor
function in the affected limb.
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The original sample size for the study was estimated to be 50 patients per treatment group. 
This assumed variability of 2.0 for the principal measure, 90% power, a true difference of 
zero between hydromorphone 4 mg and morphine sulphate 20 mg and a difference of 0.25 
in favour of hydromorphone 6 mg over morphine sulphate 20 mg. After 52 patients 
completed the study the variability for the principal measure was re-estimated to be 2.24. 
Using this revised variability and 90% power, and assuming a true difference of zero 
between hydromorphone 4 mg and morphine sulphate 20 mg and a difference of 0.25 in 
favour of hydromorphone over morphine sulphate 20 mg, it was determined that 60 
evaluable patients per treatment group were required. Subsequently, it was concluded that 
the study precision was adequate to meet its objectives; the revised sample size estimate of 
variability was 2.24, whilst the actual variability for the principal measure was 2.16 for the 
“full analysis” set and 1.92 for the per-protocol set.
According to the protocol, treatment with hydromorphone 2, 4 and 6 mg was to be 
considered equivalent to morphine sulphate 20 mg if the two one-sided tests for non­
inferiority and non-superiority from the analysis of the AUC (0-48 hour) of pain at rest/48 
for the “full analysis” set were significant at the 2.5% level. Results from the analysis 
showed this, and it was concluded that that the means for all three hydromorphone treatment 
groups were within ± 1.5 of the mean for morphine sulphate 20 mg. The actual adjusted 
means for the four treatments were 4.6 (hydromorphone 2 mg), 4.0 (hydromorphone 4 mg), 
3.5 (hydromorphone 6 mg) and 3.9 (morphine sulphate 20 mg). The results also imply an 
ordering between the treatments, with hydromorphone 6 mg as the most effective treatment, 
hydromorphone 2 mg as the least effective treatment and hydromorphone 4 mg and 
morphine sulphate 20 mg being very similar. From these data, we can conclude that the 
equipotency ratio for morphine : hylrromorphone in this setting is between 4 to 5.
The equivalence zone (or “delta”) that was used for the study was + 1.5 on the 11 -point pain 
scale from the Brief Pain Inventory. The selection of 1.5 as the value was based on 
consultation with clinical experts in pain management but it was not possible to validate this 
with any precise data. The same value has been presented as a clinically significant change 
on an 11-point scale in published papers and abstracts (Rowbotham 1998, Stubhaug 2000). 
Conversely, various recommendations exist for setting delta, such as half of the difference 
between active and placebo, 10% of the rating scale or half the standard deviation of the
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measure at baseline. One possible approach to identifying what is a clinically significant 
change in pain scores is to look at the change following patients’ discontinuation from the 
study. The majority of patients discontinuing from the randomised phase of the study were 
likely to be suffering inadequate analgesia. Following discontinuation, the investigators 
were at liberty to select analgesia to bring about control of the patients’ pain. The 
consequent mean reduction in pain-at-rest scores through this process was approximately 3 
points on the scale.
Because this was an equivalence study, it is argued by some that using the per-protocol set 
of patients to ascertain equivalence is more relevant than using the “full analysis” set. The 
per-protocol set excludes patients who withdrew during the first three hours after the first 
dose of study medication. The logic for excluding these patients is that as the study was a 
multiple-dose comparison over 48 hours, the inclusion of patients with little data and only 
one dose is somewhat irrelevant. Also the number of patients who withdrew “early” (i.e. at 
any point up to 3 hours post first dose) were reasonably similar in each of the four treatment 
groups: seven patients (10%) in the hydromorphone 2 mg treatment group, four patients 
(6%) in the hydromorphone 4 mg treatment group, three patients (4%) in the 
hydromorphone 6 mg treatment group and six patients (9%) in the morphine sulphate 20 mg 
treatment group. Therefore, removing early dropouts would be unlikely to bias the analysis 
in favour of a particular treatment. As a result of excluding these twenty patients the 
variability was less and therefore the confidence intervals were narrower. This was because 
patients who withdrew early generally had higher pain scores and as the analysis used was 
last-observation-carried-forward, this resulted in their having higher AUC values. Although 
the treatment group means were much closer together, the treatment group ordering 
remained the same as for the “full analysis” set. Based on these data, non-inferiority of 
each hydromorphone dose against morphine could have been inferred using a limit of 0.9 
rather than the 1.5 quoted in the study protocol. For the per-protocol analysis, the actual 
adjusted means for the four treatments were 3.9 (hydromorphone 2 mg), 3.8 
(hydromorphone 4 mg) 3.4 (hydromorphone 6 mg) and 3.8 (morphine sulphate 20 mg).
Because the primary efficacy endpoint pain score is based on a relatively long time period 
(48 hours), the question of how to handle patients dropping out o f the study has to be 
considered. In this study, it was elected to use last-value-carried-forward (LOCF [Gillings 
1991]) to allow inclusion of data from patients who withdrew prior to the 48-hour time
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point. This is one of the accepted methods of assessing such patients in studies in analgesia, 
and it provides a conservative estimate of efficacy. This is because patients who withdrew 
due to poor efficacy would have a high pain score at the time of discontinuation and this 
high score will be carried forward for the remainder of the 48-hour period, for the purposes 
of analysis. Separate analyses were conducted to test the effect o f this carryforward method 
and they validated this approach.
As part o f the protocol specifications, pain at rest data was recorded up to 48 hours for all 
patients irrespective of whether they had withdrawn. Graphical illustration of this data 
(Figure 19), shows the effect of the use of rescue analgesia and indicates that the mean 
profiles for each treatment group were very similar.
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Although the data for the number and total dosage of study medication taken seemed fairly 
consistent across treatment groups, there was some evidence to suggest that patients in the 
hydromorphone 2 mg treatment group were taking more study medication per unit time than 
the other three treatment groups. Assuming a dosing interval of 4.5 hours (midway between 
the protocol defined dosing interval of 3 to 6 hours), the median dose per 4.5 hours could be 
calculated and referred back to the original randomised dose. For the hydromorphone 2-mg 
treatment group, the median dose per 4.5 hours was 1.8 mg (90% of the randomised 2-mg 
dose). The equivalent values for the other treatment groups were 2.61 mg (65%) for the 
hydromorphone 4 mg treatment group, 4.23 mg (71%) for the hydromorphone 6 mg 
treatment group and 13.14 mg (66%) for the morphine sulphate 20 mg treatment group. 
From these data, we can conclude that patients in the hydromorphone 2-mg treatment group 
did in fact talce a greater percentage of the randomised dose in order to remain in the study. 
Furthermore, when analysing the average time between doses it can be shown that the 
median time was shorter in the hydromorphone 2 mg treatment group, namely 5.6 hours 
compared to the other three treatment groups: 6.6 hours in the hydromorphone 4 mg 
treatment group, 6.4 hours in the hydromorphone 6 mg treatment group and 7.0 hours in the 
morphine sulphate 20 mg treatment group.
Results were similar for the analyses of pain on movement: actual adjusted mean values for 
AUC (0-48 hours) of pain on movement/48 for the “full analysis” set were 6.6 for the 
hydromorphone 2 mg treatment group, 6.1 for the hydromorphone 4 mg treatment group,
5.7 for the hydromorphone 6 mg treatment group and 5.8 for the morphine sulphate 20 mg 
treatment group. As expected mean AUC pain on movement scores were higher than the 
pain at rest scores.
The mean pain at rest scores at baseline in this study were much higher (5.8), than in the 
earlier single-dose clinical study, where the value was 4.4. This arose as a result of one of 
the inclusion criteria in the current study which stated that patients entered into the study 
were to have pain at rest scores of at least 4 at randomisation. After randomisation, mean 
pain scores remained higher than in the earlier study, for the first three hours. After this 
point mean pain levels were lower than in the earlier study, as the multiple dose aspect of 
the study started having an effect.
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For the analysis of AUC (0-48 hours) pain at rest/48 for the “full analysis” set, there was an 
ordering o f the responses within the three hydromorphone randomised groups. The adjusted 
means were 4.6 (hydromorphone 2 mg), 4.0 (hydromorphone 4 mg) and 3.5 
(hydromorphone 6 mg). The mean difference of 1.1 (98.3% Cl 0.1,2.0) between the 
hydromorphone 6 mg and 2 mg groups, was statistically significant, indicating that there 
was evidence of increasing efficacy between the three hydromorphone doses. Although the 
actual difference of 1.1 was in the protocol defined equivalence region, the upper bound of 
the confidence interval implies that the superiority of the hydromorphone 6-mg dose over 
the hydromorphone 2-mg dose camiot be discounted. Furthermore as discussed previously, 
there was some evidence that patients in the hydromorphone 2-mg group were taking more 
medication than the patients in the other two hydromorphone groups. This implies that the 
true difference between the 2-mg and 6 mg groups was in fact slightly larger.
As in the single-dose study, a high proportion of patients withdrew from this study. In total, 
99 (37%) patients withdrew from the study (the withdrawal rate in the single-dose study 
was also 37%). This included 47 patients (17%) who withdrew because of lack of efficacy, 
although, as referred to earlier (see Section 5.3.5), the different categories overlap to a large 
degree. Completion rates in the respective countries varied (79% in France, 64% in the UK 
and Eire, and 52% in the Netherlands). Within countries, there were marked differences 
between centres in respect to the percentage of patients completing the study period. Within 
each centre, however, the completion rate did not vary greatly between the study treatments. 
This suggests that the variability was due to investigator technique, rather than treatment- 
related factors. More patients withdrew from the hydromorphone 2-mg treatment group. 
Seventy-eight out of the 99 (79%) patients who withdrew from the study used rescue 
medication other than the 50% “rescue” dose. Morphine was the most commonly used 
rescue medication, being administered in 48 (62%) patients. The proportion of patients 
receiving morphine as rescue medication was similar across the dose groups. There were no 
statistically significant differences between the treatment groups for the time to withdrawal.
The safety profile of hydromorphone was good. There was no statistically significant 
difference between the foiu treatment groups in the proportion of patients reporting adverse 
events. Most adverse events were mild and the relationship to therapy was unlikely or none 
for approximately 40% of the reported events. Nausea, vomiting, pyrexia and sedation were 
the most common adverse events. Generally, the reports of nausea, vomiting and sedation
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were assessed by the investigator as being probably or possibly related to treatment, whilst 
the reports of pyrexia were assessed as having an unlikely or no relationship to treatment. 
This is not unexpected as nausea, vomiting and sedation are commonly reported side effects 
associated with opioids at the start of treatment, which usually resolve within a few days 
(O’Neill 1997). Some of the event rates are suggestive of trends, but statistical testing of 
these differences failed to demonstrate significance. This is typical of the need for far larger 
patient numbers to detect differences in adverse event profiles compared with numbers 
needed for efficacy assessment (McQuay 1998). One factor that could have affected the 
relative incidence of adverse events is the way in which all patients were stabilised on 
morphine (PCA) and then either continued on morphine orally, or switched to 
hydromorphone. Patients are not thought to react equally to all opioids, even those of 
similar receptor affinity (Bruera 1996). It is possible that during the morphine PCA phase, 
patients who responded well to morphine were selected out of the total patient population, 
thus selecting a subset of patients who would be more likely to obtain good efficacy and 
tolerability from morphine than hydromorphone. Another possibility was that patients 
became tolerant to the side effects of morphine during the PCA phase of the study. 
Subsequently during the double-blind phase of the study, patients treated with 
hydromorphone had to become re-acclimatised to their opioid treatment whereas those 
randomised to receive morphine did not.
A total of 14 patients withdrew from the study due to adverse events (three in the 
hydromorphone 2-mg treatment group, five in the hydromorphone 4-mg treatment group, 
five in the hydromorphone 6-mg treatment group and one in the morphine sulphate 20-mg 
treatment group). The serious adverse events reported during the double-blind phase of the 
study were all considered to have an unlikely or no relationship to study medication by the 
investigator. There were no clinically significant differences in respiratory rate, level of 
sedation or nausea and vomiting gradings between the four treatment groups.
5.3.7 Conclusions
Hydromorphone 2mg, 4mg and 6mg were considered equivalent to morphine 20mg in the 
treatment of pain in the post-operative recovery of patients who underwent primary knee 
replacement surgery. Efficacy increased with increasing doses, the 6-mg dose being 
statistically significantly more potent than the 2-mg dose. The 4-mg dose was closest in
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efficacy to the morphine sulphate 20-mg dose, suggesting an equipotency ratio of 5 for this 
setting. The tolerability of the three hydromorphone doses was comparable to morphine 
sulphate 20 mg. These findings confirm impressions gained from more than 50 years of 
clinical use in North America. Namely, hydromorphone is an effective and safe analgesic 
in the treatment o f acute pain.
The results o f this study were given as an oral presentation at the European Congress of 
Anaesthesiology in Florence, Italy, June 2001. The presenting author was Dr Slappendel. 
(Slappendel 2001b).
10/01/02
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5.4 Active-controlled study in cancer pain
5.4.1 Study summary
The title of the study was “A randomised, double blind, eontrolled study of hydromorphone 
(immediate and controlled-release) versus morphine (immediate and controlled-release) in 
cancer pain” . The co-ordinating investigator was Dr Magdi Hanna, Director o f the 
Analgesics & Pain Relief Research Unit, King's College of Medicine and Dentistry, 
Bessemer Road, London SE5 9RS.
The primary objective was to demonstrate the clinical equivalence of efficacy between 
hydromorphone [immediate- (IR) and controlled-release (CR)] and morphine (IR and CR). 
Equivalence of efficacy was assessed using the “worst pain” item of the Brief Pain 
Inventory (BPI). Secondary objectives included a comparison of the following variables 
between hydromorphone and morphine: other assessments of pain from the BPI; number of 
breakthrough pain medication doses taken; time to dose stabilisation during both IR and CR 
phases o f the study; number of patients dropping out during each phase; number of patients 
changing dose level during the CR phase; mean number of dose level changes during the 
CR phase; safety and tolerability.
The methodology was of a multicentre, double blind, randomised, active-controlled, 
multiple-ascending-dose study to evaluate the clinical equivalence and tolerability of an IR 
and CR formulation of hydromorphone and morphine in patients with cancer pain. Study 
medication was titrated for each patient until pain control was achieved; patients received 
hydromorphone 12 to 108 mg/day or morphine 60 to 540 mg/day for up to 24 days (the IR 
formulations were given for 2 to 9 days and the CR formulations for 10 to 15 days). 
Assessments of pain were made at intervals throughout the study.
Two hundred patients were randomised and received study medication: 77/99 (78%) 
patients completed the hydromorphone IR phase and 86/101 (85%) completed the morphine 
IR phase. For the CR phase, 60/77 (78%) patients completed in the hydromorphone group 
and 73/86 (85%) in the morphine group. Data for 190 patients were included in the analysis 
of the primary variable for the IR phase and for 157 patients in the CR phase.
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The diagnostic criteria were; inpatients, outpatients or day patients >18 years of age, who 
had cancer pain suitable for treatment with once-daily strong opioid analgesics and who 
required between 60 to 540 mg of oral morphine or equivalent every 24 hours for up to 24 
days.
The measures of efficacy were Brief Pain Inventory, number of breakthrough pain 
medication doses, time to dose stabilisation in IR and CR phases, number of patients who 
dropped out during each phase, number of patients who changed dose level in CR phase, 
mean number of dose level changes in CR phase. The measures of safety were adverse 
events.
The results of the study showed that there were decreases in “worst pain” in both treatment 
groups, confirming the basic efficacy of the two treatments under the study conditions. 
According to the protocol, treatment with hydromorphone was to be considered equivalent 
to morphine if the 95% two-sided confidence interval for the difference between the 
adjusted means for the principal measure of efficacy (“worst pain” score of BPI in the past 
24 hours) lay within -1.5 to 1.5. For the IR phase this was true and therefore 
hydromorphone IR was proven to be equivalent to morphine IR (mean differenee o f 0.2, 
95% Cl -0 .4  to 0.9). For the CR phase the lower limit of the 95% confidence interval was 
less th an -1.5 which implied that the superiority of hydromorphone could not be disproved. 
However, the upper limit was less than 1.5 and therefore non-inferiority of hydromorphone 
was proven. Furthermore, there was a statistically significant difference between the 
treatment groups in favour of hydromorphone for the CR phase for both the “per protocol” 
and the “full analysis” sets (mean difference of -0.8, 95% Cl -1 .6  to -0.01, p^O.046).
The dose levels at which patients reached dose stable pain control were similar in the two 
treatment groups, suggesting that the packaging of the six dose levels of the respective 
treatments was well matched.
For the secondary efficacy variables (other BPI variables) there were no statistically 
significant differences between the treatments. There was also a trend in favour of 
hydromorphone for “pain now” p.m. at the end of CR phase (p=0.09).
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Although the use of breaktlirough pain medication was statistically significantly higher for 
the hydromorphone group in the IR phase, by the end of the CR phase there was no 
difference between the two treatment groups, again suggesting equivalence of the two 
therapies. The number of patients having dose level changes during the CR phase was 
similar in both treatment groups.
The overall safety profiles of the two treatments were generally similar and there were no 
statistically significant differences between the treatments for the proportion of patients 
reporting adverse events. Overall, irrespective of study phase, 80/99 (81 %) hydromorphone- 
treated patients reported 347 adverse events compared to 90/101 (89%) patients in the 
morphine treatment group who reported 355 adverse events.
The nature o f the adverse events reported during hydromorphone and morphine therapy was 
generally typical o f the events associated with these treatments. Most of the adverse events 
in the study were mild or moderate in severity and around half were recorded as being of 
unlikely or no relationship to therapy. The higher number of withdrawals in the 
hydromorphone group in the CR phase o f the study (22%) compared to morphine (15%) is 
difficult to explain but was not statistically significant. There was no statistically significant 
difference between treatment groups in the time to withdraw, irrespective of phase (p"-0.17).
The occurrence of tliree deaths during the study, together with a further 17 patients who 
experienced serious adverse events was not unexpected, given the severity of the patients’ 
conditions and the progressive nature of the disease. None of the deaths were considered to 
be related to the study therapy. Many of the serious adverse events tended to be associated 
with the underlying disease, although a proportion (32%) were considered to be definitely 
or probably related to the study treatment.
In conclusion, despite the complexity of the setting for this study, including the need for 
dose titration and the need for use of breakthrough pain medication, the results of this study 
clearly demonstrated equivalence for “worst pain” between hydromorphone IR and 
morphine IR. For the CR treatments, the superiority of hydromorphone to morphine could 
not be disproved; however, non-inferiority of hydromorphone to morphine was proven and 
there were statistically significant differences in favour of hydromorphone for the CR phase. 
The safety profiles of the two treatments were comparable with a numerical advantage for
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hydromorphone CR which was not statistically significant. Overall, hydromorphone CR 
provides a convenient, once-daily treatment for cancer pain patients which offers superior 
pain control compared to twice-daily morphine.
5.4.2 Introduction
The first principle of managing cancer pain is an adequate and full assessment of the cause 
of the pain. With effective assessment and a systematic approach to the choice of analgesic 
agents, over 80% of cancer pain can be controlled with the use of orally self-administered 
drugs, used at regular intervals (O’Neill 1997). Opioid analgesic drugs, such as morphine, 
are the most common agents used in the management of cancer pain.
The aim of this study was to investigate whether, in the treatment of patients with cancer 
pain, hydromorphone IR and morphine IR were equivalent and whether the new once-daily 
CR formulation o f hydromorphone was equivalent to twice-daily morphine CR. The study 
had to achieve these aims within the setting of the conventional management of cancer pain. 
This convention is that patients have their pain controlled using regular four-hourly doses of 
oral immediate-release medication, supplemented with identical doses of immediate-release 
medication for the purpose of treating “breakthrough pain”. Monitoring the use of 
supplemental doses and the pain eontrol achieved allows the regular four-hourly dose to be 
adjusted until an optimum balance is achieved between pain control and opioid-related side 
effects. Once this optimum dose has been determined, the total daily dose of the opioid is 
used to select a corresponding dose of a controlled-release opioid formulation. This allows 
less frequent dosing but should not compromise the pain control achieved by the patient. 
Supplemental dosing with immediate-release formulation continues when the patient is 
receiving regular controlled-release opioid for the same purpose as before, namely, the 
treatment of “breakthrough pain”. As in the case with immediate-release regular dosing, the 
dose of the regular dose of controlled-release medication can be adjusted to achieve the 
optimum balance of pain control and side effects (O’Neill 1997).
The study was established as a multinational, predominantly European one. As such, the 
applicability of the treatment paradigm, as described above, had to be confirmed with 
investigators in candidate participating countries. The treatment paradigm was found to be 
aeceptable in most cases, but not in Demnark, where there was a strong bias towards initial
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treatment o f the patient with a controlled-release formulation, avoiding the initial 
immediate-release treatment phase. This opinion also seemed prevalent in Germany, but not 
to the extent that it was not possible to carry the study out here. It was considered that in 
these specific countries, patients could go directly to the controlled-release phase of the 
study. However, this would have failed to meet the European regulatory agencies’ demand 
for efficacy data for both the immediate-release and the controlled-release formulation of 
hydromorphone.
Morphine was selected as the comparator agent, since it is widely regarded as the “gold 
standard” in the treatment of cancer-related pain (WHO 1996a). For the controlled-release 
treatment phase o f the study, there was a range of possible formulations to be used. 
Morphine twice daily (MS Contin, from Napp/Purdue-Frederick/Mundipharma) was 
selected, since it was the most widely accepted and also the most widely available agent in 
the countries participating in the study.
The duration o f treatment was made as long as practicably possible, since in the setting of 
the treatment o f chronic pain, a relatively long duration of treatment would be necessary to 
mimic the clinical setting. Two factors acted against this, however. The first was the patient 
population being studied. The relatively late-stage disease that was anticipated meant that 
patients would be relatively unstable and that there would even be some deaths within a few 
days or weeks o f randomisation. The second factor was the bulk o f the drug packaging 
required for double-blind titration to six dose-levels and the provision of two different 
formulations for each treatment. The packaging for the maximum of 24 days’ treatment that 
was selected was the size of a small suitcase for each patient. Given that the test treatments 
are controlled drugs, the drug packaging had to be held within special cabinets at many 
centres. The bulk of the packaging therefore presented a real practical problem in the 
storage o f patients’ drug supplies.
The selection criteria were originally set in a fairly stringent manner to try and control for as 
many factors as possible affecting pain control in cancer pain patients. Unfortunately, this 
seemed to hinder recruitment. Additionally, from the data collected from the initial set of 
patients, it became clear that despite the controls in the protocol, the disease state itself 
(usually relatively late-stage cancer) meant that there were many other factors affecting pain 
control which it was impossible to control for. Therefore, given these two observations,
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some restrictions on selection criteria were lifted relatively early in the study. These 
included factors such as concomitant chemotherapy and radiotherapy. From the final 
outcome o f the study, it seems that this relaxation in selection criteria did not adversely 
affect the result.
The “worst pain” question in the Brief Pain Inventory was selected as the primary efficacy 
measure. It is one o f a series o f questions that a patient answers when they complete the 
inventory. The decision was based on;
a) The general acceptability of numerical rating scales as pain measures.
b) The “worst pain” measure in the Brief Pain Inventory is judged to be the most clinically 
significant measure (Daut 1983).
c) We were informed by the statistician with Dr Cleeland’s group (from whom the BPI 
originated), Professor Tito Mendoza, that the “worst pain” measure was the most 
sensitive measure to use in a clinical study.
d) The availability o f a validated translated version of the pain scale for the countries 
involved in the study. For the case of the Swedish and Flemish languages, we carried 
out specific validation studies to create a translated version (Mendoza 2001a.), but for 
all other languages, they were already available.
The general statistical approach to the study was one of seeking equivalence, rather than a 
difference from the comparator. This is a conventional approach in European registration 
studies where there is an established “gold standard” treatment and where the laiowledge of 
the pharmacological and pharmaceutical details of the test product do not suggest the 
possibility of a clear advantage. The clinically significant zone o f ± 1.5 was established 
through consultation with opinion leaders in the same way as described for the multiple- 
dose acute pain study (see section 5.3.6).
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5.4.3 Objectives
The preplanned objectives of the study were;
• To demonstrate the clinical equivalence of efficacy between hydromorphone 
(immediate- and controlled-release) and morphine (immediate- and controlled-release). 
Equivalence o f efficacy was assessed using the mean of the last two days of each 
treatment phase for the “worst pain” item of the Brief Pain Inventory (BPI) as reported 
by the patient.
• Other assessments from the BPI
• Number of breaktlnough pain medication doses taken
• The time to dose stabilisation during both phases of the study
• The number of patients dropping out during each phase
• The number of patients having to change dose level during the controlled-release phase 
o f the study
• The mean number o f dose level changes during the controlled-release phase of the study
• Safety and tolerability
5.4.4 Methods
This was a multicentre, phase III, randomised, double blind, double dummy, active- 
controlled, parallel-group, multiple ascending dose, equivalence study comparing 
hydromorphone and morphine in the treatment of cancer pain. The study comprised two 
phases: an immediate-release (IR) phase during which patients received the IR medication 
(hydromorphone or morphine) and were titrated to pain control, followed by a controlled- 
release (CR) phase during which the patient received the CR formulation of the medication.
The study was conducted at 37 centres in the United Kingdom, Holland, Sweden, Belgium, 
France, Germany, Spain and Canada. The plamied sample size was 140 patients, 
randomised equally to the hydromorphone or morphine treatment groups. The sample size 
was increased to 170 patients following the results of a planned, blinded interim analysis 
which was conducted after 55 patients had completed treatment. The purpose of the analysis 
was to re-estimate the variability of the primary variable. This analysis was repeated after
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120 patients had completed the study and the sample size was increased fuither to 
200 patients.
5.4.4.1 Patient selection
Individuals eligible for entry into this study comprised male or female inpatients, 
outpatients or day patients aged 18 years or older, who had cancer pain and were currently 
receiving strong oral or transdennal opioid analgesics, or for whom strong opioid analgesics 
were appropriate. Patients must have had pain suitable for treatment with a once-daily 
formulation, have required or been expected to require between 60 to 540 mg of oral 
morphine or morphine equivalent every 24 hours for the chronic management of cancer pain 
and been reasonably expected to achieve stable opioid requirements. These patients were to 
be able, in the opinion of the investigator, to comply fully with the study requirements, 
including completing the BPI, and to have given written informed consent before entry.
Individuals not eligible for this study comprised any of the following groups: patients with
pain which was not considered to be potentially responsive to opioids; patients who only
experienced pain on movement; patients with a requirement for other opioid analgesics
(apart from study medication) after randomisation; patients with a recent (within the
previous six months) or current history of drug and/or alcohol abuse; women of child
bearing potential who were pregnant or lactating, seeking pregnancy or failing to take
adequate contraceptive precautions; patients with intolerance of or hypersensitivity to
hydromorphone (or other opioids); patients who were receiving or had received monoamine
oxidase inhibitors (MAOIs) within the previous two weeks (Rossiter 1993); patients
previously entered into this study; patients who had participated in another study with an
investigational drug in the previous four weeks; patients with gastrointestinal disease of
sufficient severity to be likely to interfere with orally administered analgesia including:
dysphagia, vomiting, no bowel movement or bowel obstruction due to impaction within the
five days prior to the start of the study, severe gut narrowing that may have affected the
absorption or transit of orally administered drugs, particularly the insoluble OROS® outer
coating; and patients in whom the risks of treatment with morphine/hydromorphone would
have outweighed the potential benefits, including such risk categories as raised intracranial
pressure, hypotension, hypothyroidism, asthma, reduced respiratory reserve, pro static
hypertrophy, hepatic impairment, renal impairment, elderly and debilitated, convulsive
disorders and Addison’s disease.
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S.4.4.2 Study procedures
Patients were informed of the nature of the study and wiitten informed consent for 
participation in the study was obtained prior to the performance of any study procedures.
The patient was assessed for eligibility for the study according to the inclusion/exclusion 
criteria. Eligible patients were assigned a patient number which determined the medication 
they received during the study (hydromorphone or morphine). The baseline assessments 
included recording the patient’s demographic data, fertility status, medical history and 
current status. Cancer diagnosis and the nature o f predominant pain was recorded. A 
pregnancy test was performed, if  applicable. Medication and non-drug therapy history were 
also recorded and a physical examination was performed, including the Mini-Mental State 
Examination and the Eastern Co-operative Oncology Group (ECOG) Performance Status 
Score. The ECOG Performance Status Score was recorded by the investigator at baseline 
and at the end of both the IR and CR phases. This measured the patient’s level of activity 
and capability to care for themselves on a scale of zero to four, with four being the worst 
category (patient completely disabled, unable to carry on any self-care, totally confined to 
bed or chair). The patient completed the baseline patient diary assessments for the BPI, 
including “worst pain” in the past 24 hours and “pain now” ratings.
Opioids, other than study medication, were not allowed during the study. Monoamine 
oxidase inliibitors (MAOIs) were not allowed during the study nor within two weeks prior 
to entry. Adjuvant analgesics such as paracetamol, nonsteroidal anti-inflammatory drugs, 
anxiolytics, antidepressants, anti arrhythmic drugs, hormone therapy, corticosteroids, 
anticonvulsants, and neuroleptics were allowed but had to be maintained at stable doses for 
the duration o f the study. Adjuvant analgesics were not to be started during the study. Doses 
of other any other concomitant medications were to be kept constant during the study, when 
possible.
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A diagram of the study design is given below:
Figure 20. Study design
Screening
a:
IR Phase SR Phase
2 to 9 days^ 10 to 15 days'*
Hydromorphone Hydromorphone
12 to 108 mg/day 16 to 96 mg/day
Morphine Morphine
60 to 540 mg/day 60 to 520 mg/day
^\R phase was complete when pain was controlled (<3 requirements for breakthrough pain medication in the last 24 h) and 
dose stable (same dose level and no doses missed, except the 02.00 IR dose) for at least two consecutive days.
“^ CR phase was complete after a minimum of 10 days on CR medication if pain was controlled and dose stable for at least the 
previous two days.
5.4.4.2.1 Immediate-release (IR) phase
After completion o f the baseline assessments, the investigator explained the use of the study 
and brealcthrough pain medication. The IR phase medication was dispensed and the patient 
diary was given to the patient for completion during the study. During the IR phase, dose 
titration began with the dose level of the IR formulation which the investigator considered 
to be the most appropriate for the individual patient. Contact with the patient during the IR 
phase was daily, preferably by home or clinic visit but, if appropriate, by telephone. Any 
changes in concomitant medication and therapy and any adverse events were recorded. The 
patient was questioned regarding pain control, including the use of breakthrough pain 
medication and completion of the diary with details of medication taken and “worst pain” 
and “pain now” morning (a.m.) and evening (p.m.) ratings. The dose was up-titrated to the 
next dose level if  the patient had more than three breaktlirough pain episodes requiring 
breaktlii'ough pain medication within the previous 24 hours. Doses could not be titrated 
more frequently than once a day. Dose titration was continued until dose stable pain control 
was achieved. Dose stable pain control was defined as being on the same dose level of study 
medication for a minimum of two consecutive days with no regular doses being missed 
(however, missing the 02.00 IR dose was permissible) and <3 requirements for 
breakthrough-pain medication in the previous 24 hours.
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The duration of the IR phase was a minimum of two days and a maximum of nine days. For 
patients who had been using fentanyl patch analgesia, the IR phase was no shorter than 
seven days to allow a five-day washout from the effects of the patch.
When dose stable pain control had been achieved, contact was made by home or clinic visit 
and the end of the IR phase evaluation was carried out. The patient completed the diary, 
including the “worst pain” and “pain now” ratings from the BPI. The remaining questions 
on the BPI were completed by the investigator in consultation with the patient. The 
investigator recorded changes in concomitant medication and therapy and any adverse 
events. A physical examination was performed. The patient diary was collected and 
checked. Patients who achieved dose stable pain control entered the CR phase. Patients who 
did not achieve dose stable pain control by day nine were withdrawn from the study and the 
final evaluation was performed (as conducted on completion of the study).
5.4.4.2.2 Controlled-release phase
The investigator explained the use of the CR study medication and breaktlirough pain 
medication and the CR medication was dispensed. The CR phase lasted a minimum of 10 
days and a maximum of 15 days. Dosing in the CR phase, including dose level changes, 
always started with the morning dose. CR phase dosing began at the final IR dose level.
During this phase, each patient was contacted at least every three to four days, preferably by 
home or clinic visit but, if appropriate, by telephone. Changes in concomitant medication 
and therapy and any adverse events were recorded. The patient was questioned regarding 
the maintenance of pain control and completion of the diary. Up-titration to the next dose 
level occurred as in the IR phase (more than tln*ee breakthrough pain episodes requiring 
breakthrough pain medication within a 24-hour period), except that doses could be titrated 
only every second day. This was to allow for pharmacokinetic steady-state to be achieved 
for the controlled-release formulations (Shah 1997).
To complete the CR phase, patients must have achieved dose stable pain control for at least 
the final two days. The CR phase could be completed after day 10 if  dose stable pain control 
had been achieved for at least the previous two days. Upon completion of the CR phase, 
contact was made by home or clinic visit for the final evaluation. The patient completed the
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diary, including the “worst pain” and “pain now” ratings from the BPI and the remaining 
questions on the BPI were completed by the investigator in consultation with the patient. 
The investigator recorded changes in concomitant medication and therapy and any adverse 
events. A physical examination was performed including the Mini-Mental State 
Examination and the ECOG Performance Status Score. Patient diaries were collected and 
checked. At the end o f the study period, patients were treated for their pain according to the 
local standard of practice or, where the particular centre had decided to take part in a 
follow-on study, the patient was offered hydromorphone CR with IR as breakthrough pain 
medication for the ongoing treatment of pain for a period of up to one year. The patient’s 
treatment code was not broken at the time o f moving on to the follow-on study. This follow- 
on study is currently in progress and will not be reported until 2002.
The methods o f this study were presented at the European Association for Palliative Care 
congress in Berlin, in December 2000 (Hanna 2000) by Dr Hanna, the co-ordinating 
investigator for the study. The authors of this abstract were M Hamia, M Goulder (the 
project statistician) and the author, but due to uncertainties in the electronic abstract 
submission process, only Dr Hanna was listed as an author.
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S.4.4.3 Study assessments
The schedule of efficacy and safety assessments made during the study is given below;
Table 69. Study schedule
Investigator
assessment/procedure
Screening Baseline IR phase 
2 -9  days 
Daily^
End of IR 
phase
CR phase 
10-15 days 
Daiiy*^
End of CR 
phase or 
at
withdrawal®
Clinic or home visit X X X
or phone call
X X
or phone call
X
inclusion/exclusion
criteria
X X
Medical history X
Physical examination X X X
ECOG Status X
Concomitant medication X X X X X
Brief pain inventory X X X
Dispense medication X as required X as required
Dose titration as required^ as required®
Adverse events X X X . ........... r .......X
Final status X
Patient assessment
"Worst pain" in past 24 
hours & "Pain now” 
(morning and evening)
X X X X X
Patient diary X X
a; iR phase ended when patient achieved dose stable pain control for at least 2 consecutive days, 
b: CR phase was complete after a minimum of 10 days on CR medication if pain was controlled and dose 
stable for at least the previous two days, 
c: Assessment to be made on day last dose of medication taken 
d; Doses were not to be titrated more frequently than once a day. 
e: Doses were not to be titrated more frequently than every second day.
f: Contact was also to be made 3 days after last dose of study drug to determine patient’s adverse event
status
Patient’s assessment of “worst pain” in the past 24 hours and “pain now” were recorded 
using the following 11 -point numerical/descriptive rating scale taken from the Brief Pain 
Inventory:
0 1 2 3 4 5 6 7 8 9  10
No Pain as bad
pain as you can
imagine
Assessments of “worst pain” in the past 24 hours were scored by the patient, at baseline and 
once a day, every day, in the patient diary, just before taking the mid-morning dose of study 
medication. “Pain now” was scored by the patient, at baseline and twice a day, every day, in 
the patient diary, just before taking the mid-morning (a.m.) and evening (p.m.) doses, 
respectively.
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The Brief Pain Inventory was completed by the investigator in consultation with the patient 
at baseline and at the end of the both IR and CR phases (with the exception of the “worst 
pain” and “pain now” sections, which the patient completed as described above). The 
variables recorded included: least pain in the past 24 hours and average pain (both measured 
on an 11-point scale); the percentage pain relief the treatment had provided; how pain had 
interfered with the following (each measured on an 11-point scale): general activity, mood, 
walking ability, normal work, relations with other people, sleep, enjoyment of life.
Validated language versions of the Brief Pain Inventory were used in each respective 
country.
The date and time of use of breakthrough pain medication as well as the dose level and any 
changes in the dose level of study medication were recorded daily in the patient diary 
tlii'oughout the study.
All adverse events reported spontaneously by the patient or in response to questioning or 
observation by the investigator were recorded using the same categorisation as in the acute 
pain studies. Standard medical terminology was to be used according to the description 
published by Moulin (1996) for common opioid side effects and, where possible, a 
diagnosis was to be given rather than individual signs or symptoms. Changes in the severity 
o f cancer pain were not reported as adverse events (unless they led to withdrawal from the 
study) since pain severity was recorded as part of the efficacy data. Adverse event data were 
collected from the start of study medication until three days after the last dose.
S.4.4.4 Study medication, blinding and randomisation
In the IR phase o f the study, patients received either hydromorphone hydrochloride (HCl) 2, 
4, 6, 8, 12 or 18 mg every four hours or morphine sulphate 10, 20, 30, 40, 60, or 90 mg 
every four hours. In the CR phase of the study, patients received either hydromorphone 16, 
24, 32, 48, 72 or 96 mg every 24 hours or morphine sulphate 30, 60, 90, 120, 175, 260 mg 
every 12 hours. The doses were selected according to the available tablet strengths and a 
working equipotency value of 1:5. Dose titration began with the IR dose level which the 
investigator considered to be most appropriate for each individual patient.
In both the IR and CR phases, patients could also receive breakthrough pain medication: 
either hydromoi-phone or morphine sulphate, supplied as the IR formulation; a single dose
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of breakthrough pain medication contained Vg of the patient’s daily dose in the IR phase and 
as close an approximation as was feasible in the CR phase. All study medication was 
administered orally.
For the IR formulations, all tablets were encapsulated in size 0 brown capsules. CR 
morphine sulphate and matching placebo were encapsulated in brown supro B capsules. CR 
hydromorphone and matching placebo were presented as tablets. Sufficient medication 
supplies were packed and labelled for 400 patients, including overage. Study medication at 
all dose levels, for both the IR and CR phases, as well as breakthrough medication, was 
packed in blister cards (colour coded for each dose level to aid dose level recognition) in 
containers with drug for 3 days’ dosing. Medication was dispensed to suit individual patient 
dose requirements. The procedure for allocating medication was similar in both the IR and 
CR phases. The investigator started the patient at the desired dose level and the number of 
3-day packs required was dispensed. In the IR phase this was up to three 3-day packs, 
giving enough supplies for 9 days at one dose level. In the CR phase this was up to five 3- 
day packs, giving enough supplies for 15 days at one dose level. The same number o f packs 
of breakthrough pain medication, at the appropriate dose level, in both the IR and CR 
phases were also dispensed. Further medication was dispensed as required in cases of dose 
level changes.
Patients who met the study entry criteria were allocated a patient number in accordance with 
a central computer-generated randomisation list. Patients received numbers sequentially at 
each centre and the treatment they received was predetermined by the randomisation list. 
The patient number was identical to the treatment number pre-printed on the patient pack of 
medication.
Six dose levels were chosen for both IR and CR formulations as shown in the Tables 70 and 
71. For the IR phase, the minimum dose of 10 mg morphine was chosen, as this was the 
smallest tablet size available. The lowest hydromorphone dose for this phase was matched 
to the morphine dose based on a 5:1 equipotency ratio. The number of dose steps was based 
on the likely requirements of the patients in this study setting of cancer pain. For the CR 
phase, it was not always possible to identically match the hydromorphone and morphine 
doses.
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Table 70. Dose levels o f IR morphine and hydromorphone
Morphine Hydromorphone
Dose level Dose (mg) every 4h Dose (mg) every 4h
1 10 2
2 20 4
3 30 6
4 40 8
5 60 12
6 90 18
Table 71. Dose levels of CR morphine and hydromorphone
Morphine Hydromorphone
Dose level Dose (mg) every 12h Dose (mg) every 24h
1 30 16
2 60 24
3 90 32
4 120 48
5 175 72
6 260 96
Dose titration began with the dose level of the IR formulation which the investigator 
considered to be most appropriate for each individual patient. The “oral morphine 
equivalent” of a previous opioid could be calculated using the following conversion factors 
as a guide:
Table 72. Oral morphine equivalent conversion table
Opioid Conversion factor fo r oral m orphine equivalent
Meperidine (pethidine) X 0.2
Codeine X 0.3
Hydrocodone X 1.8
Oxycodone x 2
Methadone X 3
Hydromorphone X 5
Levorphanol X 15
For those patients who were already receiving opioid medication at entry to the study, the 
investigator was to consider incorporating a reduction in the dose conversion calculation to 
allow for incomplete cross-tolerance.
For all patients, the dose level could be increased in steps, missing none, until pain control 
was achieved (<3 episodes of breaktlii'ough pain in the last 24 hours). If more than 3 
breakthrough pain episodes requiring breakthrough pain medication occurred within a 24- 
hour period, the investigator was to increase the dose to the next level. The dose level was 
not to be altered more frequently than once daily in the IR phase. It was recommended that 
patients consult with the investigator prior to changing to the next dose level.
To enter the CR phase of the study, patients must have had dose stable pain control for at 
least two consecutive days of the IR phase. The earliest a patient could have entered the CR
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phase was on the morning of day 3 of the IR phase, provided that the dose was stable and 
the pain was controlled for the first two days.
In changing from the IR formulation to the CR formulation of the study medication, the 
patient was to be given the same dose level as their final IR formulation 24-hour dose. Thus, 
if  a patient’s pain was controlled on dose level 3 of the IR formulation, they were 
transferred to dose level 3 of the CR formulation. Dosing in the CR phase, including dose 
level changes, always started with the morning dose.
In the CR phase of the study, the dose level was adjusted as required, but only in single 
steps so that no dose level was skipped. The dose level was not to be altered more 
frequently than once every two days in the CR phase in order to allow steady-state drug 
levels to be reached.
The suggested IR phase dosing schedule was six times per day at 10.00, 14.00, 18.00,
22.00, 02.00 and 06.00 hours. The suggested CR phase dosing was twice per day at 10.00 
and 22.00 hours (a double dummy teclmique was used to blind the hydromorphone once 
daily CR medication). In the IR phase the 02.00 hour dose could have been omitted 
completely, or omitted prospectively and a double dose given at 22.00 hours the previous 
day. Other dosing schedules were acceptable, if more convenient, provided that the dosing 
intervals of 4 and 12 hours in the IR and CR phases were strictly maintained and the doses 
were taken at the same time every day.
Regular dosing with study medication was to be done within one hour of the target time. In 
the IR phase, where dosing was delayed for greater than one hour, the delayed dose was to 
be taken as soon as possible. If  the delay was as great as 4 hours, then a double dose was to 
be taken. Dosing delays of greater than 4 hours resulted in the delayed dose being missed. 
When dosing was delayed in the CR phase, the delayed dose was to be taken as soon as 
possible. Dosing delays of greater than 4 hours resulted in the delayed CR dose being 
missed completely and CR dosing re-commencing at the next scheduled time. During the 
intervening period patients were to use breakthrough pain medication as required to control 
pain.
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All Study medication (both capsules and tablets), was to be swallowed whole and not 
crushed, broken or chewed and was to be taken with fluid. The timing with respect to meals 
was not controlled.
This was a double blind, double-dummy study. Although the investigator and the patient 
were aware of the dose level being administered, both remained blind to the identity of the 
medication. The IR morphine and IR hydromorphone capsules were identical in appearance 
and were taken every 4 hours. However, the CR morphine was presented as a capsule to be 
taken every 12 hours and the CR hydromorphone was presented as a tablet to be taken every 
24 hours. This was because of tablet sizes, it did not prove to be feasible to place the 
hydromorphone CR tablets inside a capsule. Thus, it was necessary to use placebo tablets 
and capsules in a double dummy technique in order the maintain blinding in the CR phase. 
Patients who received morphine CR twice daily were also given a placebo to match 
hydromorphone in the morning. Similarly, patients receiving hydromorphone CR once daily 
also received a placebo to match morphine in the morning and evening. Thus, both the 
patient and the investigator were unaware of the identity of the medication. Each 
participating centre had access to the treatment code for individual patients in the same way 
as described for the acute pain studies.
5.4.4 5 Data entry and statistical analysis
Data entry was performed in the same manner as that described for the acute pain studies. A 
random sample of 12 patients had all their information checked. The error rates were 0.01% 
for adverse events, 0.06% for withdrawal information, 0.06% for study medication and 
0.02% for the principal measure of efficacy. The error rates were considered to be 
satisfactory and any discrepancies found were amended before analysis.
The statistical methods described in the protocol were expanded to produce a detailed 
statistical plan. This was discussed and agreed with the author and the Study Director, 
before the blind was broken and data made available for analysis. All statistical analyses 
were performed using the statistical analysis system SAS, release 6.12 under the Microsoft® 
Windows'^'^ NT operating system (SAS Institute Inc 1990).
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The two treatments were to be considered equivalent (for the immediate and controlled- 
release formulations separately), if the 95% two-sided confidence interval for the treatment 
difference fell wholly within the interval ±1.5. This interval was determined as being 
clinically relevant through consultation with opinion leaders in analgesia during the 
plamiing of the study. This difference was measured using the mean of the last two post­
baseline recorded values (or last value, if  only one value was available) for the “worst pain” 
score of BPI in the past 24 hours (principal measure of efficacy) in each respective 
treatment phase.
The “full analysis” set included all patients who took at least one dose of study medication 
and with at least one assessment performed within each of the respective phases of the 
study. Any patient with treatment administration errors was analysed according to the 
treatment actually taken. All efficacy variables were analysed using this set. For the 
principal measure of efficacy, the last two post-baseline recorded values at the end of each 
phase were used in the analysis (or last value, if only one value was available). This was to 
allow for the inclusion of patients who withdrew.
Because this was an equivalence study a per-protocol analysis was also performed. The per- 
protocol analysis set included all patients in the “full analysis” set excluding patients with 
major protocol violations and deviations. Only the analyses relating to the principal measure 
of efficacy were performed using this set. Any difference between this analysis and the 
analysis o f the “full analysis” set was to be explored and explanations identified. All 
relevant protocol deviations were assessed under blind conditions and documented.
All patients taking at least one dose of study medication were included in the analysis of 
safety. No assessments were excluded from this set. The safety set was analysed as treated.
The treatment groups were assessed for comparability with respect to baseline information, 
in particular the BPI “worst pain” in the past 24 hours, ECOG performance status and 
nature of predominant pain. Any clinically significant difference was ineorporated as a 
covariate into an additional sensitivity analysis.
For all efficacy variables 95% two-sided confidence intervals for the difference between 
hydromorphone and morphine were calculated.
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The principal measure of efficacy was the mean of the last two post-baseline recorded 
values (or last value, if  only one value is available) for “worst pain” in the past 24 hours. 
The two treatments were to be considered equivalent (for each phase separately) if  the 95% 
two sided confidence interval for the difference between the adjusted means for the two 
treatments (taken from an analysis o f covariance [Armitage 1987, p 282-95] with factors for 
treatment and country with the baseline value for “worst pain” used as a covariate) lay 
within -1.5 to 1.5. An additional analysis, including a factor for the treatment-by-country 
interaction was performed. If the interaction was significant at the 10% level, the source of 
the interaction and its impact on treatment equivalence was to be assessed. A sensitivity 
analysis was to be performed on CR phase data, if there was evidence of relevant treatment 
group differences in the IR phase. This analysis was to include additional covariates such as 
time in IR phase (in days) and “worst pain” at the end of the IR phase.
The 95% two-sided confidence interval for the treatment difference between the adjusted 
means for the following variables at endpoint in the IR and CR phases respectively were 
also calculated.
• least pain in the past 24 hour s
• average pain
• pain relief
• each of the seven questions relating to how pain has interfered with their life
• sum of the seven questions relating to how pain has interfered with their life
The adjusted means were estimated using the same approach as for the principal measure 
with the score at baseline for the variable used as a covariate (no additional analyses, 
including a factor for the treatment-by-country interaction, were performed), although no 
aetual equivalence region was defined.
The 95% two-sided confidence interval for the treatment difference between the adjusted 
means at endpoint in the IR and CR phases for the mean of the last two post-baseline days’ 
values (or last value, if only one value is available) for “pain now” a.m. and p.m. was 
estimated using an analysis of variance with factors for treatment group and country. Data 
were not available at baseline for some patients for these two variables. Ninety-five percent 
confidence intervals were also calculated for the within treatment changes between the 
endpoint values for the IR and the CR phase for all the above variables.
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The time (in days) to dose stabilisation during both phases was analysed by the logrank test 
(Armitage 1987, p 429-31). For the IR phase this was defined as the number of days in the 
phase. Patients who withdrew from the study or who were excluded from the IR per- 
protocol analysis because they were considered not to be dose stable were censored at the 
time of last IR phase dose. For the CR phase this was defined as the first occurrence where 
the patient was dose stable (i.e. on the same dose level) for at least two days and had 
adequate pain control (i.e. had taken no greater than three doses of breakthrough medication 
in the last 24 hours). Since pharmacokinetic steady state was not achieved with CR 
medication until 48 hours after the first dose or any dose level change, the data from the 
first two days of the CR phase was not used to calculate time to dose stabilisation. Thus, the 
earliest a patient could be declared dose stable during the CR phase was on CR day 4. 
Patients who did not become dose stabilised were to have their value censored at the time of 
their last CR phase dose.
Summary statistics with appropriate 95% two sided confidence intervals are presented for 
the following variables:
• the number of patients having to change CR dose level (patients with starting CR dose 
levels different to last IR dose levels were omitted from this analysis)
• the mean number of dose levels changed during the CR phase (patients with starting CR 
dose levels different to last IR dose levels were omitted from this analysis)
• number of breakthrough-pain medication doses taken on the last two post-baseline days 
of each phase
Extent o f exposure was described by the number of days of treatment within each phase of 
the study, and the number of days on each dose level within eaeh study phase. When two 
different dose levels were taken on the same day, only the higher dose level was counted for 
calculation purposes.
The general handling of adverse event data was the same as that described for the acute pain 
studies. For tabulations concerning the CR phase, events that started during the IR phase 
and continued into the CR phase were included. For the overall and CR phase adverse 
events tabulations, post-treatment emergent events were defined as those events that 
commenced more than two days after the last study non-breakthrough medication dose. For
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the IR phase tabulations, post-treatment emergent events were defined as those events that 
commenced more than two days after the last study IR medication dose (for those patients 
who did not enter the CR phase) and any day after the last study IR medication dose (for 
those patients who did enter the CR phase). All adverse events with the onset date on the 
same day as the first IR dose were assumed treatment emergent.
The difference between the treatment groups in the proportion of patients with adverse 
events within each phase are presented together with 95% confidence intervals for the 
difference in the proportion. Also the differences between the treatment groups in the 
proportion o f patients reporting the more frequently (i.e. reported by at least 5% of the study 
population) reported adverse events are presented.
For the commonly reported adverse events associated with morphine (Moulin 1996), an 
additional tabulation was produced of all events ongoing or starting during the double-blind 
phase. The ongoing adverse events were not included in the other adverse event tabulations 
mentioned above, as they were not regarded as treatment emergent.
Differences between the treatment groups in the proportion of patients withdrawing are 
presented together with 95% confidence intervals for the difference in the proportion. The 
time to withdrawal from the study (irrespective of phase) was analysed by the logrank test.
Statistical assumption checking, for parameters such as normality of distribution, was 
performed in the same way as described for the acute pain studies.
Assuming the variability (sd) to be 2.0 (estimated from a previous published data, Serlin 
1995) and 90% power, then a sample size of 47 evaluable patients per group entering the 
CR phase was originally required. Assuming a 30% drop-out/non-evaluable patient rate in 
each treatment group, approximately 70 patients per group were required to be randomised. 
After complete data had been received for 55 randomised patients the variability for the 
principal measure of effieacy was estimated for both phases o f the study. The new estimates 
were 2.24 for the IR phase and 2.50 for the CR phase. These two variability estimates were 
calculated by taking the root mean square error from analysis of covariance models with 
factors for treatment group and country with baseline “worst pain” score as a covariate for 
each phase separately. These two root mean square errors were the sole output from a
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program that accessed the treatment code. An appointed independent person within the 
Biostatistics and Data Management department, who had access to the randomisation, ran 
this program. A member of the Company’s Quality Assurance department witnessed the 
running o f this program. Using the revised variability for the CR phase of 2.5 and assuming 
90% power and a two-sided two-sample t-test, then 74 patients per group were required to 
enter the CR phase. As the IR phase dropout rate at the time of the calculation was 10%, 82 
patients per group were required to be randomised into the study.
After data had been received for 120 randomised patients, the blinded variability for the 
principal measure of efficacy was estimated for the CR phase o f the study. This estimate 
was 2.7. This variability was estimated by taking the root mean square error from an 
analysis of covariance model with a factor for country and a covariate for baseline “worst 
pain” score (i.e. no factor for treatment code was included). Using this revised variability 
and assuming 90% power and a two-sided two-sample t-test, then 84 patients per group 
were required to enter the CR phase. As the IR phase dropout rate was 18% at the time of 
the calculation, 100 patients per group were required to be randomised into the study.
The actual variability estimated from the root mean square error (MSB) from the analysis of 
covariance for the CR phase analysis was 2.46 for the “full analysis” set. The corresponding 
figure for the per-protocol set was 2.25.
5.4.5 Results
A total o f 202 patients were screened for entry into the study between 28 June 1999 and 
23 April 2001 of which 200 actually took study medication. O f the 200 patients randomised, 
163 (82%) completed the IR phase and entered the CR phase and of these, 133 completed 
the CR phase (82%). Overall, 133/200 (67%) patients completed both phases of the study. A 
flow diagram of patient entry and completion is given below:
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Figure 21. Flow diagram of patient entry and completion
No. patients screened = 202
Completed SR ptiase 
n=73
Completed SR phase 
n=60
Completed IR phaseCompleted IR phase 
n=77
No. patients randomised = 200
Entered hydromorphone SR phase 
n=77
Entered morphine SR phase 
n=86
Entered hydromorphone IR phase Entered morphine IR phase 
n=101
Withdrawals:
Adverse events n=6 
Lack of efficacy n=5 
Consent withdrawn n=S 
Death n=0
Disease progression n=1 
Administrative reasons n=0 
Protocol violation n=0
Withdrawals:
Adverse events n=9 
Lack of efficacy n=6 
Consent withdrawn n=3 
Death n=0
Disease progression n=0 
Administrative reasons n=1 
Protocol violation n=3
Withdrawals:
Adverse events n=7 
Lack of efficacy n=1 
Consent withdrawn n=4 
Death n=2
Disease progression n=0 
Administrative reasons n=0 
Protocol violation n=1
Withdrawals.
Adverse events n=4 
Lack of efficacy n=3 
Consent withdrawn n=2 
Death n=1
Disease progression n=3 
Administrative reasons n=0 
Protocol violation n=0
Patients were recruited into the study from eight countries. Table 73 gives the number of 
patients completing and entering each of the double-blind phases of the study within each 
country:
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Table 73. Summary o f number of patients com pleting and entering each of the two double-blind
phases o f the study w ith in  each country
Country/ IR phase CR phase
number
of
centres
Hydro­
morphone
Morphine Overall Hydro­
morphone
Morphine Overall
United Kingdom 
8 21/34 (62%) 18/25(72%) 39/59 (66%) 16/21 (76%) 16/18 (89%) 32/39 (82%)
Spain
5 16/19 (84%) 19/21(90%) 35/40(88%) 12/16 (76%) 16/19 (84%) 28/35 (80%)
France
4 3/3 (100%) 3/4 (75%) 6/7 (86%) 3/3 (100%) 2/3 (67%) 5/6 (83%)
Netherlands
6 10/12 (83%) 16/17(94%) 26/29 (90%) 9/10 (90%) 14/16 (88%) 23/26 (88%)
Germany
4 3/6 (60%) 8/9(89%) 11/15(73%) 2/3 (67%) 7/8 (88%) 8/11 (80%)
Sweden
3 5/5 (100%) 4/6 (67%) 9/11 (82%) 4/5 (80%) 4/4 (100%) 8/9 (89%)
Belgium
5 14/15 (93%) 13/14(93%) 27/29 (93%) 9/14 (64%) 9/13 (69%) 18/27 (67%)
Canada
2 5/5 (100%) 5/5(100%) 10/10(100%) 5/5 (100%) 5/5 (100%) 10/10(100%)
Total 37 
Overall 77/99(78%) 86/101(85%) 163/200(82%) 60/77(78%) 73/86(85%) 133/163(82%)
Withdrawals and reason for withdrawal, as recorded by the investigator, are summarised in 
Table 74. Although more patients withdrew from the hydromorphone group in each phase, 
the 95% confidence intervals for the difference in the proportion of patients withdrawing 
contained zero for each phase as was the case for both phases combined, implying these 
differences were not statistically significant. There was no statistically significant difference 
between treatment groups in the time to withdraw irrespective of phase (p=0.17). The 
Kaplan-Meier mean estimates were 16.5 days and 17.8 days for the hydromorphone and 
morphine groups respectively.
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Table 74. Summary o f patient w ithdrawals during the double-blind phase
Reason for IR phase CR phase Both phases
withdrawal Hydro­
morphone
Morphine Hydro­
morphone
Morphine Hydro­
morphone
Morphine
n 99 101 77 86 99 101
Adverse events 9 (9%) 7 (7%) 6 (8%) 4 (5%) 15 (15%) 11 (11%)
Lack of efficacy 6 (6%) 1 (1%) 5 (6%) 3 (3%) 11 (11%) 4 (4%)
Consent withdrawn 3 (3%) 4 (4%) 5 (6%) 2 (2%) 8 (8%) 6 (6%)
Death - 2 (2%) - 1 (1%) - 3 (3%)
Disease progression - - 1 (1%) 3 (3%) 1 (1%) 3 (3%)
Administrative 1 (1%) - - - 1 (1%) -
reasons
Protocol violation 3 (3%) 1 (1%) - - 3 (3%) 1 (1%)
Total withdrawn 22 (22%) 15(15%) 17(22%) 13 (15%) 39 (39%) 28 (28%)
Difference in the 7% 7% 12%
proportion of 
patients withdrawn 
95% Cl -6%,21% -8%,22% -4%,28%
Table 75 summarises major and minor protocol deviations during the study. Major protocol 
deviations led to exclusion of the patient from the per-protocol analysis of the relevant 
phase of the study.
Table 75. Summary of protocol deviations during the double-blind phase
Deviation^ Treatment group 
Hydromorphone Morphine
Overall
Major deviations
Took strong opioids during study 1 2 3
Not dose stable at end of the IR phase 2 4 6
Not dose stable at end of the CR phase 4 4 8
Number of patients with major deviations 6 9 15
Minor deviations'*
Took weak opioids during study 7 4 11
Took adjuvant pain therapies (other than opioids) 
that did not remain at constant dosage during the 
study and which were taken for "pain-related" 
reasons
18 12 30
IR phase > 9 days 4 - 4
Started taking IR medication after entering CR phase 2 - 2
CR phase < 10 days and completed study - 1 1
CR phase > 15 days 3 1 4
Starting CR dose level different to last IR dose level 3 4 7
Baseline laboratory assessments after first IR dose 5 2 7
Number of patients with minor deviations 35 21 56
Number of patients with a deviation 37 26 63
a Not mutually exclusive 
b Includes two patients, one in each treatment 
group who were taking weak opioids for 
indications other than pain
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5.4.5.1 Efficacy
A total o f 200 patients entered the double-blind phase of the study; the number of patients 
providing data for the primary measure of efficacy within each phase of the study is given 
in Table 76. Two patients (numbers 287 and 322) provided no post-baseline efficacy data 
and therefore 198 patients were included in the “full analysis” set. A total of 193 (97%) 
patients provided at least one post-baseline “worst pain” score, although two of these 
patients did not provide post-baseline scores within the IR phase o f the study.
Table 76. Summary of number o f patients providing data fo r “ w orst pain” (primary measure of 
efficacy) w ith in  each phase o f the study (“ fu ll analysis" set)
IR phase CR phase
Hyd. Morphine Overall Hyd. Morphine Overall
Number entering phase 99 101 200 77 86 163
No post baseline data/no 
CR data
4 3 7 1 1 2
No baseline and IR follow- 
up data but completed the 
study
1 1 2
Completed study without 
CR data
1 1
Number provid ing data 94 97 191 76 84 160
No baseline - 1 1 1 2 3
Number included In 
A NOG VA of “ w orst 
pain” at the end o f each 
phase
94 96 190 75 82 157
a Analysis required a "worst pain" score at baseline
The per-protocol analysis set included all patients in the “full analysis” set excluding the 
following:
• patients failing to complete the respective phase
• patients completing the respective phase but having less than two days of dose stable 
pain control at the end of the phase (For the IR phase, this was solely determined by the 
investigator’s adjudication at the end of the phase. For the CR phase, a patient was 
considered not dose stable for analysis purposes, either if  the patient was considered not 
dose stable by the question on the last available daily contact report, or if a dose of CR 
medication had been missed in the last 24 hours of the phase as recorded on the contact 
report)
The assessments subsequent to any use of other strong (i.e. not including agents such as 
codeine, tramadol) opioid analgesics were also excluded from the per-protocol analysis.
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All efficacy variables were analysed using the “full analysis” set whereas the per-protocol 
set was restricted to the principal measure o f efficacy. The number of patients providing 
data for the per-protocol analysis of this variable is given in Table 77.
Table 77. Summary o f number o f patients provid ing data fo r “ w ors t pain” (primary measure of 
efficacy) w ith in  each phase of the study (per-protocol set)
IR phase CR phase
Hyd. Morphine Overall Hyd. Morphine Overall
Number entering phase 99 101 200 77 86 163
Number providing data 
Excluded from  PR set
94 97 191 76 84 160
Provided data but withdrew 
from phase
18 12 30 16 12 28
Took strong opioids but 
completed phase
1 1 2 1 1
Not dose stable but 
completed phase
2 4 6 4 4 8
Number excluded 21 17 38 20 17 37
Number included In PR* 
analysis
73 80 153 56 67 123
No baseline - 1 1 1 2 3
Number Included in 
ANCOVA o f “ w ors t pain” 
at the end of each phase^
73 79 152 55 65 120
PR = “per protocol”
Analysis required a “worst pain” score at baseline
The treatment groups were balanced in terms of age, sex, race and weight. Mean age was 
59.8 years with range 19 to 82 years. One hundred and two patients (51%) were female. 
One hundred and ninety-seven (98.5%) patients were Caucasian, 2 (1%) Oriental and 1 
(0.5%) patient was classified as “Other”. Mean weight was 66.9 kg with range 35.0 to 
110.0 kg.
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Table 78. Entry profile: demographic information for all patients who took study treatment
V a r i a b l e T r e a t m e n t
H y d r o m o r p h o n e
g r o u p
M o r p h i n e
O v e r a l l
T o t a l  n u m b e r  o f  p a t i e n t s 9 9 1 0 1 2 0 0
A g e M e a n 6 0 . 7 5 9  . 0 5 9 . 8
( y r ) s d 1 2  . 5 1 1 .  4 1 1  . 9
n 9 9 1 0 1 2 0 0
R a n g e 2 7 . 0 , 1 9 . 0 , 1 9 . 0 ,
8 2 . 0 8 1 .  0 82.  0
S e x F e m a l e 5 3  ( 5 4 % ) 4 9  ( 4 9 % ) 1 0 2  ( 5 1 %
M a l e 4 6  ( 4 6 % ) 5 2  ( 5 1 % ) 9 8  ( 4 9 %
R a c e C a u c a s i a n 9 9 9 8 1 9 7
O r i e n t a l 0 2 2
O t h e r 0 1 1
W e i g h t M e a n 6 6 . 3 6 7  .  4 6 6 .  9
( k g ) s d 1 5  . 3 1 3  .  3 1 4  . 3
n 9 6 9 9 1 9 5
R a n g e 3 5 . 0 , 3 7 . 5 , 3 5 . 0 ,
1 1 0 . 0 9 6  . 0 1 1 0  . 0
The most common cancer type was breast cancer recorded for 56 (28%) patients. Forty 
(20%) patients were recorded as having lung cancer and 38 (19%) gastrointestinal cancer. 
The most common location of métastasés was bone which was recorded for 107 (54%) 
patients. A total of 133 (67%) patients had their predominant pain in bone or soft tissue, 34 
(17%) had mixed pain, 33 (17%) had visceral pain and there were no reports of neuropathic 
pain. The lack o f any patients with predominantly neuropathic pain probably reflects the 
investigators’ belief that opioids are not of reliable benefit in this pain type (Arner 1988). 
Tliree (1.5%) patients had an ECOG score of 4 at baseline (worst category) with a further 32 
(16%) having a score of 3. The mean ECOG score was 1.6. For the 195 patients with 
baseline data, the mean “worst pain” score was 6.3, a total of 21 (11%) patients had the 
maximum score of 10 and four (2%) patients reported no pain at baseline (Table 79). Thus, 
patients’ self-reported pain from both extremes of the pain scale is present at the start of the 
study. This is entirely expected since on one hand, patients with satisfactory pain control 
could be enrolled into this study, and on the other hand, it could be expected that some 
investigators would use the study as an exercise in the management of the pain in a patient 
who was currently experiencing poor pain control. The latter scenario would most obviously 
be the case where patients were progressing to the use o f strong opioids for the first time in 
their chronic pain management. Only 41% of patients were receiving strong opioids at 
baseline (Table 80).
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Table 79. Cancer diagnosis, nature of predominant pain and baseline scores for ECOG and “worst pain” In the past 
24 hours for all patients who took study treatment
Treatment group
Hydromorphone Morphine
Overall
Total number of patients 99 101 200
Cancer type Breast 23 33 56
Lung 20 20 40
Bone 1 1 2
Oral cavity 3 3 6
Gastrointestinal 20 18 38
Genitourinary 19 12 31
Lymphoma 3 - 3
Leukaemia 1 2 3
Other 9 12 21
Location of métastasés None 11 15 26
Brain 2 5 7
Bone 48 59 107
Bone marrow 3 2 5
Lung 23 17 40
Liver 19 21 40
Kidney 1 1 2
Lymph node 29 20 49
Other 27 19 46
Nature of predominant pain Visceral 19 14 33
Bone or soft tissue 61 72 133
Mixed 19 15 34
Neuropathic - - -
ECOG score at baseline" 0 1 5 6
1 54 49 103
2 28 28 56
3 15 17 32
4 1 2 3
Mean 1.6 1.6 1.6
sd 0.8 0.9 0.8
"worst pain" in the past 24 hours at n (with data) 97 98 195
baseline‘s
Mean 6.3 6.2 6.3
sd 2.7 2.5 2.6
a Not mutually exclusive
b 0 = patient fully active, able to carry out all-disease functions without restrictions, 1 = patient restricted in physically
strenuous activity, but ambulatory and able to carry outwork of a light or sedentary nature, 2 = patient ambulatory and
capable of self care, but unable to work or carry out any work activities, up and about more than 50% of waking hours, 
3 = patient capable of only limited self care, confined to bed or chair more than 50% of the waking hours, 4 = patient 
completely disabled, unable to carry on any self care, totally confined to bed or chair 
c Measured on a 11-point scale (0 = no pain; 10 = pain as bad as you can imagine)
Table 80 summarises the various previous pain therapies reported. The two most common 
were morphine (68 patients) and tramadol (15 patients). A total of 81 (41%) patients 
reported the previous use of strong opioids.
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Table 80. Summary of previous pain therapies
Therapy^ Treatment group
Hydro- Morphine 
morphone (n=101) 
(n=99)
Overall
(n=200)
Number of patients reporting a previous adjuvant pain 50 (51%) 54 (54%) 104 (52%)
therapy
Strong opio ids
Number of patients reporting 39 (39%) 42 (42%) 81 (41%)
DIAMORPHINE 2 1 3
FENTANYL 2 2 4
KETOBEMIDONE 1 1 2
METHADONE - 2 2
MORPHINE 32 36 68
PARACETAMOL + OXYCODONE 1 - 1
PETHIDINE 2 - 2
Weak opio ids
Number of patients reporting 17 (17%) 15 (15%) 32 (32%)
CODEINE 2 1 3
DIHYDROCODEINE 2 1 3
PARACETAMOL + CODEINE 2 3 5
PARACETAMOL + ASPIRIN + CAFFEINE + CODEINE 1 - 1
PARACETAMOL + CAFFEINE + CODEINE 1 - 1
PARACETAMOL + DEXTROPROPOXYPHENE 4 1 5
PARACETAMOL + DIHYDROCODEINE - 2 2
TRAMADOL 7 8 15
Others
Number of patients reporting 7 (7%) 9 (9%) 16 (16%)
ACETYLSALICYLIC ACID 1 1
BENZYDAMINE HYDROCHLORIDE - 1 1
CLODRONATE DISODIUM 1 - 1
DEXAMETHASONE 1 - 1
DICLOFENAC 1 2 3
GABAPENTIN 1 - 1
HYDROCORTISONE 1 - 1
KETOROLAC 1 1
NALOXONE 1 1 2
NAPROXEN 1 2 3
PARACETAMOL 2 1 3
PREDNISOLONE - 1 1
a Not mutually exclusive
Pain therapies ongoing or started during the study are summarised in Table 81. Three (2%) 
patients took strong opioids during the study (this was designated a major protocol 
violation) and 9 (5%) took weak opioids (a minor protocol violation). Thirty (15%) patients 
took adjuvant pain therapies (other than opioids) that did not remain at constant dosage 
during the study and which were taken for “pain-related” reasons. The patients who took 
strong opioids were excluded from the per-protocol analysis.
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Table 81. Summary of pain therapies ongoing or starting during the double-blind phase
Hydromorphone
(n=99)
Morphine
(n=101)
Overall
(n=200)
Number of patients reporting a 63 (64%) 65 (64%) 128 (64%)
therapy"
Strong opioid
Number of patients reporting 1 (1%) 2 (2%) 3 (2%)
MORPHINE 1 2 3
Weak opioid
Number of patients reporting 6 (6%) 3 (3%) 9 (5%)
CODEINE PHOSPHATE 1 1
DIHYDROCODEINE 2 - 2
PARACETAMOL+CODEINE 1 1 2
PARACETAMOL+DEXTROPROPO - 1 1
XYPHENE
TRAMADOL 2 1 3
Steroid
Number of patients reporting 12 (12%) 18 (18%) 30 (15%)
BETAMETHASONE 2 2
DEXAMETHASONE 8 13 21
PREDNISOLONE 1 - 1
PREDNISOLONE SODIUM - 1 1
SULFOBENZOATE
PREDNISONE 4 2 6
NSAID
Number of patients reporting 29 (29%) 35 (35%) 64 (32%)
DICLOFENAC 17 15 32
DICLOFENAC+MISOPROSTOL 1 - 1
DIFLUNISAL 2 - 2
FLURBIPROFEN 1 4 5
IBUPROFEN 3 4 7
INDOMETACIN 3 5 8
NAPROXEN 5 6 11
NSAID'S - 1 1
ROFECOXIB - 1 1
Sim ple analgesic
Number of patients reporting 26 (26%) 20 (20%) 46 (23%)
ACETYLSALICYLATE LYSINE 1 1
ACETYLSALICYLIC ACID 1 - 1
FLUPIRTINE 1 - 1
METAMIZOLE 6 3 9
METHYLPREDNISOLONE 1 - 1
PARACETAMOL 19 16 35
Antidepressant
Number of patients reporting 13(13%) 13 (13%) 26(13%)
AMITRIPTYLINE 7 8 15
DOSULEPIN 5 4 9
IMIPRAMINE 1 - 1
NORTRIPTYLINE - 1 1
Anticonvu lsant
Number of patients reporting 9 (9%) 8 (8%) 17 (9%)
CARBAMAZEPINE 1 2 3
GABAPENTIN 5 5 10
VALPROATE SODIUM 3 1 4
Miscellaneous adjuvant
Number of patients reporting 3 (3%) 6 (6%) 9 (5%)
CLODRONATE DISODIUM 1 4 5
CLONIDINE 1 - 1
PAMIDRONATE DISODIUM 1 2 3
not mutually exclusive
The mean o f the last two recorded scores for “worst pain” at the end of each of the 
respective study phases were the principal measure of efficacy for the “full analysis” set. 
These are presented in Table 82. For the two treatments to be considered equivalent the
28/09/01
MD Thesis for Dr Colin JA Durnin 2001 Page 161
95% two-sided confidence interval for the difference between the adjusted means for the 
two treatments had to lie w ith in-1.5 to 1.5. This was the case for the IR phase, indicating 
that hydromorphone IR was equivalent to morphine IR. For the CR phase, the lower limit 
was less than -1 .5  which implied the superiority of hydromorphone could not be disproved. 
However, the upper limit was less than 1.5 and therefore non-inferiority of hydromorphone 
was proven. Furthermore there was a statistically significant difference between the 
treatment groups in favour of hydromorphone for the CR phase. The adjusted mean for 
hydromorphone was 3.5 compared to 4.3 for morphine (p=0.046). For both phases, the term 
for baseline score was highly statistically significant (p<0.001). The term for treatment 
group-by-country interaction was statistically significant at the 10% level for the IR phase 
analysis (p=0.08). “Worst pain” decreased during the study in both treatment groups. For 
the cohort o f patients with data for both phases, mean “worst pain” decreased by 1.0 (95% 
Cl 0.5,1.6) for hydromorphone-treated patients from the end of the IR phase to the end of 
the CR phase. For the morphine-treated patients, mean “worst pain” decreased by 0.5 (95% 
Cl -0.1,1.0). Figure 22 presents the mean “worst pain” profiles during the whole of the 
study for the observed datasets based on the “full analysis” set.
Table 82. Analysis o f covariance fo r the mean o f the last two recorded scores fo r “ w orst pain” (“ fu ll analysis” set)
Mean of the last two recorded scores 
for “worst pain”"
IR phase CR phase
Hydromorphone Morphine Hydromorphone Morphine
Total number of patients 94 97" 76" 84"
Mean 5.0 4.8 3.5 4.1
sd 2.7 2.4 2.5 2.7
Range 0,10 0,9 0,10 0,9.5
Adjusted mean‘s 5.0 4.8 3.5 4.3
Difference in adjusted means" 0.2 -0.8
se (of difference) 0.3 0.4
95% 01 for difference -0.4,0.9 -1.6,-0.01
n Mean se 95% Cl
OR -  IR (Hydromorphone) 75 -1.0 0.3 -1.6,-0.5
OR -  IR (Morphine) 83 -0.5 0.3 -1.0,0.1
Analysis of covariance F 2 F ■ 2
Baseline score 58.35 1,180 <0.001 21.52 1,147 <0.001
Treatment group 0.41 1,180 0.52 4.04 1,147 0.046
Country 0.31 7,180 0.95 0.45 7,147 0.87
Treatment group-by-country 1.83 7,173 0.08 1.72 7,140 0.11
a Measured on a 11-point scale (0 = no pain; 10 = pain as bad as you can imagine)
b One patient did not provide a baseline score so not included in ANCOVA
c Two patients did not provide a baseline score so not included in ANCOVA 
d Adjusted for baseline and country
e A negative difference favours hydromorphone
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Table 83 presents the results from the per-protocol analysis of the above. The conclusions 
were the same, with statistical significance in favour of hydromorphone at the end of the CR 
phase (p=0.049). The adjusted means were 2.9 for hydromorphone and 3.8 for morphine. 
The lower limit of the 95% Cl was again less than -1.5 implying the superiority of 
hydromorphone could not be disproved. The treatment group-by-country interaction was 
statistically significant at the 10% level in both phases (p=0.04 for the IR phase and 
p=0.098 for the CR phase).
Table 83. Analysis of covariance for the mean of the last two recorded scores for “worst pain” (“per protocol” set)
Mean of the last two recorded scores 
for "worst pain” "
IR phase CR phase
Hydromorphone Morphine Hydromorphone Morphine
Total number of patients 73 80" 56" 67"
Mean 4.5 4.5 3.0 3.7
sd 2.6 2.4 2.1 2.5
Range 0,10 0,9 0,8 0,9.5
Adjusted mean" 4.6 4.8 2.9 3.8
Difference in adjusted means" -0.2 -0.8
se (of difference) 0.3 0.4
95% Cl for difference -0.9,0.5 -1.7,-0.004
n Mean se 95% Cl
CR -  IR (Hydromorphone) 55 -1.4 0.3 -2.1,-0.7
CR -  IR (Morphine) 63 -0.5 0.3 -1.1,0.1
Analysis of covariance F # 2 F df 2
Baseline score 60.95 1,142 <0.001 15.89 1,110 <0.001
Treatment group 0.28 1,142 0.60 3.96 1,110 0.049
Country 0.40 7,142 0.90 0.80 7,110 0.59
Treatment group-by-country 2.21 7,135 0.04 1.79 7,103 0.098
iv ic a o u l c u  UN d  i i ii o v a i c  — i lu  \ j a i i  i, i v  (jciii i a o  v a u  a o  y v u  v a n  ii i
One patient did not provide a baseline score so not included in ANCOVA 
Two patients did not provide a baseline score so not included in ANCOVA 
Adjusted for baseline and country 
A negative difference favours hydromorphone
Removal from the per-protocol analysis of the patients from tlii’ce of the four poorest 
recruiting counties rendered the treatment group-by-eentre term not statistically significant 
(omitting Canada p=0.23, omitting France p=0.20 and omitting Germany p-0.12), the only 
exception being Sweden where hydromorphone was favoured (p=0.03). Furthermore for the 
four largest recruiting countries the adjusted treatment means always strongly favoured 
hydromorphone. Table 84 presents the adjusted means for each treatment group by country 
for the per-protocol analysis of the CR phase data.
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Table 84. Adjusted treatment means by country from the analysis of covariance for the mean 
of the last two recorded scores for “worst pain” at the end of the CR phase {per-protocoi set)
Country Adjusted means for "worst pain” at the end of the CR phase
Hydromorphone {n=55) Morphine (n=65)
United Kingdom (n=29) 1.8 (n=14) 4.0 (n=15)
Spain (n=24) 3.4 (n=11) 3.6 (n=13)
Netheriands (n=20) 2.8 (n=8) 4.2 (n=12)
Belgium (n=17) 1.9 (n=9) 3.6 (n=8)
Canada (n=9) 5.4 (n=4) 3.5 (n=5)
Germany (n=9) 4.6 (n=2) 3.3 (n=7)
Sweden (n=8) 3.8 (n=4) 4.5 (n=4)
France (n=4) 3.1 (n=3) 0.0 (n=1)
a From analysis of covariance, adjusted for baseline, treatment group and country
b Measured on a 11-point scale (0 = no pain; 10 = pain as bad as you can imagine)
For the 157 patients who provided baseline and endpoint CR phase “worst pain” data in the 
“full analysis” set, there was an imbalance between the treatment groups in the total days of 
IR phase exposure. For these patients, mean exposure to hydromorphone was 6.0 days 
(n=75) compared to 4.8 days (n=82) exposure to morphine. As a result o f this imbalance 
sensitivity analyses were performed on the CR phase data for the “full analysis” and per- 
protocol sets introducing two extra covariates in the analysis of covariance. These were the 
mean of the last two recorded scores for “worst pain” at the end o f IR phase and length of 
IR phase (in days). The results of these analyses are presented in Table 85. In both cases, 
the treatment group comparisons were again statistically significantly in favour of 
hydromorphone (p=0,03 in both cases) and the lower limit of the 95% Cl was again less 
than -1.5 implying the superiority of hydromorphone could not be disproved. In addition, 
the covariate for “worst pain” at the end of the IR phase was significant (p<0.001 in both 
cases) and the covariate for length of IR phase was not significant (p=0.I7 and p=0.47 for 
the IR and CR phases respectively).
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Table 85. Analysis of covariance for the mean of the last two recorded scores for “worst pain” in the CR phase 
with additional covariates for length of IR phase and “worst pain” at the end of the IR phase (“full analysis” and 
per-protocol sets)
Mean of the last two recorded scores 
for “worst pain” for the CR phase"
“ Fuii anaiysis" set Per-protocoi set
Hydromorphone Morphine Hydromorphone Morphine
Total number of patients 76" 84" 66" 67"
Mean 3.5 4.1 3.0 3.7
sd 2.5 2.7 2.1 2.5
Range 0,10 0,9.5 0,8 0,9.5
Adjusted mean" 3.4 4.3 2.9 3.8
Difference in adjusted means" -0.8 -0.9
se (of difference) 0.4 0.4
95% Ci for difference -1.6,-0.06 -1.7,-0.1
Anaiysis of covariance F Ë F H
Baseline score 0.68 1,145 0.41 0.86 1,108 0.36
“Worst pain" at end of IR phase 27.23 1,145 <0.001 14.58 1,108 <0.001
Length of IR phase (in days) 1.91 1,145 0.17 0.54 1,108 0.47
Treatment group 4.54 1,145 0.03 4.74 1,108 0.03
Country 0.74 7,145 0.64 0.73 7,108 0.64
a Measured on a 11-point scaie (0 = no pain; 10 = pain as bad as you can imagine)
b One patient did not provide a baseiine score so not included in ANCOVA
c Two patients did not provide a baseiine score so not included in ANCOVA 
d Adjusted for baseline and country
e A negative difference favours hydromorphone
Table 86 summarises the results from the analyses of the secondary efficacy variables 
derived from the BPI.
Table 86. Summary of analyses for each of the variables from the BPI questionnaire by study 
phase (“full analysis” set)
Variable Adjusted means® forIR  phase Adjusted means® for CR phase
Hyd. Morphine Difference^ 
(95% Ci)
Hyd. Morphine Difference'^ 
(95% Cl)
Least pain‘d 1.8 2.2 -0.4 (-0.9,0.1) 1.8 1.8 0.1 (-0.5,0.6)
Average pain'^ 3.6 3.6 0.1 (-0.5,0.6) 3.3 3.3 0.05 (-0.6,0.7)
Pain now am° 3.3 3.3 0.01 (-0.7,0.7) 2.5 2.8 -0.4 (-1.1,0.3)
Pain now pm° 3.6 3.6 0.02 (-0.7,0.7) 2.6 3.3 -0.6 (-1.4,0.1)
Pain relief^ 64.2 65.6 -1.3 (-8.2,5.5) 69.8 69.3 0.4 (-7.4,8.3)
How pain had interfered with
General activity^ 4.2 4.2 -0.02 (-0.8,0.8) 3.7 4.1 -0.5 (-1.4,0.5)
Mood® 3.2 3.3 -0.1 (-0.8,0.6) 3.0 3.1 -0.1 (-1.0,0.7)
Walking ability® 3.6 3.8 -0.2 (-1.0,0.6) 3.8 3.8 -0.03 (-1.0,0.9)
Normal work® 4.6 5.4 -0.8 (-1.6,-0.01)f 4.6 4.8 -0.2 (-1.2,0.9)
Relations with 2.5 2.3 0.2 (-0.6,0.9) 2.7 2.5 0.1 (-0.7,1.0)
other people®
Sleep® 2.4 2.1 0.2 (-0.4,0.9) 1.8 2.3 -0.5 (-1.3,0.3)
Enjoyment of 4.1 4.0 0.2 (-0.7,1.0) 3.6 3.5 0.1 (-0.9,1.0)
life®
Sum of the 23.9 23.6 0.3 (-3.9,4.5) 23.0 23.4 -0.3 (-5.6,5.0)
seven variables
a Adjusted for baseiine (if appropriate) and country from ANOVA/ANCOVA
b A negative difference favours hydromorphone
c Measured on a 11 -point scaie (0 = no pain; 10 = pain as bad as you can imagine)
d Measured on a 11-point scaie (0% = no relief; 100% = complete relief)
e Measured on a 11-point scaie (0 = does not interfere; 10 = completely interferes)
f Treatment p-vaiue = 0.046
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The lack o f differences in these measures confirmed the expectations that “worst pain” is 
the most sensitive measure in the BPI. The one significant (at the 5% level) difference 
(normal work) is probably only a consequence of multiple testing.
There was, however, a trend in favour of hydromorphone for the mean of two last recorded 
scores for “pain now” p.m. at the end of CR phase, although the treatment group difference 
was not statistically significant (p-0.09). Figure 23 presents the mean “pain now” p.m. 
profiles during the CR phase for the observed and carryforward datasets.
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Patients in the hydromorphone group took longer to dose stabilise in the IR phase. The 
mean Kaplan-Meier estimates for the time to stabilise in this phase were 6.5 and 5.2 days 
for the hydromorphone and morphine groups respectively (p=0.0013). The actual 
percentage of patients dose stabilised at the end of IR phase was 74% (hydromorphone) and 
80% (morphine). There was no difference between the treatment groups in the time to dose 
stabilisation in the CR phase. The mean Kaplan-Meier estimates for the time to stabilise in 
this phase were 4.3 and 4.6 days for the hydromorphone and morphine groups, respectively 
(p=0.39). The actual percentage of patients dose stabilised at least once during the CR phase 
was 92% (hydromorphone) and 94% (morphine). Figure 24 presents the Kaplan-Meier 
estimates for time to dose stabilisation for the IR phase.
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Eighteen out of 74 (24%) patients in the hydromorphone treatment group had to change 
their dose level during the CR phase compared to 23/82 (28%) patients in the morphine 
treatment group. O f the 18 patients who had CR dose level changes in the hydromorphone 
group, 14 had one change and four had two changes. Of the 23 patients who had CR dose 
level changes in the morphine treatment group there were 16 and seven patients having one 
and two dose level changes, respectively. Seven patients (three in the hydromorphone 
treatment group and four in the morphine treatment group) with starting CR dose levels 
different to last IR dose were omitted from these analyses.
In the IR phase, a higher proportion of patients in the hydromorphone treatment group 
(65%) were using breakthrough pain medication on the last two days of the IR phase 
compared with the morphine treatment group (54%). The adjusted mean number of 
breakthrough pain medication doses were 2.1 for the hydromorphone treatment group and 
1.4 for the morphine treatment group and the difference between the treatment groups was 
statistically significant (p=0.02). At the end of the CR phase, the number o f patients using 
breakthrough pain medication was similar in the morphine group (53%) compared with the 
hydromorphone group (51%). The adjusted mean number of breakthrough pain medication 
doses taken on the last two days of the CR phase were 1.7 for the hydromorphone treatment 
group and 1.5 for the morphine treatment group; there was no statistically significant 
difference (p=0.52) between the two treatment groups.
5.4.5.LI Statistical/analytical issues
There were significant treatment group-by-country interactions for the analysis of the 
primary variable of “worst pain”. This can be explained by the countries which recruited the 
largest number of patients favouring hydromorphone whilst countries which recruited 
smaller numbers of patients in general favoured morphine.
5.4.5.1.2 Efficacy conclusions
Hydromorphone IR was equivalent to morphine IR for the primary variable of “worst pain”. 
For the CR treatments, the superiority of hydromorphone to morphine for the primary 
variable could not be disproved; however, non-inferiority of hydromorphone to morphine 
was proven and there was a statistically significant difference in favour of hydromorphone 
for the CR phase. The secondary efficacy measures did not have any significant differences,
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but there was a trend towards a superior outcome for the hydromorphone group in the SR 
phase for “pain now” in the evening.
5.4.S.2 Safety
Table 87 summarises the number of days of treatment within each phase of the study and 
for both phases combined, by treatment group. The mean exposure to hydromorphone in the 
IR phase (5.7 days) was higher than the equivalent figure for morphine (4.7 days). Mean 
exposure in the CR phase for the two treatment groups was very similar: 11.4 days for 
hydromorphone and 11.5 days for morphine.
Table 87. Extent o f exposure by study phase and overall
Exposure (number of days)"  Treatment group
Hydromorphone Morphine
IR phase
n 99 101
Mean 5.7 4.7
sd 2.2 2.1
Median 6.0 4.0
Range 1,11 1,9
Total exposure 562 479
CR phase
n 77 86
Mean 11.4 11.5
sd 3.2 3.3
Median 12.0 12.0
Range 1,17 1,16
Total exposure 878 986
Both phases combined
n 99 101
Mean 14.4 14.4
sd 6.5 5.6
Median 17.0 16.0
Range 1,24 1,22
Total exposure 1426 1454
Day of last dose -  day of first dose +1
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Table 88 summarises the extent of exposure as total mg per day.
Table 88. Extent of exposure (total mg/day consumption)
Treatment group
Hydromorphone_______ Morphine
IR phase
n 99 101
Mean 28.0 129.0
sd 20.0 86.8
Median 22.3 106.7
Range 12,96 60,540
CR phase
N 77 86
Mean 35.4 151.8
Sd 23.4 95.6
Median 29.1 120.0
Range 16,96 60,520
Table 89 summarises the endpoint dose level for each study phase by treatment group. A 
total o f 70/101 (69%) of morphine-treated patients were receiving either dose level 1 and 2 
at the end of the IR phase compared to 55 (56%) of hydromorphone-treated patients. At the 
end of the CR phase, 8/77 (10%) of hydromorphone-treated patients were receiving dose 
level 6 compared to 2/86 (2%) of morphine-treated patients.
Table 89. Endpoint dose levei fo r each study phase
Endpoint dose 
levei
IR phase CR phase
Hydromorphone Morphine Hydromorphone Morphine
n 99 101 77 86
1 33 (33%) 40 (40%) 22 (29%) 25 (29%)
2 22 (22%) 30 (30%) 14 (18%) 23 (27%)
3 23 (23%) 11 (11%) 17(22%) 15 (17%)
4 9 (9%) 14 (14%) 11 (14%) 13 (15%)
5 6 (6%) 5 (5%) 5 (6%) 8 (9%)
6 6 (6%) 1 (1%) 8 (10%) 2 (2%)
Mean 2.5 2.2 2.8 2.6
The number of patients reporting an event and the number of events reported within each 
phase and for both phases combined by treatment group are summarised in Table 90 below. 
A higher proportion of hydromorphone-treated patients reported adverse events in the IR 
phase than morphine-treated patients with the opposite being the case in the CR phase. 
There was, however, no statistically significant difference between the treatments for the 
number of patients reporting adverse events. Overall, irrespective of study phase, 80/99
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(81%) hydromorphone-treated patients reported 347 adverse events compared to 90/101 
(89%) patients in the morphine treatment group who reported 355 adverse events.
Table 90, Summary of treatment emergent adverse events reported during the double­
blind phase
Treatment group
Hydromorphone Morphine
IR phase
Total number of patients 99 101
Number of patients reporting an adverse event 66 (67%) 61 (60%)
Difference in proportion of patients reporting (95% Cl) 6% (-10%,23%)
Number of events reported 191 163
CR phase®
Total number of patients 77 86
Number of patients reporting an adverse event 61 (79%) 75 (87%)
Difference in proportion of patients reporting (95% Cl) -8% (-22%,6%)
Number of events reported 229 256
Both phases combined
Total number of patients 99 101
Number of patients reporting an adverse event 80 (81%) 90 (89%)
Difference in proportion of patients reporting (95% Cl) -8% (-20%,4%)
Number of events reported ______ 347______________ 355_______
a Events that started during the IR phase and continued Into the CR phase are included in 
these figures
The severity and relationship to therapy of adverse events reported within each phase and 
for both phases combined by treatment group are summarised in Table 91. Overall the 
majority of adverse events were mild or moderate in severity. A total of 73/347 (21%) of 
adverse events during hydromorphone therapy had definite or probable relationship to 
therapy compared to 97/355 (27%) during morphine therapy.
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Table 91. Summary o f severity and relationship to  therapy o f treatm ent emergent adverse
events during the double-blind phase
No of reports 
Treatment group 
Hydromorphone Morphine
IR phase
Severity Mild 88 (46%) 85 (52%)
Moderate 82 (43%) 58 (36%)
Severe 20 (10%) 19 (12%)
Unknown 1 (1%) 1 (1%)
Relationship to therapy Definite 8 (4%) 12 (7%)
Probable 50 (26%) 41 (25%)
Possible 50 (26%) 41 (25%)
Unlikely 33(17%) 23 (14%)
None 50 (26%) 46 (28%)
CR phase"
Severity Mild 97 (42%) 116 (45%)
Moderate 104 (45%) 98 (38%)
Severe 28(12%) 40 (16%)
Unknown - 2 (1%)
Relationship to therapy Definite 6 (3%) 12(5%)
Probable 30 (13%) 51 (20%)
Possible 57 (25%) 54 (21%)
Unlikely 50 (22%) 56 (22%)
None 86 (38%) 83 (32%)
Both phases combined
Severity Mild 152 (44%) 167 (47%)
Moderate 152 (44%) 130 (37%)
Severe 42(12%) 55 (15%)
Unknown 1 (0,3%) 3(1%)
Relationship to therapy Definite 10 (3%) 19 (5%)
Probable 63 (18%) 78 (22%)
Possible 91 (26%) 81 (23%)
Unlikely 70 (20%) 67 (19%)
None 113 (33%) 110 (31%)
Events that started during the IR phase and continued into the CR phase are included in 
these figures
The most commonly reported events (i.e. reported by at least 5% of patients in any 
treatment group) are summarised in Table 92.
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Table 92. Summary of treatm ent emergent adverse events reported by at least 5% of 
patients in any treatment group during double-blind phase
MedDRA preferred term Number of patients reporting
Treatment group
Hydromorphone Morphine Difference in 
proportion 
reporting (95% 
Cl)
IR phase N=99 N=101
CONSTIPATION 22 (22%) 10 (10%) 12% (0%,25%)
NAUSEA 18 (18%) 20 (20%) -2% (-15%, 12%)
VOMITING 16(16%) 21 (21%) -5% (-18%,9%)
SOMNOLENCE 10(10%) 11 (11%) -1% (-11%, 10%)
DIZZINESS (EXC VERTIGO) 8 (8%) 6 (6%) 2% (-7%,11%)
HEADACHE 8 (8%) 6 (6%) 2% (-7%, 11%)
DIARRHOEA 8 (8%) 1 (1%) 7% (0%,14%)
PRURITUS 5 (5%) 4 (4%) 1% (-6%,8%)
ASTHENIA 5 (5%) 3 (3%) 2% (-5%,9%)
ABDOMINAL PAIN 5 (5%) 1 (1%) 4% (-2%, 10%)
CR phase" N=77 N=86
CONSTIPATION 28 (36%) 19 (22%) 14% (-3%,31%)
NAUSEA 15 (19%) 23 (27%) -7% (-23%,9%)
SOMNOLENCE 8 (10%) 9 (10%) -0% (-12%, 11%)
ASTHENIA 8 (10%) 8 (9%) 1% (-10%, 12%)
VOMITING 7 (9%) 19 (22%) -13% (-26%,0%)
CONFUSION 7 (9%) 2 (2%) 7% (-2%. 16%)
DIARRHOEA 6 (8%) 2 (2%) 5% (-3%, 14%)
PYREXIA 6 (8%) 1 (1%) 7% (-1%,14%)
INSOMNIA 5 (6%) 4 (5%) 2% (-7%, 11%)
ANXIETY 5 (6%) - 6% (-0%,13%)
ANOREXIA 4 (5%) 5 (6%) -1% (-9%,8%)
ABDOMINAL PAIN 4 (5%) 4 (5%) 1% (-8%,9%)
PRURITUS 4 (5%) 4 (5%) 1% (-8%,9%)
DIZZINESS (EXC VERTIGO) 3 (4%) 8 (9%) -5% (-15%,4%)
ANAEMIA 2 (3%) 5 (6%) -3% (-11%,4%)
CONDITION AGGRAVATED 1 (1%) 5 (6%) -5% (-11%,2%)
OEDEMA LOWER LIMB 1 (1%) 5 (6%) -5% (-11%,2%)
Both phases combined N=99 N=101
CONSTIPATION 32 (32%) 25 (25%) 8% (-8%,23%)
NAUSEA 28 (28%) 34 (34%) -5% (-21%, 10%)
VOMITING 18(18%) 27 (27%) -9% (-23%,6%)
SOMNOLENCE 13(13%) 16(16%) -3% (-15%,9%)
DIARRHOEA 13(13%) 3 (3%) 10% (1%,19%)
ASTHENIA 10(10%) 9 (9%) 1% (-9%, 11%)
HEADACHE 10 (10%) 6 (6%) 4% (-5%, 13%)
DIZZINESS (EXC VERTIGO) 9 (9%) 12 (12%) -3% (-13%,8%)
CONFUSION 8 (8%) 3 (3%) 5% (-3%,13%)
PRURITUS 7 (7%) 7 (7%) 0% (-9%,9%)
PYREXIA 7 (7%) 2 (2%) 5% (-2%, 12%)
ABDOMINAL PAIN 6 (6%) 4 (4%) 2% (-5%, 10%)
INSOMNIA 5 (5%) 5 (5%) 0% (-7%,7%)
ANXIETY 5 (5%) - 5% (-0%,10%)
ANOREXIA 4 (4%) 7 (7%) -3% (-11%,5%)
ANAEMIA 4 (4%) 6 (6%) -2% (-9%,5%)
SWEATING INCREASED 3 (3%) 5 (5%) -2% (-9%,5%)
OEDEMA LOWER LIMB 2 (2%) 6 (6%) -4% (-11%,3%)
CONDITION AGGRAVATED 1 (1%) 6 (6%) -5%{-11%,1%)
URINARY TRACT INFECTION 1 (1%) 5 (5%) -4% (-10%,2%)
NAUSEA AGGRAVATED - 5 (5%) -5% (-10%,0%)
Events that started during the IR phase and continued into the CR phase are included in 
these figures
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Table 93 lists the number of patients who had the commonly reported side effects associated 
with morphine (Moulin 1996) ongoing or starting during the double-blind phase. This table 
includes patients who had ongoing adverse events at the time of randomisation which were 
not attributable to treatment and were therefore not included in other Tables of adverse 
events. The proportion of patients reporting these adverse events during hydromorphone 
treatment was similar to that reported for morphine treatment.
Table 93. Summary of adverse events commonly reported with morphine ongoing or 
starting during double-blind phase
Adverse event (associated MedDRA preferred terms) Number of patients reporting 
Treatment group 
Hydromorphone Morphine 
(n=99) (n=101)
ABDOMINAL PAIN (abdominal pain , abdominal pain 
upper)
6 (6%) 8 (8%)
BLURRED VISION (diplopia) - 1 (1%)
CONFUSION (confusion, disorientation) 8 (8%) 5 (5%)
CONSTIPATION (constipation, constipation 
aggravated)
34 (34%) 25 (25%)
DIARRHOEA (diarrhoea ) 13 (13%) 3 (3%)
DIZZINESS (dizziness (exc. vertigo)) 9 (9%) 12 (12%)
DRY MOUTH (dry mouth) 4 (4%) 3 (3%)
FATIGUE (asthenia, fatigue, fatigue aggravated, 
lethargy, malaise, sedation, sedation aggravated, 
somnolence, weakness)
24 (24%) 29 (29%)
ITCHING (pruritus ) 7 (7%) 7 (7%)
NAUSEA (nausea, nausea aggravated) 28 (28%) 37 (37%)
POOR APPETITE (anorexia, appetite decreased ) 4 (4%) 9 (9%)
SLEEPLESSNESS (insomnia ) 6 (6%) 5 (5%)
VOMITING (vomiting ) 18 (18%) 27 (27%)
Number of patients reporting any of the above 72 (73%) 78 (77%)
A total of 192 (96%) patients reported continuing a concomitant medication into the double­
blind phase. The most common categories reported were laxatives (112 patients), 
psycholeptics (81 patients) and antacids, drugs for treatment of peptic ulcers and 
antiflatulants (80 patients). A total of 126 (63%) patients reported starting a medication 
during the double-blind phase. This high percentage is indicative of the unstable condition 
of the majority of these cancer patients. The most common category reported was laxatives 
(49 patients).
Tables 94 and 95 summarise the use of laxatives and anti-emetics ongoing or started during 
the study. As expected constipation and nausea were some of the most common adverse 
events reported during the study.
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Table 94 Summary of laxatives ongoing or starting during the double-blind phase
Hydromorphone
(n=99)
Morphine
(n=101)
Overall
(n=200)
Number of patients reporting a therapy" 69 (70%) 71 (70%) 140 (70%)
ARACHIS OIL 1 1
BISACODYL 5 5 10
CARBOXYMETHYLCELLULOSE 1 - 1
SODIUM
CASCARA DRY EXTRACT 2 1 3
CO-DANTHRAMER 2 2 4
COLOPEG - 1 1
COLOXYL WITH DANTHRON 4 1 5
DOCUSATE 4 2 6
DORBANEX 17 12 29
FLEET ENEMA 4 2 6
GLYCEROL 3 1 4
ISPAGHULA 2 - 2
LACTITOL - 1 1
LACTULOSE 26 27 53
LIQUIDEPUR - 1 1
MACROGOL 3 4 7
MAGNESIUM HYDROXIDE 2 4 6
MAGNESIUM HYDROXIDE+LIQUID 6 2 8
PARAFFIN
MAGNESIUM OXIDE 1 2 3
MAGNESIUM SULFATE 1 1
MINERAL OIL EMULSION 1 1
PARAFFIN 1 4 5
PARAFFIN, LIQUID - 3
PHOSPHATES ENEMA 1 1 2
POLYETHYLENE GLYCOL 1 1
PSYLLIUM HYDROPHILIC MUCILLOID 1 1 2
SENNA 10 11 21
SENNA+DOCUSATE SODIUM 1 1
SENNOSIDES 1 - 1
SODIUM CITRATE+SODIUM LAURYL 2 2
SULPHOACETATE
SODIUM CITRATE+SODIUM LAURYL 1 4 5
SULPHOACETATE+SORBITOL
SODIUM LAURYL SULFATE 1 - 1
SODIUM PICOSULFATE 9 14 23
STERCULIA - 1 1
" not mutually exclusive
Table 95 Summary of anti-emetics ongoing or starting during the double-blind phase
Therapy " Hydromorphone Morphine Overall
(n=99) (n=101) (11=200)
Number of patients reporting a previous 26 (26%) 40 (40%) 66 (33%)
medication
CYCLIZINE 5 8 13
GRANISETRON 3 4 7
METOCLOPRAMIDE 18 30 48
ONDANSETRON 5 1 6
PROCHLORPERAZINE 2 2 4
TROPISETRON 2 3 5
not mutually exclusive
In summary then, for the adverse events reported, there were no statistically significant 
differences between the treatment groups in terms of the number of patients reporting 
adverse events either in the IR or CR phases or for both phases combined.
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Tliree patients died during the double-blind study period (patient numbers 78, 94 and 171 ; 
all received morphine therapy). Patient number 78, a 68 year old, female Caucasian died 
following a stroke (cerebrovascular accident) after two days of the morphine IR treatment 
period. Relationship to therapy was recorded as unlikely. Patient number 94, a 52 year old, 
male Caucasian experienced rapid progression of disease with physical and mental 
deterioration and died after five days of the morphine CR phase. Relationship to therapy 
was recorded as unlikely. Patient number 171, a 20 year old, male Caucasian was found 
dead after eight days of treatment in the morphine IR phase. The adverse event leading to 
death was recorded as progressive disease. Relationship to therapy was recorded as none.
Serious adverse events (SAEs) were defined in the protocol as any event that was life 
threatening or resulted in death, required inpatient hospitalisation or prolongation of 
existing hospitalisation, resulted in persistent or significant disability/incapacity, a 
congenital anomaly/birth defect or other medically important conditions. SAEs were 
reported for 23 patients during the double-blind study period (10 in the hydromorphone 
group and 13 in the morphine group). Twelve patients were withdrawn from the study as a 
consequence of their serious adverse events (four in the hydromorphone group and eight in 
the morphine group, including the three deaths during study treatment described above). 
Summary details are provided in Table 96.
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Table 96. Summary o f serious adverse events by phase
Patient
No.
MedDRA term Severity Relationship 
to therapy
Outcome
IR phase
Hydromorphone
2 WEAKNESS Moderate None Ongoing
5® AGITATION Severe Definite Resolved
MYOCLONIC JERKS Moderate Definite Resolved
VOMITING Moderate Probable Resolved
264 PATHOLOGICAL FRACTURE Severe None Resolved
303® VOMITING Severe Possible Resolved
363 ASTHENIA Severe None Death^
Morphine
1® HALLUCINATIONS Moderate Probable Resolved
ABNORMAL DREAMS Moderate Probable Resolved
78® CEREBROVASCULAR ACCIDENT Severe Unlikely Death
171® CONDITION AGGRAVATED Severe None Death
287® CONVULSIONS Severe None Unknown
CR phase
Hydromorphone 
20 PYREXIA Mild None Resolved
23 PAIN EXACERBATED Moderate Probable Residual effect
170 DIZZINESS (EXC VERTIGO) Moderate Probable Residual effect
NAUSEA Moderate Probable Residual effect
226 HYPERCALCAEMIA Moderate Unlikely Resolved
NAUSEA Moderate Unlikely Resolved
255® PNEUMONIA ASPIRATION Severe Possible Resolved
HYPOTENSION Moderate Possible Resolved
LOSS OF CONSCIOUSNESS Moderate Possible Resolved
VOMITING Moderate Possible Resolved
363® DELIRIUM Severe Possible Resolved
Morphine
6 PLEURAL EFFUSION Severe None Ongoing
CONDITION AGGRAVATED Severe None Death
22 PULMONARY EMBOLISM Moderate Unlikely Residual effect
29 ABDOMINAL PAIN Severe None Residual effect
VOMITING Severe None Residual effect
79® METASTATES TO BRAIN Severe Unlikely Death
94® DYSPNOEA Severe Possible Death
FALL Severe Possible Death
CONDITION AGGRAVATED Severe Unlikely Death
113 CONSTIPATION Moderate Probable Resolved
115® ILEUS PARALYTIC Severe Unlikely Resolved
METASTATES TO ABDOMINAL CAVITY Severe Unlikely Ongoing
172® NAUSEA Severe Probable Resolved
VOMITING Moderate Probable Resolved
212 CONDITION AGGRAVATED Severe None Death
SOMNOLENCE Severe Probable Resolved
Post-treatment 
81 RESPIRATORY FAILURE (EXC Severe None Death
255
NEONATAL)
LEUCOCYTOSIS Moderate Unlikely Resolved
a Withdrawn
b Adverse event started in IR phase, patient was withdrawn because of a serious adverse event in CR 
phase and subsequently died 
0 Patient withdrawn because of death in double-blind study period
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In summary, then, for deaths and serious adverse events, the proportion of patients reporting 
events during the study was similar in both treatment groups. Given the severity of the 
patients’ underlying disease state, the occurrence of such events was not unexpected and 
many were related to the patients’ background illness. Around a third (32%) were recorded 
as definitely or probably related to the study treatment. None of the deaths were considered 
to be related to the study therapy.
Details of adverse events leading to withdrawal are listed in Table 97. This includes both 
serious and non-serious adverse events.
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Table 97. Adverse events leading to  withdrawal by phase
Patient
No.
Reason for 
withdrawal
MedDRA term Severity Relationship to 
therapy
IR Phase
5 Adverse events AGITATION® Severe Definite
MYOCLONIC JERKS® Moderate Definite
VOMITING ® Moderate Probable
18 Adverse events NAUSEA Mild Possible
100 Adverse events NAUSEA Severe Probable
VOMITING Severe Probable
215 Adverse events PRURITUS Mild Probable
SOMNOLENCE Moderate Probable
296 Adverse events ACCIDENT Moderate Probable
CONFUSION Severe Probable
ECCHYMOSIS Moderate Probable
OEDEMA LOWER LIMB Moderate None
HALLUCINATIONS Moderate Probable
303 Adverse events VOMITING ® Severe Possible
309 Adverse events MOOD ALTERATION Severe Definite
PERIPHERAL NEUROPATHY Severe None
322 Adverse events VOMITING Mild Probable
369 Adverse events DIARRHOEA Moderate Unlikely
Morphine
1 Adverse events HALLUCINATIONS ® Moderate Probable
ABNORMAL DREAMS® Moderate Probable
42 Adverse events NAUSEA Mild Definite
VOMITING Moderate Definite
NAUSEA AGGRAVATED Severe Definite
78 Death CEREBROVASCULAR ACCIDENT 
a
Severe Unlikely
171 Death CONDITION AGGRAVATED® Severe None
287 Adverse events CONVULSIONS ® Severe None
295 Adverse events SOMNOLENCE Moderate Possible
330 Adverse events CONSTIPATION Moderate Probable
DIZZINESS (EXC VERTIGO) Mild Probable
MYALGIA Mild Unlikely
SOMNOLENCE Mild Probable
VOMITING Mild Unlikely
339 Adverse events SEDATION Severe None
ANXIETY AGGRAVATED Severe None
365 Adverse events CONFUSION Moderate Probable
NAUSEA Moderate Probable
SOMNOLENCE Moderate Probable
VOMITING Moderate Probable
Classified as a serious adverse event 
Onset date post-treatment
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Table 97. Adverse events leading to  withdrawal by phase (continued)
Patient
No.
Reason for 
withdrawal
MedDRA term Severity Relationship to 
therapy
CR Phase
Hydromorphone
147 Adverse events HALLUCINATION Moderate Probable
237 Adverse events AGGRESSION Moderate Possible
ANXIETY Moderate Possible
CONFUSION Moderate Possible
255 Adverse events PNEUMONIA ASPIRATION® Severe Possible
HYPOTENSION ® Moderate Possible
LEUCOCYTOSIS "
RESPIRATORY FAILURE (EXC Severe Possible
NEONATAL)
LOSS OF CONSCIOUSNESS ® Moderate Possible
VOMITING ® Moderate Possible
331 Adverse events ARTHRALGIA Mild None
SWEATING INCREASED Mild Possible
363 Adverse events DELIRIUM® Severe Possible
370 Adverse events DIARRHOEA Mild Unlikely
Morphine
79 Disease METASTASES TO BRAIN® Severe Unlikely
progression
94 Death CONDITION AGGRAVATED® Severe Unlikely
115 Disease ILEUS PARALYTIC® Severe Unlikely
progression
METASTATES TO ABDOMINAL Severe Unlikely
CAVITY®
172 Adverse events NAUSEA® Severe Probable
VOMITING ® Moderate Probable
212 Adverse events LOWER RESPIRATORY TRACT Severe None
INFECTION
SOMNOLENCE® Severe Probable
261 Withdrew SWEATING INCREASED Moderate Unlikely
consent
ANOREXIA Moderate Unlikely
OEDEMA AGGRAVATED Moderate Unlikely
FATIGUE AGGRAVATED Moderate Unlikely
276 Adverse events CONFUSION Moderate Definite
DRY MOUTH Severe Definite
INSOMNIA Severe Definite
333 Adverse events VOMITING Moderate Possible
Classified as a serious adverse event 
Onset date post-treatment
Figure 25 presents the Kaplan-Meier estimates for the time to withdrawal (irrespective of 
study phase) by treatment group. There was no statistically significant difference between 
treatment groups in the time to withdraw irrespective of phase (p=0.17).
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Table 98 summarises laboratory abnormalities which were reported as treatment emergent 
adverse events. The numbers of patients were similar in each group.
Table 98. Number (percentage) of patients experiencing specific treatment emergent 
laboratory abnormalities
MedDRA preferred term Number of patients reporting
Hydromorphone
(n=99)
Morphine
(n=101)
ANAEMIA 4 (4%) 6 (6%)
LEUCOCYTOSIS - 1 (1%)
LEUCOPENIA 2 (2%) 1 (1%)
NEUTROPENIA 2 (2%) -
PANCYTOPENIA - 1 (1%)
THROMBOCYTOPENIA 3 (3%) -
BLOOD POTASSIUM DECREASED 1 (1%)
GLYCOSURIA PRESENT 1 (1%)
HAEMATURIA PRESENT 2 (2%) 1 (1%)
HAEMOGLOBIN DECREASED - 2 (2%)
LABORATORY TEST ABNORMAL 1 (1%)
PLATELET COUNT ABNORMAL 1 (1%)
PLATELET COUNT DECREASED 1 (1%)
PROTEINURIA PRESENT 1 (1%)
TRANSAMINASE INCREASED 1 (1%)
WHITE BLOOD CELL DECREASED 1 ( 1%)
WHITE BLOOD CELL INCREASED 1 (1%)
HYPERCALCAEMIA 1 (1%) 1 (1%)
HYPOKALAEMIA - 1 (1%)
In conclusion, the overall tolerability of hydromorphone was comparable with morphine.
5.4.6 Discussion
It is generally aclmowledged that controlled studies in cancer pain are difficult to conduct 
owing to the potentially confounding factors associated with the seriousness of the disease 
state, high withdrawal rate and the effects.of the many concomitant medications required by 
the patients. This study is therefore unique, being the first international, multi centre, phase 
III, randomised, double-blind, parallel-group study, involving a complex multiple ascending 
dosing schedule, to successfully assess the equivalence of efficacy between hydromorphone 
(IR and CR) and morphine (IR and CR). The investigators’ ability to titrate dose to effect 
within the design of the study meant that the particular doses selected would not interfere 
with the outcome of the study. These dose levels were selected on the basis that oral 
hydromorphone is five-times more potent than morphine, within the constraints imposed by 
available dose strengths. The element of dose titration within the study also allows an 
estimate o f equipotency to be derived from the exposure data gathered. Thus, the mean 
amount o f milligrams consumed per day of 28.0 for the hydromorphone group and 129.0
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(1:4.61) for the morphine group in the IR phase and 35.4 for the hydromorphone group and 
151.8(1:4.29) for the morphine group in the CR phase. When the mean dose per day at the 
end of the CR phase is used, the value is 1:4.32. This suggests that a factor of between four 
and five is appropriate to use when calculating equipotency.
Eleven-point pain scales have been shown to be effective measures in studies of chronic 
pain patients (Jensen 1999). “Worst pain” was specifically chosen as the primary variable 
for assessing efficacy in this study, since there is evidence to suggest that it is this most 
intense pain that patients experience which interferes most with daily life activities (Daut 
1983). O f all the parameters assessed in the BPI, “worst pain” is also the most sensitive 
measure in the clinical study setting (Cleeland 1994b, Mendoza 2001b). This certainly 
seems to have been the case in this study, where “worst pain” was the only measure with 
sufficient sensitivity to detect a statistically significant difference between the treatment 
groups.
In order to ensure that the study was adequately powered, the protocol made provision for 
the variability of the principal measure to be re-estimated during the study. The original 
sample size was approximately 70 patients per treatment group assuming a variability of 2.0 
for the primary efficacy variable. After 55 patients had completed the study, the revised 
estimate was 2.24 for the IR phase and 2.50 for the CR phase. Based on these data, the 
sample size was increased to 82 patients per group to be randomised into the study. A 
further re-estimation of variability for the CR phase was performed after 120 patients had 
completed the study. This estimate was 2.7 and the sample size was increased to 100 
patients per group to be randomised. It was subsequently concluded that the study precision 
was adequate to meet the objectives since the actual variability for the principal measure of 
efficacy for the CR phase (2.46 for the “full analysis” set and 2.25 for the per-protocol set) 
was less than the estimated value.
The two treatment groups were balanced at entry for demographic and baseline variables of 
BPI “worst pain” in the past 24 hours, ECOG performance status and nature of predominant 
pain. The mean baseline values for “worst pain” scores was 6.3 on an 11-point scale, which 
was comparable to those seen in other cancer pain studies such as Paice, 1998 where the 
mean value was 6.99. These scores equate with moderate to severe pain (Seriin 1995).
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Completion rates for both phases of the study were high (82%), with an overall completion 
rate of 67%. The withdrawal rate in the CR phase of the study was comparable to that seen 
in published data where patients had been titrated to pain control prior to randomisation 
(O’Brien 1997; Broomhead 1997; Morlarty 1999) but greater than those seen in a longer (30 
days) crossover trial reported by Ahmedzai (1997).
Table 99. Completion rates In comparable studies
study Duration of treatment (days) Completion rate (%)
□0118 11 133/163 (82%)
O’Brien 1997 14 69/85 (81%)
Morlarty 1999 6 89/100 (89%)
Broomhead 1997 7 152/172 (88%)
Ahmedzai 1997 30 110/202 (54%)
The results of the study showed that there were decreases in “worst pain” in both treatment 
groups, confirming the basic efficacy of the two treatments under the study conditions (see 
Figure 26).
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According to the protocol, treatment with hydromorphone was to be considered equivalent 
to morphine if  the 95% two-sided confidence interval for the difference between the 
adjusted means for the principal measure of efficacy (“worst pain” score of BPI in the past 
24 hours) lay within -1.5 to 1.5. For the IR phase this was true and therefore 
hydromorphone IR was proven to be equivalent to morphine IR. For the CR phase the lower 
limit of the 95% confidence interval was less than -1.5 which implied that the superiority of 
hydromorphone could not be disproved. However, the upper limit was less than 1.5 and 
therefore non-inferiority of hydromorphone was proven. Furthermore, there was a 
statistically significant difference between the treatment groups in favour of hydromorphone 
for the CR phase for both the “per protocol” and the “full analysis” sets (p=0.046 for the 
“full analysis” set and p=0.049 for the per-protocol set).
The dose levels at which patients reached dose stable pain control were similar in the two 
treatment groups, suggesting that the packaging of the six dose levels of the respective 
treatments were well matched.
For the secondary efficacy variables there were no statistically significant differences 
between the treatments (i.e. other BPI variables, ECOG, Mini-Mental state), except for how 
pain had interfered with normal work at the end of the IR phase where hydromorphone was 
favoured (p=0.046), but this is probably just an artefact of multiple testing. There was also a 
trend in favour of hydromorphone for “pain now” p.m. at the end of CR phase (p^0.09).
The most likely explanation for this finding is that measurement of this variable coincided 
with the period of sustained higher plasma concentrations characteristic of the 
hydromorphone CR formulation (Knoll Pharmaceutical Company study D-101; Knoll 
PhaiTTiaceiitical Company study DO 108; Knoll Pharmaceutical Company study C-96-054- 
01), whereas plasma concentrations of morphine from the twice-daily administered CR 
formulation would have been at trough levels. Additionally, it has been remarked that for 
some patients, existing twice-daily formulations require tlu'ee-times-daily administration in 
order to maintain plasma levels sufficiently (Hanks 2001). This observation would increase 
the chance of a “trough effect” being of clinical relevance. Another possible explanation for 
the lower pain scores for the hydromorphone treatment group in the CR phase is improved 
compliance. Patients with chronic cancer pain are not generally regarded as being poor 
medicators, but some reports from other therapeutic areas suggest that a once-daily
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formulation will result in more accurate use of medication, compared with twice-daily 
formulations (Bloom 2001).
There were some interesting differences between the two drugs in the IR phase. Firstly, time 
to dose stabilization was statistically significantly longer in the IR phase for hydromorphone 
than morphine IR (6.5 days verus 5.2 days). Second, the higher rates of patients reporting 
adverse events in the hydromorphone treatment arm during the IR phase (67 versus 60% for 
morphine), which contrasted with the lower rates in the SR phase (79 versus 87% for 
morphine). Thirdly, the higher dropout rates for the hydromorphone group in the IR phase 
(22 versus 15% for morphine). And lastly, the use of breakthrough pain medication was 
statistically significantly higher for the hydromorphone group in the IR phase. These may 
be explained by the fact that almost a third o f the patients used morphine prior to starting 
the study. In order to explore this possibility, these parameters were examined using only 
those patients who were receiving morphine prior to the start o f the study. The findings are 
shown in Table 100.
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Table 100 Time to dose stabilisation, adverse event reporting, reason for withdrawal and use of 
breakthrough medication -  all in IR phase only
Morphine pre-treatment 
population
Full study population
Hydromorphone Morphine Hydromorphone Morphine
n
Time to; dose stabilisation
32 36 99 101
n (%)
A n (%)
66%
12
78% 74%
6
80%
Mean time (days) 
A time (days)
7.2
1.5
5.7 6.5
1.3
5.2
Adverse events
% reporting 
A % reporting
75%
22
53% 67%
7
60%
Reason for withdrawal
n (%)
A n (%)
31%
12
19% 22%
7
15%
Adverse events 6 2 9 7
Lack of efficacy 2 1 6 1
Protocol violation 1 1 3 1
Withdrawal of consent 1 3 3 4
Administrative reasons - - 1 -
Death - - - 2
Use of breakthrough medication
n (%)
A n(%)
61%
8
53% 65%
11
54%
Mean no. doses 
A no. doses
1.9
0.4
1.5 2.1
0.7
1.4
111 general, this supports the possibility that pre-treatment with morphine biased these 
results, since the differences between the treatment groups were more in favour of the 
moiphine group in the subpopulation that was already receiving morphine at the time of 
randomisation. The exceptions to this general trend was hi use of breakthrough medication 
and the number of patients withdrawing due to lack of efficacy, in which the morphine 
treatment group was relatively less favoured in the morphine-pretreated subpopulation. 
Overall, then, this suggests that the IR dose titration part of the study allowed the morphine- 
prior-treatnient-factor to be accommodated for, following which the CR treatment phase 
proceeded with a final outcome in favour of hydromorphone CR.
In the CR phase, the withdrawal rate was also greater for the hydromorphone group (22%) 
compared with the morphine group (15%). This finding is difficult to account for, given that 
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the other measures made in this phase suggest at least parity (the secondary measures of 
efficacy) or in some cases (the primary efficacy endpoint and adverse event reporting), 
superiority o f the hydromorphone once-daily treatment.
The overall safety profiles of the two treatments were generally similar and there were no 
statistically significant differences between the treatments for the proportion of patients 
reporting adverse events. Despite the high incidence of adverse event reporting in the 
treatment of pain with opioids in the cancer pain setting, published studies have indicated 
that overall, patients still attain benefit from these therapies (Savage 1999, Sjogren 2000) 
and the active management of these side effects is well described (Portenoy 1994). The 
number of adverse events reported during the morphine IR phase was higher than that 
reported in published data (Broomhead 1997). The number of adverse events reported in the 
hydromorphone IR phase was greater than for the morphine IR phase. The longer duration 
o f the IR phase for hydromorphone-treated patients may account for this difference.
Effective treatment of cancer pain is a balance between pain control and adverse events 
(Portenoy 1994). In this study, the dose levels at which patients reached adequate pain 
control were similar in the two treatment groups and comparable (129 mg per day in IR 
phase and 151.8 mg per day in CR phase) to another published study in cancer pain where 
the daily CR morphine dose was 138 mg (Broomhead 1997). Further, the pain scores being 
reported at the completion of the CR phase (adjusted means 3.5 and 4.3 for hydromorphone 
and morphine, respectively) correspond to mild pain (Seriin 1995), in contrast to the 
moderate to severe pain recorded at the time of randomisation.
The nature of the adverse events reported during hydromorphone and morphine therapy was 
generally typical o f the events associated with these treatments (Paice 1998, Morlarty 
1999). There were some numerical trends suggesting more events overall in the morphine 
treatment group, more constipation and diarrhoea in the hydromorphone treatment group 
and more nausea and vomiting in the morphine group, but none o f these differences 
appeared to be statistically significant. Regarding the gastro-intestinal adverse events, 
laxative use appeared to be equal in both groups (70% of patients reporting use in both 
groups), whereas anti-emetic use was greater in the morphine treatment group (40% of 
patients) than the hydromorphone group (26% of patients).
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Most of the adverse events in the study were mild or moderate in severity and around half 
were recorded as being of unlikely or no relationship to therapy. The higher number of 
withdrawals in the hydromorphone group in the CR phase of the study is difficult to explain 
but was not statistically significant.
The occurrence of three deaths during the study, together with a further 17 patients who 
experienced serious adverse events was not unexpected, given the severity of the patients’ 
conditions and the progressive nature of the disease. None of the deaths were considered to 
be related to the study therapy. Many of the serious adverse events tended to be associated 
with the underlying disease, although a proportion (32%) were considered to be definitely 
or probably related to the study treatment.
5.4.7 Conclusions
Despite the complexity of the study design and the known difficulties associated with the 
management of cancer patients, the results of this study clearly demonstrated equivalence 
for “worst pain” between hydromorphone IR and morphine IR. For the CR treatments, the 
superiority of hydromorphone to morphine could not be disproved; however, non-inferiority 
o f hydromorphone to morphine was proven and there were statistically significant 
differences in favour of hydromorphone for the CR phase. From examining the secondary 
efficacy measures to try and find an explanation for this finding in the CR phase, it would 
appear to be related to the difference in “pain now” reporting at time of trough plasma 
levels, suggesting a superior controlled-release performance of the hydromorphone CR 
formulation. There are no other studies published in cancer pain where one 
opioid/formulation has demonstrated a superior mean pain score over another.
The safety profiles of the two treatments were comparable, although numerical trends and 
concomitant medication use suggested some possible advantages of one drug over another, 
although these were not statistically significant.
Overall, hydromorphone CR provides a convenient, once-daily treatment for cancer pain 
patients which offers superior pain control compared to twice-daily morphine.
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6 Overall discussion
This thesis is presentation of a segment of a large body of work undertaken over 5 years 
with a budget running to several million pounds. Clearly, this size of project could not be 
undertaken by one individual but instead, depends on a team approach involving many 
disciplines. The role o f the author in this process was continuous and pivotal, since the only 
medical input to the project from within the company was from the author. In addition, the 
author had responsibility for the key activities of seeking expert opinions, reviewing 
literature data and the design, conduct, analysis and reporting o f separate studies. Most 
importantly, the author had overall responsibility for the entire clinical programme, 
including its budget, and was held responsible by Knoll for this. The amount of data 
produced by the project far exceeds what could be condensed into one thesis. Therefore, the 
approach taken was to concentrate on the three clinical studies that the author was most 
closely involved with and limit the degree of detail used to deal with other parts o f the 
project.
On first inspection, the area of pain management with opioids may be regarded as an area 
that has been well characterised through decades of study and well supplied with various 
agents and formulations for the treatment of patients. On closer inspection, however, there 
are gaps in the armamentarium of both knowledge and treatment options. The work reported 
here begun with the premise that a new range of formulations of an existing opioid would 
add significantly to the useful treatment options available to doctors in Europe. Within this 
general scope, some important gaps in the information regarding pain management were 
identified. One of these was the period following parenteral opioid PCA treatment for 
moderate to severe postoperative pain and the other was the need for prospective, double­
blind, randomised, controlled data in the setting of chronic cancer pain. As such, the clinical 
programme o f studies was devised that could achieve registration o f the range of 
formulations for hydromorphone and within this aim, collect data that would add 
significantly to available knowledge on postoperative acute pain and chronic cancer pain.
Hydromorphone is a far less well established opioid in Europe than morphine. This is less 
so in the USA where it has been consistently marketed by Knoll since the early part of the 
last century and is now available through several companies in the USA. O f the different 
marketed brands o f hydromorphone available in the USA, Dilaudid is the most established -
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SO much so that it gets mentioned in current medical “soaps” such as “ER” ! The difference 
between the two continents in the perception of hydromorphone is presumably attributable 
to the differences in the ways that the product has been promoted by Knoll over the bulk of 
the last century. Comparing hydromorphone with morphine from first principles would lead 
to the conclusion that it is surprising that it is morphine and not hydromorphone that is the 
more accepted product. Hydromorphone is the more water soluble of the two (Martindale 
1993), it is more potent and from the limited information available on metabolites and their 
pharmacological actions, hydromorphone would appear to present a simpler profile with the 
lack o f a pharmacologically active 6-glucuronide metabolite. The greater water solubility 
results in the opportunity to create more potent parenteral formulations. This has limited 
applications, however, given that infusion volumes are only of any practicable consequence 
in the setting where relatively large doses are required for patients where there is limited 
subcutaneous mass to receive the infusion. This can be the case in palliative care patients. A 
possible economic advantage could be made of the smaller infusion volumes possible 
through the reduced need for changing infusion syringes for devices such as PCA pumps. 
The economic forces and the technology itself are relatively recent phenomena, however, 
and are too recent to have affected the relative status of the two compounds. The greater 
potency on a milligram-per-milligram basis is also of a rather academic interest, since there 
are no demonstrable benefits in this increased potency other than possible issues regarding 
volume o f administration as described above. The possible advantage of the less 
complicated metabolite profile has not become a major practical issue, since there is a lack 
of consensus regarding the problems that the active morphine-6-glucuronide causes. 
Additionally, both compounds share a 3-glucuronide metabolite and the activity of the 
hydromorphone - 3 - G has not been well characterised in the literature.
The recent pharmacokinetic studies of hydromorphone reviewed from the literature present 
an uncomplicated picture of the molecule. In both formulations, it exhibits dose 
proportionality and age and sex have little clinically relevant effect on the 
pharmacokinetics. The oral bioavailability is less (18.7%) than previously reported (50.7%), 
but is similar to current estimates for morphine (29.2%, Hasselstrom 1993). The reduced 
oral bioavailability figures are attributed to the assay methodology in the older studies being 
less able to differentiate parent drug from metabolites. The figure for oral bioavailability 
that was quoted previously was at odds with pharmacodynamic data which suggested a ratio 
of 0.2 when comparing parenteral and oral doses (Houde 1986). The revised oral
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bioavailability figure is in agreement with these estimates from pharmacodynamic studies. 
Another feature o f the improved sensitivity and selectivity of current hydromorphone assays 
is the characterisation of a long terminal elimination half-life (15 hours, Durnin 2001b), 
compai’ed with the value quoted in the literature (2.36 hours, Parab 1988). This new value is 
derived from a subset of healthy volunteers where it was possible to calculate the terminal 
elimination half-life. In those where a secondary peak occurred, it was not possible to make 
a good estimation of this. The clinical relevance of this longer terminal elimination half-life 
seems to be limited, however, since it only applies to relatively low plasma concentrations 
(around 10% of Cmax) that have no significant clinical effect. The secondary peaking in 
plasma levels referred to above may be attributable to hepatic recirculation of drug and 
metabolite. From the food effect study, there appears to be an interaction taking place (30% 
increase in AUC and 25% decrease in Cmax) which, again, is similar to findings for 
morphine (Gourlay 1989). The clinical significance of this finding is limited, however, since 
the effects on Cmax are unlikely to be of significance to a patient who is well enough to 
ingest a high fat meal. In terms of the effects on total bioavailability, again, a significant 
clinical consequence is hard to envisage since other factors occurring during a 24-hour 
period would have effects on the degree of pain control experienced. In respect to effects of 
renal and hepatic impairment, the results would have been expected from the knowledge of 
the pharmacokinetic properties of hydromorphone and its 3-glucuronide. The implications 
o f the effects of increased bioavailability of the parent compound are clear, but for the 3- 
glucuronide, this is more open to debate, since the effects of what is generally ascribed to be 
an inactive metabolite are a matter for discussion (Smith 2000). The clinical relevance of 
the metabolite would appear to be restricted to patients receiving relatively high doses, 
however. In summary, the current picture of hydromorphone immediate-release 
pharmacokinetics is very similar to that for morphine.
The sustained-release formulation of hydromorphone clearly achieves a very flat plasma 
level profile with release of drug from the formulation apparently continuing for up to 24 
hours after administration and with an oral bioavailability comparable with the 
corresponding dose in the immediate-release formulation. Food had little clinically relevant 
effect on the pharmacokinetics of the sustained-release formulation.
All three of the main clinical studies were positive, which was a great relief to all 
concerned. One might have thought that embarking on a programme of studies for an
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established product would present few hurdles. In practice, however, many analgesic studies 
have negative outcomes and making an analgesic model work thi'ee times without fail is a 
noteworthy achievement (Schachtel 1991). It is theoretically possible to achieve a positive 
outcome using an equivalence methodology by running a bad study (Djulbegovic 2001). For 
example, if  the test and control treatment are both inefficacious, then they may still be 
equivalent according to the statistical definition. One method to address this issue is to 
include a sensitivity analysis within the equivalence methodology. Incorporating a placebo 
arm in the study usually does this and a statistically significant difference between the 
placebo treatment and the active(s) is the proof of sensitivity. The problem with applying 
this to pain studies of anything other than a short duration comes with the ethical difficulties 
of placebo treatment. We encountered significant problems with ethics committees even 
with the single-dose study where the study period was of six hours’ duration and immediate 
rescue therapy was available. Added to this is the regulatory authorities’ insistence that the 
primary efficacy measure must be pain itself and not surrogates such as the use o f rescue 
medication. In the equivalence studies included in this thesis, the proof of efficacy of test 
and control treatment arms comes from the reduction in pain scores during the study period. 
In the chronic cancer pain study, this is clearly demonstrated in Figure 22 where the pain 
scores are seen to diminish with both treatments during the study period. Given that the 
clu'onic pain stimulus is assumed to remain relatively constant for the duration of the study 
and that no other opioid therapies are permitted, this is the proof of efficacy in this trial. For 
the multiple-dose postoperative study, the pain scores were also seen to have diminished 
during the study phase (Figure 15) when no analgesic therapy other than test/control was 
available to the patients. However, in this case, it could not be assumed that the pain 
stimulus was constant tlu’ough the study period. Additional proof of efficacy is provided, 
however, by the statistically significant difference in dose response between the 2-mg and 
the 6-mg dose level (mean difference 1.1, 98.3% Cl 0.1,2.0). Another possible problem with 
the conduct of equivalence studies is lax conduct allowing many protocol deviations, which 
results in both treatments being declared equivalent simply tlii'ough the process of 
regression towards the mean. This factor is tested for in the analysis of two datasets within 
each study. The first is the “full analysis” or “intent to treat” dataset and the second is the 
“per protocol” dataset. In both studies, both analyses produced the same result, thus 
confirming that study conduct was sufficiently rigorous. Thus, one can conclude that the 
two equivalence studies certainly were also positive in their outcome.
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The selection of the primary efficacy endpoint for the chronic cancer pain study was 
straightforward, since there were published reports to suggest that “worst pain” was the 
most clinically relevant and we were advised that it was also the most sensitive in a clinical 
trial setting (see section 5.4,6). The results of the study confirmed these earlier findings such 
that the primary efficacy variable was the most sensitive measure. For the postoperative 
studies, however, there was a conflict between what was perceived to be the more clinically 
relevant endpoint, pain on movement, and the suggestion from the literature that opioids 
were more effective with pain at rest (Rainer 2000). The conservative approach was taken, 
but in retrospect, the pain on movement seems to be the more sensitive measure, since there 
were more statistically significant differences compared with placebo with this measure (see 
section 5.2.5.1). The findings from the majority of the secondary efficacy parameters seem 
to bear out that pain itself is the most sensitive measure in analgesia trials and that the 
greater the pain level recorded, the greater the chance of demonstrating statistically 
significant differences.
The selection of the clinical equivalence zone (±1.5 on the 11-point numerical scale) has 
been described in sections 3 and 5.3.2. On inspection of the data from the two equivalence 
studies, in retrospect, a range of ±1.0 would have been easier to explain the findings from 
the studies. In the case of the multiple-dose postoperative study, this range would have 
resulted in inferiority being declared for the 2-mg dose, equivalence for the 4-mg dose and 
superiority for the 6-mg dose on the basis of the “pain at rest” scores from either the “per 
protocol” or the “full analysis” set. In the same study, had “pain on movement” been used, 
then both the 2 and 4-mg doses would have been declared inferior and the 6-mg dose would 
have been equivalent. These results would have fitted more conveniently with the findings 
from the single-dose study, namely that the 2-mg dose was not statistically significantly 
different from placebo whereas the 4-mg dose was. The apparent difference between the 
efficacy o f the 2-mg dose in the single-dose versus the multiple-dose study may be due to 
several factors. First, although the SPID value for the 2-mg dose was not statistically 
significantly different from placebo for pain at rest or on movement, the plot for mean pain 
score at rest was lower for the 2-mg dose and although this was only transitory for the pain 
on movement plot, the value at one hour post-dose was statistically significant. Also, results 
between two studies, even if they are identical, will not always agree. Finally, the flexible 
dosing regimen in the multiple-dose study meant that the patients in the 2-mg dose received 
doses more frequently than the 4-mg group. The respective median dosing intervals were
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5.6 and 6.6 hours. For the clu’onic cancer pain study, the results would have been the same 
as those for the ±1 .5  value, namely that equivalence would have been declared for the 
immediate-release phase, but superiority of hydromorphone for the SR phase, irrespective 
of whether the “per protocol” or the “full analysis” data set were used.
The two postoperative studies were very similar in design and shared many common 
features such as study centres and study procedures. One of the significant differences 
between the studies related to the baseline qualifying pain score included in the multiple- 
dose study. The effect of this was that the mean value for pain at rest in the single-dose 
study was 4.4 whereas for the multiple-dose study it was 5.8. In retrospect, including a 
qualifying baseline score in the single-dose study would have probably improved the 
sensitivity in the single-dose study (Averbuch 2000).
The withdrawal rates in the two postoperative pain studies varied across countries, and there 
appeared to be some consistency between the two studies in this respect. The rates of study 
completion for the single-dose study in the UK, France and the Netherlands were 53%, 88% 
and 47%, respectively, with the respective figures for the multiple-dose study being 64%, 
79% and 52%. As one would expect, the number of withdrawals due to lack of efficacy was 
greater in the placebo controlled study (34%), compared to the active control one (17%). 
Another factor that varied consistently between countries across the two studies was the 
duration of the PCA. In the single-dose study, the median duration (in hours) was 39.0, 20.3 
and 21.0 respectively for the UK, France and the Netherlands. The corresponding figures 
for the multiple-dose study were 35.2, 21.1 and 20.0, respectively. The centres that took part 
in each study were not the same for both studies, but from the 24 involved in the single-dose 
study and the 27 involved in the multiple-dose study, 12 were common to both. These are 
examples of important factors in clinical trials that cannot be controlled for between centres 
and countries in the setting of a multi centre, international study.
The single-dose study in acute pain confirmed the findings in the published literature that 
oral doses of hydromorphone are statistically significantly superior to placebo. In contrast to 
the published literature, however, it was not possible to discern differences in tolerability 
between the hydromorphone doses tested.
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In the acute pain setting, the single-dose study demonstrates an increase in efficacy when 
the single dose increased from 2 to 4 mg, but not from 4 to 6 mg. The most obvious and 
simple explanation is that the 100% increase between 2 and 4 mg was sufficient to 
distinguish a difference, but the 50% increase from 4 to 6 mg was not sufficient. This study 
was originally designed to evaluate 2, 4 and 8-mg doses, but theoretical concerns (based 
around the interpretation of equipotency figures) from a regulatory authority about the 
safety o f the 8 mg dose prevented its use. The dose-responsiveness observed in this study 
mirrors that described in the published studies of parenteral doses reviewed in section 
4.2.2.2.
In the setting o f the multiple-dose acute pain study, 2, 4 and 6 mg were not distinguishable 
in terms o f their therapeutic equivalence to morphine 20 mg. These findings are in general 
agreement with a small published study comparing hydromorphone with morphine (Turek 
1987). The three dose levels selected were distinguishable by the mean pain scores that 
they attained. The lack of a difference in the equivalence outcome between 2 and 4 mg was 
partly attributable to an increased frequency of dosing in the 2-mg dose group, compared 
with the 4-mg dose group. This is an inevitable consequence of a flexible dosing regimen, 
which was in turn a requirement of caring for a group of patients in the post-operative 
setting over an extended period. In summary, 2-mg doses of hydromorphone IR can be 
effective in the acute pain setting, but a more reliable response is obtained from a 4-mg 
dose.
The onset and duration of action of single oral doses of hydromorphone from the single­
dose, placebo controlled trial are in general agreement with the published data reviewed in 
section 4.2.2.3.4. However, the onset of action, which would appear to be within one hour, 
is somewhat earlier than would have been expected from some of the literature data. It is, 
however, in agreement with the pharmacokinetic data from recently published studies 
(Durnin 2001a, b, c, d, e, f). Also, the duration of action from the single-dose study (from 
the analysis of time for pain to return to baseline score) would appear to be between three 
and four hours, rather than the longer durations quoted in some of the references.
The “Gold Standard” reference therapy for strong opioids is clearly morphine and this was 
the comparator used in both the multiple-dose acute pain study and the chronie pain study. 
The comparative multiple-dose study in postoperative pain has established statistically that
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hydromorphone is within the efficacy range of morphine, which is the “global standard” in 
moderate to severe pain. In this study, for all tliree dose levels when dosed on a flexible “3- 
hourly as required” basis, therapeutic equivalence was demonstrated. The key to equal 
efficacy with all opioids is, of course, the equipotency ratio used to calculate doses for 
comparison. For this study, a ratio of 1:5 was expected to be the outcome and indeed, the 
value was calculated as being between 1:4 and 1:5, depending on the dataset used (“intent to 
treat” or “per protocol”) and the measure of pain used (pain at rest or pain on movement). 
For the cancer pain study a ratio of 1:5 was again used for the calculation of doses of the 
respective medications. Using the daily dose of each respective treatment at the end of the 
SR phase and not taking rescue medication into account (since the use of this was very 
similar between the two treatment groups); the equipotency value worked out to be 4.32. 
These data suggest more consistency than those published in the literature, which vary from 
two to 10. One specific concern raised from the literature is the possibility that the existing 
dose conversion ratios were predominantly based on single-dose data, citing a paper where 
dosing for 13 days had produced a value of 3:1, in contrast to the 7:1 value obtained at the 
start of dosing (Dunbar 1996, Anderson 2001). The data from the cancer study in this thesis 
arise from a mean dosing period of 16 days; therefore, this argument would not appear to be 
valid.
In the comparative chronic pain study, patients were titrated to dose-stable pain control in 
both IR and CR phases of the study and assessed for equivalence of efficacy using items of 
the BPI. This study demonstrated the clinical equivalence of efficacy between 
hydromorphone and morphine in the IR phase of the study whilst the superiority of 
hydromorphone could not be disproved in the CR phase. This finding is consistent with the 
published study by Moriarty (1999) which found hydromorphone to be as effective as 
morphine in the treatment of chronic cancer pain.
Patients receiving morphine (the comparator treatment) prior to baseline probably affected 
both of the equivalence trials. In the case of the multiple-dose postoperative study, this was 
an inevitable consequence of the study design. All patients were receiving morphine 
parenterally prior to randomisation. In the cancer pain study, about one third of patients 
were receiving morphine prior to randomisation. One would expect this to have at least 
some effect on the outcome of the two studies. In the case of the postoperative study, at the 
time of randomisation, all patients should have had their pain satisfactorily controlled. An
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element of selection could have occurred in the PCA part o f the study, whereby those 
patients who did not tolerate morphine well dropped out of the study, leaving a selected 
group of “morphine responsive” patients. It is, unfortunately, not possible to explore this 
issue, since data was not collected in the PCA part of the study in such a way as to enable 
this withdrawal phenomenon to be well characterised. Therefore, the subset of patients 
continuing to randomisation to the morphine treatment arm remained on morphine, except 
that it was administered by a different route. One would anticipate that this group would 
follow a smoother clinical course than those in the hydromorphone treatment arms who had 
to become accustomed to a new agent. In the case of the cancer pain study, another factor 
would have come into play. Patients could enter this study irrespective of their current pain 
control and there was no stabilisation period prior to randomisation. For those patients 
already receiving morphine and enjoying good pain control, one would expect them to fare 
better if  they were randomised to continue to receive morphine. On the other hand, those 
having problems with morphine could be expected to fare better if  they were allocated 
hydromorphone, on the theoretical basis of receiving benefit from opioid “switching” 
(Bruera 1996). Unfortunately, the patients’ current status on existing therapy was not well 
documented in the cancer pain study, so it is not possible to identify which group each 
patient would fall into. The data from the initial IR phase would suggest, however, that the 
former was more often the case, since the hydromorphone treatment group exhibited longer 
times to pain stabilisation and more adverse event reporting (see section 5.4.6).
The adverse event data from the single-dose postoperative study was remarkable for not 
being able to distinguish between active and placebo doses. Thus, even for a drug like 
hydromorphone with a well laiown side effect profile, it was possible to administer single 
efficacious doses without any apparent change in adverse event reporting.
The safety data from the multiple-dose study in patients with acute postoperative pain 
malces a direct comparison between hydromorphone IR and morphine and finds no 
statistically significant difference. There appear to be some differences in reporting rates of, 
for example, nausea, in morphine’s favour, but very large numbers of patients would need 
to be studied to demonstrate statistical significance. Similarly, in the cancer pain study, no 
statistically significant differences were found between the treatments in terms of safety 
parameters. What appeared to be a possibly important trend in the postoperative data 
concerning apparently higher rates of nausea with hydromorphone compared with morphine
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were not mirrored in the cancer pain study. In fact, the trend was in the opposite direction in 
the cancer pain study. The nature of the adverse events reported during hydromorphone and 
morphine treatment in the cancer pain study was generally typical of the events associated 
with these treatments as reported in the published literature (Paice 1998, Moriarty 1999).
The main focus regarding safety parameters centred on adverse events, serious adverse 
events, deaths and withdrawal rates. Additional inspection of the data for less common, but 
more significant events failed to suggest any safety concerns. Clearly, a significant element 
in the consideration of safety in respect to hydromorphone is its extensive use in North 
America for most of the 20^ '^  century. The published data on the use of hydromorphone 
makes many comparisons with other opioids and although individual studies identify 
differences in specific safety measures, the general picture is of the comparability, rather 
than the difference of hydromorphone compared with other opioids. An important issue 
regarding the reporting of safety data from clinical trials is the power of the comparisons 
being made. In fact, none of the studies in this thesis are sufficiently powered to detect 
differences in reporting rates. Sample sizes far larger even than these relatively large studies 
are required to make a true assessment of these differences (Edwards 1999). For a 
hypothetical case o f a treatment which causes an adverse event at a rate of 40% and a 
comparator treatment with a corresponding rate of 30%, in order to achieve 90% power at a 
5% significance level, 492 patients would be required for each treatment group.
The incidence of adverse event reporting varied greatly between the single and multiple- 
dose postoperative studies. For opioid-related events, either ongoing or occurring after 
randomisation, the total number of patients reporting in treatment groups in the single-dose 
study were between 14 and 27%. This contrasts with 42 to 61% in the multiple-dose study. 
This provides dramatic evidence of the difference in reporting rates caused by increased 
dosing and longer observation periods in a similar setting and patient population.
Respiratory depression is clearly a direct pharmacological action of opioids, including 
hydromorphone. In the treatment of chronic pain, this is generally of less concern since 
doses can be titrated gradually and patients are ambulant. The more immediate concern is in 
the acute pain setting and this concern had an effect on the programme of studies when one 
regulatory authority questioned the use of an 8-mg dose of hydromorphone in the single 
dose postoperative pain study. In response to this concern, the dose was subsequently
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reduced to 6 mg. The results of both postoperative pain studies, however, were that there 
were no reports o f respiratory depression.
One pharmaco-epideniiological study involving hydromorphone has been published.
Miller’s publication (Miller 1980) was of a prospectively collected series of cases from 22 
hospitals over 12 years where parenteral narcotics were used. Although Miller points out 
that hydromorphone was administered to patients with a higher fatality rate, longer duration 
of hospital stay, higher diagnosis rate of neoplasm and for a longer duration of exposure, he 
concludes that these factors are not sufficient to account for a higher adverse event reporting 
rate for hydromorphone. The total proportion of patients reporting adverse events for 
hydromorphone was 18.3%, compared with 5.8% for morphine. The sample is further 
distorted however, by another two factors. The first relates to sample size; 1821 received 
morphine and 115 received hydromorphone and secondly, morphine was substantially used 
for pre-medication and as a treatment for heart failure, bronchospasm, anxiety, angina and 
“numerous other indications”, whereas hydromorphone was used exclusively for pain. It is 
hard to reconcile the findings of this study with the numerous controlled comparison of 
hydromorphone with other opioids. The numerous factors that weaken the comparison in 
this study may account for a large paid of the difference observed.
The conduct of both postoperative pain studies was relatively straightforward in respect to 
centre selection and the recruitment phases. Both of these studies completed the recruiting 
o f patients more quickly than expected. The single-dose study completed recruiting 200 
patients in five months, while the multiple-dose study recruited 270 patients in nine months. 
In contrast to these studies, consultants warned from the very early stages of planning the 
cancer pain study that recruitment would be a big problem (Jordhoy 1999, Hardy 2000). 
This certainly was the case, with recruitment of 200 patients taking nearly two years, 
despite the involvement of eight countries and more than 30 centres. This study also needed 
adjustment to inclusion criteria made in order to attempt to boost recruitment. In making 
these changes, the concern is always that by making selection criteria less strict, the quality 
o f the study will suffer. Fortunately, the integrity of the study was not adversely affected, 
however.
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7 Overall conclusions
Hydromorphone is undoubtedly a strong opioid. It has been shown in clinical practice and 
clinical studies over the last 30 years and up to the present date, to be within the range of 
potency, efficacy and safety of other strong opioids such as morphine. It is well accepted 
that there are significant variations in individual patients in the response of one opioid 
compared to another (McQuay 1999), particularly in relationship to adverse side effects as 
well as efficacy. Publications support the beneficial effects of transferring patients from one 
opioid to another if  they have either not responded or suffered severe side effects (de Stoutz 
1995).
The range of efficacy and potency of hydromorphone in the acute pain, as well as the 
clironic pain studies has addressed moderate to severe pain. On this basis, it is appropriate 
that hydromorphone will be indicated for the management of moderate to severe pain. The 
safety data are within the same range as other strong opioids currently used for management 
of moderate to severe pain. From the above, it is then possible to recommend treatment with 
hydromorphone in acute and chronic moderate to severe pain.
The relative risks and benefits from hydromorphone are principally those of the 
pharmacological effects of strong opioids in general. Therefore, the efficacy of analgesic 
effects comes along with the emetogenic effects, constipation, and sedation and, at high 
doses relative to the analgesic doses required for individual patients, the potential for 
respiratory depression.
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